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Abstract 
Feline immunodeficiency virus (FIV) is  an important  veterinary  pathogen  with 
comparative significance because of its similarities to its human counterpart 
HIV.    Since  FIV  is  the  only  non primate  lentivirus  which  induces  AIDS like 
symptoms in its natural host, it serves as a valuable animal model for both 
prophylactic and therapeutic studies of HIV. 
It  is  accepted  that  the  induction  of  neutralising  antibodies  (NAbs)  is  a  key 
element in the control of lentiviral infection, since T cell based vaccines alone 
failed to prevent infection in most experimental animal model systems. In this 
project a robust and reproducible in vitro neutralisation assay was developed 
and  optimised,  permitting  the  assessment  of  the  NAb  response  in  naturally 
infected cats and with the potential to evaluate candidate vaccines. 
It was demonstrated that, in general, primary FIV strains in the UK belong to 
subtype A, and therefore the development of a regional, subtype A specific, 
FIV vaccine could be considered for use in the UK.  The identification of a 
neutralisation  resistant  isolate  of  FIV  led  to  the  finding  that  a  linear 
neutralisation  determinant  was  located  within  the  V5  region  of  Env  and 
mutations in this region may lead to immune evasion in vivo.  In addition, a 
second neutralisation determinant was identified in the C3/V4 region of Env. 
Finally,  it  was  observed  that  a  small  proportion  of  naturally  infected  cats 
generated NAbs against FIV.  Of these, only a very small proportion of the cats 
had antibodies with the potential to cross neutralise strains within the same 
subtype  as  the  homologous  isolate.    Nonetheless,  a  plasma  sample  from  a 
single cat was identified that neutralised all strains tested, including strains 
from different subtypes and geographical regions.  It is likely that studies of 
the homologous isolate that induced the broad NAb response may be capable of 
inducing a similar broad response in vaccinated cats.  Such a finding would 
have  important  implications  for  the  design  of  potential  novel  lentiviral 
immunogens. Chapter one 
1 Introduction 
 
1.1 An overview of FIV 
Feline immunodeficiency virus (FIV) is a major veterinary pathogen that is an 
important  cause  of  morbidity  and  mortality  in  domestic  cats.    It  was  first 
isolated in 1986 in Petaluma, California from a cat with an immunodeficiency  
like syndrome (Pedersen et al., 1987) and was soon recognised as the feline 
homologue of human immunodeficiency virus (HIV).  Both FIV and HIV belong to 
the genus Lentivirus within the family Retroviridae, cause immunodeficiency in 
their  natural  hosts  and  share  numerous  biological,  clinical  and  pathogenic 
features (Hartmann, 1998). 
 
1.2 Epidemiological features of FIV 
FIV is highly host specific to the Felidae family, which includes the lion, the 
tiger,  the  jaguar,  the  puma,  the  pallas  cat,  the  leopard,  the  cougar,  the 
cheetah,  the  serval,  the  lynx  and  the  ocelot  as  well  as  the  domestic  cat.  
Seroconversion does not occur following exposure of humans to the virus, and 
therefore there is no risk of zoonotic transmission (Yamamoto et al., 1989).  
The  prevalence  of  infection  is  approximately  11%  in  cats  worldwide 
(Courchamp & Pontier, 1994), varying from 1 14% in cats with no clinical signs 
to up to 47% in sick cats.  In the UK the prevalence is approximately 5% in 
healthy and 47% in sick cats (Hosie & Beatty, 2007). 
FIV strains are usually classified into five subtypes (designated A E), based on 
nucleotide sequence.  Inter subtype recombinants A/B, A/C and B/C have been 
recognised (Bachmann et al., 1997).  Serological subtyping has not yet been 
conducted  for  FIV.    As  well  as  the  prevalence  differing  greatly  between 
geographical  areas,  the  subtype  distribution  is  variable  between  different 
regions (Hosie et al., 2009) (Figure 1.1).   
Transmission of virus occurs mainly by biting, via the saliva of infected cats, 
during fights or at mating (Pedersen et al., 1989).  Trans mucosal (vaginal or 
rectal),  in  utero  and  trans mammary  infections  have  been  recorded 
experimentally; however, it is unknown how often transmission occurs by these Chapter one 
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routes in nature (Bishop et al., 1996; O'Neil et al., 1995).  The prevalence of 
FIV infection is highest amongst male, free roaming, older, and sick animals, 
reflecting the route of natural viral transmission and the immune status of the 
host (Courchamp & Pontier, 1994). 
 
Figure 1.1.  The global distribution of FIV subtypes. Adapted from (Hosie et al., 
2009). 
 
1.3 Pathogenesis of FIV infection 
Infection with FIV is associated typically with generalised lymphadenopathy, 
gingivitis/stomatitis,  and  cachexia  (Callanan  et  al.,  1992).    Infected  cats 
undergo an acute viraemic phase, with varying degrees of fever, diarrhoea, 
conjunctivitis, and generalised lymphadenopathy developing a few weeks post 
infection,  accompanied  by  leucopenia  as  CD4
+  T  cells  are  rapidly  depleted.  
This phase involves a burst of virus replication before seroconversion occurs 
(Callanan et al., 1992).  The acute phase is then followed by an asymptomatic 
phase,  usually  lasting  for  several  years,  during  which  CD4
+  T  cell  numbers 
decrease slowly, a balance having been reached between the virus and the 
host immune response.  At the same time, CD8
+ T cell numbers increase; as a 
result  the  CD4
+:CD8
+  ratio  becomes  inverted  (Diehl  et  al.,  1995a).    FIV 
infection induces both antibody and cytotoxic T lymphocyte (CTL) mediated 
responses which are thought to maintain the viral load at a low and stable Chapter one 
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level during the entire latent phase (Beatty et al., 1996) (Figure 1.2).  CD4
+ T 
cell  depletion continues  and infected cats  may  start  to  display  non specific 
clinical signs, including recurrent fever, generalised lymphadenopathy, apathy, 
leukopenia, anemia, wasting, stomatitis and behavioural abnormalities.  This 
stage,  AIDS related  complex  (ARC),  may  last  for  several  months  to  years 
(Matsumura et al., 1993; English et al., 1994).  A proportion of FIV infected 
cats develop AIDS like symptoms with opportunistic infections and lymphomas 
(Shelton & Linenberger, 1995).  CD4
+ T cell numbers may drop to 200 cells/ml 
or fewer in terminally ill cats (Bendinelli et al., 1995). 
 
 
Figure 1.2.  Clinical phases of FIV/HIV infection.  During the acute phase, there 
is a peak of viraemia accompanied by a decrease in the number of CD4+ T 
cells,  and  a  CTL mediated  response  is  initiated.    A  constant  viral  load  and 
maintenance  of  CD4+  T  cell  numbers  is  associated  with  the  asymptomatic 
phase  following  the  peak  CTL  response.    Maturation  of  NAbs  occurs  at  6 8 
months  of  infection  and  levels  are  maintained  throughout  the  course  of 
infection (Richman et al., 2003).  AIDS like clinical signs occur as the immune 
response collapses.  Adapted from (Ferrantelli & Ruprecht, 2002). Chapter one 
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1.4 FIV structure and genome organisation 
The  FIV  virion  is  spherical  to  ellipsoid,  105  to  125  nm  in  diameter,  with a 
typical lentivirus structure, containing two copies of single stranded, positive 
sense RNA (Pedersen et al., 1987; Miyazawa et al., 1989a).  The viral genome 
contains approximately 9400 nucleotides and is surrounded by a conical shell, 
the  capsid  (CA),  and  is  attached  to  nucleocapsid  (NC)  proteins.    Together, 
these  form  the  viral  core.    The  core  is  enclosed  by  the  matrix  (MA)  and 
enclosed  within  the  outer  envelope  which  is  composed  of  two  layers  of 
phospholipids  (Olmsted  et  al.,  1989;  Talbott  et  al.,  1989)  containing  the 
surface (SU) and transmembrane (TM) envelope glycoproteins (Env). 
 
Figure  1.3.    Structure  of  FIV  genome.    Diagram  depicting  the  FIV  genome 
(upper)  and  the  gene  products  of  the  main  three  FIV  genes  (lower).    MA: 
matrix, CA: capsid, NC: nucleocapsid, PR: protease, RT: reverse transcriptase, 
DU: dUTPase, IN: integrase, SU: surface unit, TM: transmembrane. 
 
The FIV genome contains the three major lentiviral genes; gag, pol, and env, 
and  a  number  of  accessory  genes,  flanked  on  both  sides  by  long  terminal 
repeat  (LTR)  sequences  (Figure  1.3).    The  gag  gene  encodes  the  internal 
structural proteins CA, NC, and MA, which are necessary for maintaining the 
integrity  of  the  virion  particle.    The  pol  gene  encodes  enzymes  that  are 
necessary  for  virus  replication  and  reproduction;  the  protease  (PR),  which 
cleaves  newly  synthesised  polyproteins  to  create  the  mature  protein 
components, the reverse transcriptase (RT), which transcribes single stranded Chapter one 
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viral  RNA  into  double stranded  DNA,  the  integrase  (IN),  which  integrates 
transcribed viral DNA into the DNA of the infected  cell, and dUTPase (DU), 
which is absent in HIV and is believed to facilitate productive infection of non 
dividing cells such as macrophages.  The env gene encodes Env, comprising the 
SU and TM proteins.  As well as protecting the viral particle, Env is responsible 
for viral entry into the host cells.  The LTRs flanking the genome contain an 
untranslated 3' (U3) region, which involves promoter/enhancer elements, and 
an  untranslated  5'  (U5)  region,  which  contains  the  polyadenylation  repeat 
(Miyazawa et al., 1994; Stephens et al., 1991; Lerner et al., 1995; Tomonaga & 
Mikami, 1996). 
Other  genes  are  rev,  vif,  and  orf-A  which  encode  the  Rev,  Vif,  and  Orf A 
proteins respectively.  Rev is involved in shuttling RNAs from the nucleus and 
the  cytoplasm  by  its  binding  to  the  viral  RNA  Rev  response  element  (RRE) 
(Phillips  et  al.,  1992),  and  Vif  blocks  the  action  of  antiviral  response  by 
preventing cytidine deamination by APOBEC 3G (An et al., 2004; Mangeat et 
al., 2003), while Orf A arrests host cell division (Gemeniano et al., 2004).  FIV 
particles lack the vpu, vpr, and nef genes that are present in HIV.   
 
1.4.1 Structure of FIV Env  
Env is responsible for viral entry to the host cells and has an important role in 
the pathogenesis of infection.  Env is composed of variable regions, usually 
known as variable (V) loops, interspersed with conserved (C) domains.  The 
conserved region forms inner and outer domains as well as a β bridging sheet, 
which includes the primary and chemokine receptors binding sites required for 
viral  entry  and  considered  to  be  major  targets  for  neutralisation  (Wyatt  & 
Sodroski, 1998).  Variable loops present potentially variable epitopes to the 
immune  system.    Nine  variable  loops  have  been  identified  in  the  FIV  Env 
protein; V3 V6 in SU and V7 V9 in TM, while the V1 V2 region is located within 
the leader sequence and is not part of the mature Env of FIV (Pancino et al., 
1993;  Verschoor  et  al.,  1993).    As  well  as  the  sequence  variation  of  the 
variable  regions  amongst  FIV  strains,  which  makes  it  difficult  to  generate 
broadly  neutralising  antibodies  (bNAbs),  the  variable  loops  are  heavily 
glycosylated,  masking  potential  neutralising  epitopes  within  and  outside 
variable regions (Moulard et al., 2002; Lusso et al., 2005; Xiang et al., 2005). Chapter one 
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1.5 The replication of FIV 
Env forms spike like projections that appear on the surface of the envelope in 
trimers  (consisting  of  three  SU  and  three  TM  subunits)  attached  by  non 
covalent bonds.  The SU protein, gp120, binds to the primary receptor CD134 
(or OX40) on the surface of CD4
+ cells (Shimojima et al., 2004).  CD134 is a 
member of the tumour necrosis factor receptor family and binding of Env to 
CD134 leads to a conformational change in Env that enables a second binding 
step with the chemokine receptor CXCR4 to proceed, bringing the virus and 
cell membranes into close proximity.  Further conformational changes allow 
the TM protein, gp41, to fuse with the cell membrane, resulting in complete 
fusion of the two membranes and allowing the virus to release the core into 
the cell cytoplasm (de Parseval et al., 2005; de Parseval et al., 2004; Garg et 
al., 2004; Moore et al., 2001).  Once viral genome and enzymes are liberated 
into the host cell, the viral single stranded RNA genome is transcribed into 
double stranded DNA, which is then transported to the nucleus and integrated 
as a provirus into the host genome.  Proviral DNA is transcribed into mRNA 
which  is  then  translated  into  viral  protein  precursors.    Viral  proteins  are 
processed and cleaved by proteolysis before assembly of the viral genome and 
proteins occurs, forming pre mature virions.  Virions are released from the host 
cell by budding; during this stage the viral cores are enveloped by parts of the 
cell membrane into which the viral glycoproteins are inserted (Haseltine, 1991; 
Frey et al., 2001). 
 
1.6 The virus host interaction 
Following  an  initial  infection,  vigorous  immune  responses  are  elicited  in  an 
attempt to defend the host against viral attack.  Although unable to contain 
the massive burst of viral replication during the acute viraemic phase, it is not 
long before a state of equilibrium is reached, with the aid of humoral and cell 
mediated immune responses, and the host enters the asymptomatic phase of 
infection.    Cytotoxic  T  cell mediated  (CTL)  immunity  is  thought  to  play  an 
important role in the initial viral response, since CTL activity may be detected 
indirectly as early as one week post infection, via the detection of chemokines 
and other soluble factors which efficiently block the interaction between viral 
particles and their receptors (Song et al., 1992; Choi et al., 2000; Flynn et al., Chapter one 
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2002).  CTL activity is mediated mainly by CD8
+ T cells and recognises FIV Gag 
and  Env  proteins  (Flynn  et  al.,  1995).    The  CD4
+  T  cell mediated  response 
starts  strongly  and  effectively  early  in  infection  through  the  secretion  of 
gamma interferon (IFN γ) and interleukin 10 (IL 10), but gradually decreases 
with time as CD4
+ T cells are  major targets for FIV (Liang et al., 2000). 
Neutralising antibodies (NAbs) are crucial in controlling the infection by FIV.  
Anti FIV antibodies may be detected as early as six weeks post infection (Hosie 
et al., 1998), but NAbs require longer to mature (Moog et al., 1997).  NAbs 
inhibit  infection  by  blocking  the  entry  of  the  virus  into  susceptible  cells, 
presumably by binding gp120 trimers and so preventing attachment of the virus 
to the receptor on the target cell (Spenlehauer  et al., 2001; Binley  et al., 
2004; Labrijn et al., 2003).  The generation of NAbs is a slow process, with 
NAbs effective against the homologous virus being detected first.  It takes over 
8 months following seroconversion before it is possible to detect NAbs for HIV 1 
(Moog et al., 1997; Richman et al., 2003).  It is considered that the long period 
required  for  NAbs  to  develop  is  due  to  an  inability  to  induce  an  efficient, 
broadly neutralising response (Bower et al., 2004).   
Despite the strong immune responses generated by the host, lentiviruses are 
not cleared and persistently infected cats may proceed through ARC and enter 
the terminal AIDS phase.  FIV has its own effective weapons to elude the host’s 
defences; (i) Env is heavily glycosylated; sugar residues form a glycan shield 
which  strongly  protects  the  virus  from  antibody mediated  neutralisation 
(Burton  et  al.,  2004;  Zolla Pazner,  2004;  Doria Rose  et  al.,  2009),  (ii) 
conserved  regions,  such  as  the  primary  and  co receptor  binding  sites,  are 
flanked  and  masked  by  variable  loops,  (Burioni  et  al.,  2008;  Huang  et  al., 
2005; Kwong et al., 2002) (iii) steric masking of the epitopes renders them 
inaccessible  to  neutralising  antibodies  (NAbs)  as  they  fail  to  achieve  the 
necessary  entropic  changes  that  are  required  for  high affinity  interaction 
(Decker  et  al.,  2005;  Labrijn  et  al.,  2003;  Richman  et  al.,  2003),  (iv)  the 
substitution of non essential residues which do not form part of the functional 
epitope  may  block  antibody  binding  (Burton  et  al.,  2004),  (v)  Env  is 
internalised  from  the  surface  of  infected  cells  via  a  process  of  receptor 
mediated endocytosis and so is protected from the NAbs (Hosie et al., 2005), 
(vi)  the  disintegration  of  Env  glycoproteins  elicits  the  production  of  non Chapter one 
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neutralising antibodies (Thali et al., 1992; Chiarantini et al., 1998), (vii) the 
emergence of new viral variants, a consequence of the high mutation rate in 
the  viral  genome,  leads  to  escape  from  neutralisation  (Douek  et  al.,  2006; 
Richman et al., 2003). 
It is commonly presumed that the asymptomatic state occurs when a balance is 
achieved between viral attack and host defence mechanisms, resulting in a 
relatively low and stable viral titre.  However viral replication is not contained, 
spontaneous recovery following lentiviral infection has not been recorded and 
the host becomes persistently infected.  Virus evolves in response to immune 
pressure  and  new  variants  emerge  continuously.    As  the  lentiviral  reverse 
transcriptase (RT) lacks proof reading functions, new mutations arise regularly; 
only  those  that  do  not  affect  the  viability  and  infectivity  of  the  virus  will 
survive and contribute to genetic diversity.  The population, comprising new 
variants  of  a  viral  strain  within  an  individual,  is  known  as  a  quasispecies 
(Shankarappa et al., 1998; Lukashov et al., 1995). 
The increase in diversity often results in the emergence of more pathogenic 
strains (Balfe et al., 2004), since neutralising responses are evaded.  Factors 
that affect quasispecies diversity are both virus related (such as the initial viral 
load, virulence and antigenic diversity) and host related (availability of target 
cells and host immunocompetence).  As diversification appears to occur at a 
constant rate, this may indicate that host parameters of variation are of less 
significance (Shankarappa et al., 1998; Liu et al., 1997).  The diversity of viral 
env  gene  may  be  as  high  as  10%  within  an  infected  individual,  but 
extraordinarily, may exceed 30% amongst the different subtypes, making it a 
real challenge for the immune system to deal with (Rong et al., 2007b). 
 
1.7 The diagnosis of FIV infection 
Serological  methods  are  used  commonly  in  diagnostic  laboratories  for  the 
detection of anti FIV antibodies.  Immunofluorescence assays (IFA) and ELISA 
based  kits  are  widespread  with  positive  and  negative  predictive  values 
approaching  100%  (Levy  et  al.,  2003).    Antibodies  can  be  detected  also  by 
Western  blotting  using  gradient  purified  tissue  culture grown  virus  as  an 
antigen source (O'Connor, Jr. et al., 1989).  Antibodies may be detected as 
early as 2 4 weeks after experimental infection with FIV (Yamamoto et al., Chapter one 
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1988).  Antibody testing is reliable whereas viral antigen levels are often below 
the  threshold  of  detection  in  the  blood  of  infected  cats.    However,  the 
introduction  of  a  commercial  vaccine  to  some  countries,  which  induces 
seroconversion against the structural proteins of FIV, invalidates the serological 
diagnosis of infection. Levy et al. (2008) described an ELISA method that can 
distinguish between vaccinated and infected cats; however, the method fails 
to  detect  reliably  vaccinated  cats  that  later  became  infected,  which  is 
important since vaccination is not 100% effective and infected vaccinated cats 
could transmit infection to other cats.  In these circumstances virus isolation 
remains the method of choice to identify FIV infected cats.   
Virus  isolation  is  considered  the  gold  standard  method  for  identifying  FIV 
infected cats; however, it is expensive, time consuming and not suitable for 
routine diagnosis (Levy et al., 2004).  PCR based tests can be used to diagnose 
FIV infection; viral RNA is reverse transcribed to cDNA which is then amplified 
using  FIV   specific  primers  (Vahlenkamp  et  al.,  1995).    This  method  has 
limitations; levels of free, circulating virus can vary considerably in an infected 
cat  and  viral  RNA  is  highly  labile.    As  an  alternative,  proviral  DNA  can  be 
amplified directly from circulating peripheral blood mononuclear cells (PBMCs) 
(Leutenegger et al., 1999).  However, the sensitivity can be greatly affected by 
sample quality and quantity, sequence variation amongst field strains, and a 
lack of detectable provirus in PBMCs (Bienzle et al., 2004).  However, real time 
PCR  methods  have  been  shown  to  provide  better  sensitivity  and  allow  the 
quantification of proviral DNA (Klein et al., 1999). 
 
1.8 FIV as a model for HIV infection 
It is now widely accepted that FIV is a useful model for the study of HIV in 
terms  of  pathogenesis,  prophylaxis,  and  therapeutics.    FIV  shares  many 
similarities  with  its  human  counterpart;  from  its  genome  structure  and 
organisation, to the mechanism of infection and the pathogenesis of infection 
(Pedersen et al., 1987). 
FIV  and  HIV  have  similar  structural  and  functional  proteins  as  both  viruses 
share the three major lentiviral genes: pol, gag and env.  FIV Env consists of 
variable and conserved domains similar to HIV, although FIV lacks the first two 
variable loops present in the mature HIV Env.  Both FIV and HIV possess the Chapter one 
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accessory genes rev and vif and, although FIV does not have the vpr, vpu or nef 
genes,  it  is  believed  that  their  function  may  be  offset  by  ORF A  and  DU 
(Gemeniano  et  al.,  2004;  Chen  et  al.,  2004),  and  so  the  replication  of  FIV 
mirrors that of HIV. 
Both  viruses  target  CD4
+  T  lymphocytes  and  induce  a  progressive 
immunosuppression  in  their  hosts.    Also,  FIV  and  HIV  share  a  similar  cell 
tropism, infecting monocyte/macrophages, glial cells, B cells and CD8
+ T cells 
(Hein et al., 2000; English et al., 1993).  Infection of CD4
+ T cells leads to 
inversion of the CD4
+:CD8
+ ratio, which is considered to be a hallmark of both 
HIV and FIV infections (Garg et al., 2004; Diehl et al., 1995a).  While FIV does 
not utilise CD4 as its primary receptor, its entry mechanism resembles that of 
HIV.  All isolates of FIV utilise the CXCR4 co receptor that is used by isolates of 
HIV.  As FIV and HIV have many shared features, such as Env structure, disease 
manifestation and pathogenesis of infection, FIV is an ideal model in terms of 
vaccine development for HIV.   
As well as the many similarities between FIV and HIV, the cat model has the 
advantage  over  other  animal  models  for  HIV,  such  as  chimpanzees  and 
macaques, because of the small size of the cat and relative ease of handling.  
Cats  are  also  less  expensive,  easier  to  breed  and  have  a  relatively  short 
breeding cycle (Miller et al., 2000).  Moreover, the FIV cat model provides an 
opportunity  to  test  the  in  vivo  effects  of  immunologic  determinants  in  a 
relevant  model  system.    The  identification  of  such  determinants  has  the 
potential to contribute towards the development of effective vaccines against 
both FIV and HIV infections. 
 
1.9 FIV vaccine development 
As  a  significant  pathogen  of  the  domestic  cat  and  having  a  remarkable 
homology  with  HIV,  FIV  vaccine  development  has  comparative  as  well  as 
veterinary  importance.    It  is  likely  that  improving  our  understanding  of 
immunity  to  FIV  infection  will  contribute  also  to  the  development  of  an 
effective HIV vaccine, as FIV is widely considered to be a useful model for HIV 
(Willett et al., 1997a; Uhl et al., 2002). Chapter one 
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The ideal vaccine against any pathogen should be highly efficacious, capable of 
inducing sterilising protection against the pathogen and safe, i.e. having no 
adverse side effects.  Vaccine development against FIV, in common with HIV, 
faces a number of obstacles owing to the properties and characteristics of the 
virus so that an ideal vaccine has not yet been developed.  Ideally, an effective 
vaccine  against  FIV  should  induce  a  broad  and  potent  protective  response 
against natural challenge. 
 
1.9.1 Obstacles and challenges to vaccine development 
Although the host mounts a vigorous immune response against FIV, the virus 
can still replicate, leading to progression of infection.  Vaccine development 
faces a number of challenges: 
First, due to the highly error prone RT, diverse variants arise within infected 
individuals  as  infection  proceeds.    Continuous  viral  evolution  results  in  the 
emergence  of  a  massive  number  of  epitopes  which  are  presented  to  the 
immune system and neutralisation determinants on Env are often concealed or 
inaccessible (Zhang et al., 2004).  New variants may emerge also as a result of 
recombination  due  to  co infection  (Kyaw Tanner  et  al.,  1994;  Hayward  & 
Rodrigo, 2008).  In addition, there is enormous genetic diversity between and 
within FIV subtypes.  Diversity between subtypes has been estimated, based on 
the  nucleotide  sequence  of  the  env  gene,  and  may  reach  30%  (Burkhard  & 
Dean, 2003; Rong et al., 2007b).  Though serotypes have not yet been defined, 
serological variation within subtypes appears to be very high and therefore it 
may not be feasible for a single subtype vaccine immunogen to protect against 
all FIV strains.  An ideal vaccine would protect against infection with a wide 
range  of  isolates  but  the  idea  of  developing  multiple  regional  vaccines  has 
been proposed as an alternative (Pistello et al., 1997). 
Second, FIV persists in host cells as a non immunogenic provirus.  When the 
virus  replicates,  proviral  DNA  becomes  integrated  within  the  cat’s  genome.  
Replication proceeds with the synthesis of the viral components, packaging and 
shedding  of  mature  virions,  or  the  virus  becomes  latent,  with  the  virus 
harbouring within CD4
+ T lymphocytes (Blankson et al., 2002).  This state of 
latency renders the virus unrecognisable by the immune system and serves as a 
reservoir; virus is shed throughout the course of infection, with no possibility of Chapter one 
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removing  the  integrated  provirus  without  damaging  the  host  cell  (Marcello, 
2006).    Viral  latency  thus  prevents  the  occurrence  of  sterilising  immunity.  
Ideally,  effective  vaccination  would  induce  sterilising  immunity  (neither 
infectious  virus  could  be  isolated,  nor  viral  nucleic  acid  detected  by  PCR 
following  challenge)  or  at  least  reduce  considerably  the  viral  load,  thereby 
reducing or preventing clinical signs and transmission of infection. 
Third,  spontaneous  recovery  from  FIV  infection  is  effectively  unattainable 
(Yamamoto et al., 1989; Ishida et al., 1989) and therefore a protective vaccine 
cannot be designed that reproduces the immune responses in cats that have 
recovered from infection.  However, the study of FIV pathogenesis may provide 
clues about how a successful vaccine could be developed.  While the antibody 
response generally reduces the initial viral burst following infection, this does 
not appear to be the case for FIV, because NAbs are not yet mature in naïve 
cats and so the viral burst of replication at the acute phase is not controlled 
until the CTL response is mounted.  As a result, virus disseminates quickly to 
host  cells,  and  remains  in  a  latent  state  until  later  in  infection,  when  the 
immune response is impaired.  Indeed, as the immune system is not capable of 
eradicating  infection,  an  efficacious  vaccine  should  evoke  NAbs  and  boost 
immune responses prior to challenge and infection.  But CTL responses appear 
to be important in reducing the viral set point later in infection (Flynn et al., 
2002).  Hence, it is generally believed that an ideal vaccine should influence 
both arms of the immune response and induce both humoral and cell mediated 
immunity (Douek et al., 2006; Walker & Burton, 2008; Pu et al., 1997). 
The fourth obstacle faced in vaccine development is the difficulty in mimicking 
natural  infection  for  an  effective  vaccine  challenge  system.    In  order  to 
evaluate  accurately  the  efficacy  of  candidate  vaccines,  it  is  important  to 
mimic the natural challenge in terms of route of infection, dose, and biological 
features.  The dominant natural route of FIV transmission is via biting, which 
involves the inoculation of viral particles and perhaps also virus infected cells 
into  skin  and/or  subcutaneously  or  intramuscularly.    Kusuhara  et  al.  (2005) 
conducted  a  vaccine  trial  in  which  vaccinated  and  naïve  cats  were  housed 
together with a group of infected cats.  All of the cats were entire males, in 
order to promote fighting behaviour and hence transmission of FIV via biting.  
None of the cats vaccinated with the Fel O Vax FIV vaccine became infected, Chapter one 
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whereas five of eight unvaccinated cats became infected, providing evidence 
that vaccination protected cats against a natural challenge.  More usually, FIV 
vaccine  trials  use  experimental  routes  of  infection  for  challenge  studies, 
infecting cats with either virus or virus infected cells.  The infectious dose in 
natural infection is likely to be variable and has not been defined.  Typically, 
challenge  doses  of  10 50  median  cat  infectious  doses  of  virus  are  used  to 
ensure that all non vaccinated control cats become infected (Pu et al., 1997).   
The biological features of natural challenge have been studied and it has been 
shown  that  viral  strains  vary  significantly  in  their  virulence,  establishing 
different viral loads and inducing different effects on CD4
+ T lymphocyte cell 
numbers after challenge (Diehl et al., 1995a).  It has been established that 
even a few in vitro passages of primary HIV 1 isolates in T cell lines select for 
viral variants that are not only more adapted to growth in such cells but also 
are compromised in their innate resistance to antibody neutralisation (Sawyer 
et al., 1994; Wrin et al., 1995).  Similarly, it has been shown that laboratory 
adapted FIV strains are less virulent than naturally occurring strains, and may 
not be representative of a field challenge with primary strains (Bendinelli et 
al., 2001; Giannecchini et al., 2001a).  An effective vaccine should protect 
cats against challenge with a virulent strain representative of those circulating 
in the field; it is likely that challenge with less virulent isolates may lead to an 
overestimation of the protective response.  GL8 is a virulent primary strain 
that was isolated from an asymptomatic cat (i.e. a cat likely to be in the early 
stages of infection) and is considered representative of field isolates (Hosie & 
Beatty, 2007).  Consequently, GL8 has been used in many studies described in 
this thesis. 
Finally,  vaccination  may  induce  adverse  effects;  vaccine mediated 
enhancement of FIV infection has been encountered in several clinical trials 
(Karlas  et  al.,  1998;  Elyar  et  al.,  1997;  Siebelink  et  al.,  1995c),  perhaps 
through the generation of antibodies that facilitate virus entry or expand viral 
tropism  (Thieblemont  et  al.,  1993).    Enhancement  is  usually  observed  as  a 
higher  viral  load  (and  often  more  rapid  disease  progression)  in  vaccinates 
compared to non vaccinated controls receiving the same challenge (Hosie et 
al.,  1992;  Richardson  et  al.,  2002).    Vaccine mediated  enhancement  is  a 
significant  challenge  to  lentivirus  vaccine  development.    For  example,  the Chapter one 
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failure of Merck’s clinical trial of an adenovirus based HIV 1 vaccine caused 
major concerns for HIV vaccine development (Fauci, 2007).  Enhancement of 
FIV infection is discussed in more detail in chapter three of this thesis. 
 
1.9.2 Significance of NAbs in vaccine development 
Virus neutralisation is defined as the reduction of infectivity by antibody or by 
soluble receptor in the absence of other inactivating factors.  Two types of 
antibody neutralisation have been described; inhibition of virus binding to the 
target cell, and interference with post binding events, including fusion of the 
virus and cell membranes (Dimmock, 1993).  It is speculated that NAbs block 
the interaction between gp120 and the primary viral receptor, or  inhibit fusion 
of the virus and host cell’s membrane which, in either scenario, leads to virus 
inactivation (Poignard et al., 1996; Labrijn et al., 2003).  The ability of an 
antibody  to  neutralise  a  virus  depends  on  several  factors,  including  the 
presence of the epitope on the virion, the accessibility and conformation of 
that epitope, the assay system used to measure the virus antibody interaction 
and the presence or absence of accessory factors such as complement.  Thus, 
there are variables at both the viral and the cellular levels which may alter 
neutralisation (Golding et al., 1994). 
There is evidence to support the hypothesis that the generation of NAbs will be 
essential for a successful FIV vaccine, since in most experimental animal model 
systems, T cell based vaccines alone have been unable to prevent infection or 
provide  sterilising  immunity  (Shiver  et  al.,  2002;  Wilson  et  al.,  2006).  
Furthermore,  sterilising  immunity  against  FIV  was  achieved  through  passive 
immunisation,  and  through  maternal  transfer  of  antibody  (Hohdatsu  et  al., 
1993; Pu et al., 1995).  Monoclonal antibodies (mAbs) have also been shown to 
potently  neutralise a  broad  range  of primary  isolates  (Parren  et  al.,  1995).  
However, many researchers debate the importance of NAbs in the control or 
prevention of infection in vivo (and thus in vaccine development also) as there 
is no direct, unequivocal evidence supporting their role.  Most of the discussion 
relies on the fact that NAbs are not detected during virus clearance in the 
acute stage of infection (Moore et al., 1994), whereas cytotoxic CD8
+ T cells 
are readily detectable (Borrow et al., 1994) and effectively control the virus 
until the immune system collapses at the terminal AIDS stage.  The role of CTL  Chapter one 
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mediated  interference  is  regarded  as  highly  important  in  the  control  of 
infection.  It has, however, been proven that the antibody response plays a key 
role in Inhibiting viral replication throughout the course of infection.  It has 
been shown that the serum of HIV infected long term non progressors (LTNPs), 
defined as individuals with no AIDS symptoms over 10 years of infection, had 
higher titres of NAbs, contained NAbs that more frequently neutralised primary 
isolates and occasionally showed broad neutralising ability (Cao et al., 1996; 
Binley et al., 2008).  It has also been shown that virus evolves in response to 
the  immune  pressure  exerted  by  NAbs,  in  order  to  escape  neutralisation 
(Sather et al., 2009; Sagar et al., 2006). 
Although  broadly  neutralising  antibodies  are  identified  only  rarely  (Wyatt  & 
Sodroski,  1998),  a  number  of  cross neutralising  mAbs  that  target  HIV 1  Env 
have identified potential vaccine targets (Binley et al., 2004).  Antibody b12 
targets the primary receptor binding site (CD4bs) and is considered to be the 
most  potent  broadly  NAb;  b12  effectively  binds  to oligomeric  gp120  on  the 
virion as well as monomeric gp120 (Parren et al., 2001; Veazey et al., 2003).  
Antibody  2G12  is  another  broadly  NAb,  unusually  directed  against  the 
carbohydrate covered outer domain, or the silent face of Env, indicating that 
humoral immunity can, to a certain extent, overcome the glycan mask (Trkola 
et al., 1996; Sanders et al., 2002).  However, it has not yet been demonstrated 
that similar antibodies may be elicited via vaccination.  Antibody 2G12 has 
lower  neutralising  breadth  compared  to  antibody  b12  and  is  unable  to 
neutralise subtype C viruses, most likely due to the absence of one or more 
glycans that are required for efficient binding (Binley et al., 2004).  Antibody 
447 52D targets the GPGR domain which is predominant in clade B isolates and 
is situated at the centre of the V3 region; this antibody neutralises a broader 
range of viruses than any known anti V3 NAbs probably because of its unique 
mode  of  interaction  with  V3  (Stanfield  et  al.,  2004;  Rosen  et  al.,  2005).  
However, its interaction with its target motif is difficult to reproduce following 
experimental immunisation and V3 may be inaccessible in some clade B viruses 
due to the presence of glycan moieties (Binley et al., 2004). 
Because  conserved  regions  are  relatively  inaccessible,  one  approach  to  the 
design  of  a  successful  vaccine  immunogen  it  to  expose  these  highly 
immunogenic conserved epitopes to the immune system.  To this end, several Chapter one 
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studies have attempted either partial or complete truncation of one or more 
variable  loops,  or  mutation  of  N linked  glycosylation  sites  to  reduce  glycan 
shielding (Lu et al., 1998; Kim et al., 2003).  The outcomes have had varying 
degrees of success and the identification of key modifications that solve the 
puzzle is still awaited.  In addition, it is likely that a successful Env construct 
should mimic the native protein which exists in trimers.  Kim et al. (2005) and 
others  have  demonstrated  that  trimeric  envelop  glycoproteins  were  more 
efficient at inducing NAbs compared to simple monomeric constructs. 
A vaccine immunogen designed to elicit strong neutralising responses should 
thus be engineered to simulate the most relevant in vivo response, including 
the  induction  of  NAbs.    A  rational  approach  would  be  to  manipulate  the 
immunogen in an attempt to shift immunodominance towards more conserved 
neutralising epitopes, rather than non specific or highly variable epitopes; it is 
likely that vaccination with such an immunogen would result in the generation 
of a mature humoral response shortly after immunisation. 
 
1.9.3 Significance of FIV subtypes to vaccine induced protection 
A  number  of  vaccine  trials  have  been  conducted  to  date  with  variable 
outcomes,  ranging  from  protection  to  enhancement  (Willett  et  al.,  1997b).  
Although  a  vaccine  has  been  developed  that  is  available  commercially  in  a 
number of countries outside Europe, a vaccine capable of eliciting a strong and 
potentially  broad  protective  neutralising  response  against  virulent  primary 
isolates of FIV has not yet been developed.  It is likely that much can be learnt 
for  the  development  of  a  successful  lentiviral  vaccine  by  reviewing  the 
outcomes of various approaches that have been tested in FIV vaccine trials. 
 
1.9.3.1 Inactivated virus and infected cell based vaccines 
The most successful vaccine trials to date have used whole inactivated virus, 
inactivated virus infected cells or a combination of these.  Variable outcomes 
between different trials may be attributed to factors such as the vaccination 
schedule, the adjuvant, inactivation method, the cells used to propagate the 
vaccine virus and the challenge virus, the vaccine and challenge doses as well 
as the virulence of the challenge virus (Hosie et al., 2000).  The first successful 
vaccine trial using inactivated vaccines was conducted as early as 1991 when a Chapter one 
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vaccine derived from cells infected with the inactivated Petaluma strain (FIV 
PET) protected cats against homologous challenge (Yamamoto et al., 1991).  
The main advantage of using infected cell vaccines is that cells do not require 
expensive purification or concentration techniques and so such vaccines are 
more easily produced commercially.  Moreover, inactivated virus infected cells 
may  induce  stronger  humoral  responses  compared  to  inactivated  virus 
vaccines, although the duration of protective immunity may be only short lived 
(Matteucci  et  al.,  1997).    The  commercial  vaccine,  Fel O Vax
®,  consists  of 
inactivated  subtype  A  FIV PET  produced  in  the  cell  line  FL4  (persistently 
infected  with  FIV PET)  and  FeT 1  cells  infected  with  the  subtype  D  FIV 
Shizuoka isolate; the env genes of the two isolates vary as much as 21%.  This 
dual subtype vaccine contains abundant levels of highly stable Env protein, and 
protected cats against both subtype A and D challenges (Uhl et al., 2008; Uhl 
et al., 2002).  The Fel O Vax
® vaccine is approved in USA, Japan, UAE, Canada, 
Australia and New Zealand, but not in Europe. 
 
1.9.3.2 Live attenuated vaccines 
Attenuated virus was tested in a number of vaccine trials with some success.  
Vaccine attenuation leads to a reduction in the virulence of the virus, although 
the  vaccine  virus  remains  viable  and  replication  leads  to  a  more  rapid 
development of an immune response.  FIV can be attenuated in several ways, 
including propagation in vitro, selecting for less virulent strains (Pistello et al., 
1999),  mutagenesis  that  renders  the  virus  non infective  (for  example  by 
inducing mutation at the AP 1 binding site in the FIV transcriptional enhancer 
(Kohmoto et al., 1998)), or targeted deletions in genes required for virulence, 
such as orf-A (Pistello et al., 2005).  It is notable that lion and puma FIV strains 
have been used as attenuated viruses to vaccinate cats, with relative success 
(Vandewoude  et  al.,  2002).    On  the  other  hand,  attenuated  vaccines  are 
associated with safety concerns of potential reversion to virulence as well as 
recombination with live virus (Lockridge et al., 2000) and therefore their use 
may be restricted to the identification of protective immune responses. 
 Chapter one 
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1.9.3.3 Subunit vaccines 
Rather than presenting a whole inactivated or attenuated virus to the immune 
system, a subunit vaccine comprises an immunogenic protein fragment that, 
when combined with adjuvant, induces immune responses.  The majority of FIV 
subunit vaccines have been based on structural proteins, such as Gag or Env.  
Vaccine  trials  have  been  conducted  to  test  recombinant  capsid  protein  p24 
incorporated into immune stimulating complexes (ISCOMs) (Hosie et al., 1992), 
as well as recombinant Env incorporated into ISCOMs (Huisman et al., 1998).  
The  advantage  of  this  approach  is  that  it  permits  the  evaluation  of  the 
immunogenicity  of  particular  protein  subunits,  or  even  a  single  or  multiple 
polypeptides, such as the V3 domain (Lombardi et al., 1994) or the membrane 
proximal region of the extracellular domain of the transmembrane glycoprotein 
(Richardson et al., 1998).  Some success has been demonstrated using subunit 
vaccines,  with  immunisation  leading  to  a  reduction  in  the  viral  burden 
following challenge (Hosie et al., 1996; Leutenegger et al., 1998).  However, 
there are examples also of vaccine trials testing viral subunits that have been 
led to vaccine mediated enhancement (Flynn et al., 1997; Osterhaus et al., 
1996; Pistello et al., 2006). 
 
1.9.3.4 Recombinant and DNA vaccines 
Recombinant  vaccines  utilise  bacterial  or  viral  vectors  to  encode  particular 
immunogen  proteins  by  means  of  gene  transfer.    Feline  herpesvirus  type  1 
(Verschoor et al., 1996), canarypox (Tellier et al., 1998), Salmonella (Tijhaar 
et al., 1997) and Listeria (Stevens et al., 2004) have been commonly used as 
vectors, with full or truncated viral genes as transgenes.  Mutated proviral DNA 
bearing  defective  Vif,  integrase,  or  reverse  transcriptase  coding  genes, 
resulting in reduced viral replicative capacity, have conferred some protection 
(Flynn et al., 2000; Lockridge et al., 2000; Dunham et al., 2006a; Dunham et 
al.,  2002).    Notably,  no  potentiation  of  vaccine efficacy  has  been  obtained 
when  plasmids  containing  INFγ  were  included  (Gupta  et  al.,  2007).  
Recombinant vaccines target cellular rather than humoral immunity, but may 
elicit  humoral  immunity  depending  on  the  biochemical  features  and  the 
intensity  of  expression  of  the  non vectored  targeted  proteins  (Uhl  et  al., 
2002).    Suppression  of  viral  burden, but  not  complete  protection,  following Chapter one 
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challenge has been previously achieved (Hosie et al., 1998).  One approach to 
boost the effect of DNA vaccines is to administer DNA followed by either a dose 
of recombinant vaccine bearing genetically distant viral DNA or a viral subunit 
protein,  aiming  to  broaden  the  immunogenicity  and  enhance  the  humoral 
response (Tellier et al., 1998; Dunham et al., 2006a).  Nonetheless, compared 
to  whole  inactivated  virus  or  cell  vaccines,  DNA  vaccines  have  been  less 
successful and additional studies are required. 
 
1.9.4 Evaluation of vaccine trials 
Many approaches to vaccine development have been tested for FIV, both as a 
veterinary  vaccine  and  as  a  model  for  HIV  vaccines.    Sterilising  immunity 
against homologous virus challenge has been induced by a number of vaccines.  
However, the unsuccessful or partially successful trials have also highlighted 
many important issues and have been valuable in understanding the mechanism 
of vaccine induced protection.  Success and failure are two sides of the same 
coin. 
 
1.9.4.1 Protective vaccines 
Most success has been achieved using inactivated vaccines, particularly against 
more severe challenge systems.  In contrast, subunit vaccines performed feebly 
when used alone.  The protection observed in studies using DNA vaccines is 
promising, although different studies have reported different outcomes which 
remain poorly understood; for example, Hosie et al. (1998) reported significant 
protection  against  challenge  with  the  molecularly  cloned  homologous  PET 
strain following the vaccination of cats with a DNA vaccine based on PET, while 
Richardson  et  al.  (1997)  reported  enhancement  of  infection  rather  than 
protection  using  a  similar  DNA  vaccine  based  on  PET.    Protection  against 
homologous challenge was achieved using inactivated vaccines (Yamamoto et 
al.,  1993;  Hosie  et  al.,  2000;  Elyar  et  al.,  1997),  and  partially  using  DNA 
vaccines (Boretti et al., 2000; Lockridge et al., 2000).  Furthermore, vaccines 
have successfully elicited neutralising responses in closely related heterologous 
challenge  strains  (Hesselink  et  al.,  1999;  Hosie  et  al.,  1995).    The  major 
success in the field of FIV vaccination was afforded by the dual subtype vaccine Chapter one 
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Fel O Vax
®,  which  conferred  protection  against  heterologous  isolates  within 
subtype B (Pu et al., 2005; Kusuhara et al., 2005). 
 
1.9.4.2 Unsuccessful FIV vaccines 
In several trials FIV vaccination did not confer protection against homologous 
challenge, even using vaccines based on laboratory adapted strains (Matteucci 
et al., 1996; Hesselink et al., 1999).  Also, vaccines which provided partial 
protection, although reducing the viral burden following homologous challenge, 
did  not  prevent  infection  and  even  vaccines  that  protected  cats  against 
homologous challenge did not protect against strains from other subtypes (Pu 
et  al.,  2005;  Pu  et  al.,  2001).    Although  there  is  evidence  that  protection 
extends  to  some heterologous  virus  strains,  Fel O Vax
®  did  not  protect cats 
against challenge with GL8 (Dunham et al., 2006b) and a similar, experimental, 
inactivated virus vaccine did not protect against either GL8 or FIV AM6 (Hosie 
et al., 2000; Hosie  et al., 1995).  A major concern that has emerged from 
unsuccessful FIV vaccine trials has been one of safety, since the spectrum of 
outcomes has included enhancement of infection as well as protection.  It is 
hoped  that  much  may  be  learnt  from  unsuccessful  trials  that  will  assist  in 
future vaccine development. 
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1.10 Project aims 
The major aims of this study were as follows: 
i. To investigate the role of NAb in immunity to infection with FIV in naturally 
and experimentally infected cats. 
ii. To develop and optimise a robust, reproducible virus neutralisation assay to 
measure the NAb response generated in vivo, both in naturally infected cats 
and in vaccinates. 
iii. To study in vitro enhancement of FIV infection and evaluate its potential 
impact on vaccine development. 
iv. To examine naturally occurring UK isolates of FIV and assess susceptibility 
to neutralisation by autologous and heterologous plasmas. 
v.  To  identify  neutralisation  determinants  on  Env,  as  potential  FIV  vaccine 
immunogens.Chapter two 
2 Materials and Methods 
 
2.1 Materials and suppliers 
 
AbD Serotec Ltd., Oxford, UK 
Phycoerythrin conjugated rabbit anti mouse IgG, anti CD134, anti CXCR4. 
Abgene, Epsom, Surry, UK 
0.2 ml 96 well PCR plates 
Amersham Pharmacia Biotech UK Ltd., Little Chalfont, Buckinghamshire, UK 
Protein A, protein G, Glutathione Sepharose 4B beads 
Applied biosystem, Warrington, Cheshire, UK 
BigDye  terminator,  v1.1  cycle  sequencing  kit,  Hi Di  formamide,  genetic 
analyser plate septa 
BDH laboratory supplies, Poole, UK 
Sodium acetate, Tween 20, sodium azide, glycerol 
Becton Dickinson labware, Bedford, UK 
10 cm
2 biocoat dishes, 6 well, biocoat plates, 5 ml polystyrene rounded bottom 
tubes, 14 ml polypropylene rounded bottom tubes 
Bioline UK Ltd., London, UK 
Agarose 
Corning Inc., Corning, NY, USA 
5 ml, 10 ml and 25 ml pipettes, 25 cm
2, 75 cm
2, 162 cm
2, 225 cm
2 vented tissue 
culture flasks, 100 mm and 150 mm dishes, 15 ml and 50 ml centrifuge tubes 
Eurofins MWG GmbH, Ebersberg, Germany 
All oligonucleotides used for PCR reactions 
Fisher Scientific UK Ltd., Loughborough, Leicestershire, UK 
Tris base, boric acid, propan 2 ol, ethanol absolute, scalpel blades, NH4Cl 
IDEXX laboratories, Buckinghamshire, UK 
FIV antigen ELISA kit 
Invitrogen Life Technologies Ltd., Paisley, UK 
DH5α supercompetent cells, DNA ligase, Kanamycin Sulphate, Geneticin 418, 
HEPES  (1M),  RPMI  1640,  L glutamine  (200  mM),  penicillin/streptomycin,  5% 
trypsin EDTA, DMEM, PureLink HiPure Filter Plasmid Maxiprep kit, 1 kb ladder, 
dNTPs (25 mM each) Chapter two 
Merck Chemicals Ltd., Beeston, Nottingham, UK 
KOD Hot Start DNA polymerase 
Miltenyi Biotec, Bergisch Gladbach, Germany 
MiniMACS separation columns, goat anti mouse IgG MicroBeads, MACS magnetic 
Separator 
New England Biolabs, Hitchin Herts, UK 
Restriction enzymes, Phusion high fidelity Polymerase kit. 
Oxoid Ltd., Basingstoke, Hampshire, UK 
NaCl,  KCl,  KH2PO4,  Na2HPO4,  bactotryptone,  yeast  extract,  glucose,  MgSO4, 
MgCl2, phenol red, agar 
Perbio Science Ltd., Cramlington, Northumberland, UK 
Foetal Bovine Serum (FBS) 
Perkin Elmer Life & Analytical Sciences, Beaconsfield, Buckinghamshire, UK 
Steadylite HTS luciferase substrate, 96 well CulturePlate, adhesive seal 
Promega UK Ltd., Southhampton, UK 
T4 DNA ligase, nuclease free water 
Qiagen, Crawley, West Sussex, UK 
SuperFect
®Transfection kit, QIAquick gel extraction kit, QIAamp DNA Blood Mini 
Kit, QIAprep Spin Mini Prep kit  
Roche Diagnostics Ltd., Burgess Hill West Sussex, UK 
High fidelity RT Polymerase kit, Complete Protease Inhibitors 
Sigma Aldrich Company Ltd., Poole, Dorset, UK 
BSA,  EDTA,  bromophenol  blue,  DMSO,  spectrophtometer  quartz  cuvet, 
ethidium bromide 
StarLab Ltd., Blakelands, Milton Keynes, UK 
1.5 ml eppendorf tubes. 
Sterilin Ltd., Aberbargoed, Coerphilly, UK 
10 cm
2 agar dishes, 7 ml Bijou tubes, 30 ml Universal tubes 
Stratagene, Amsterdam, Netherlands 
QuikChange site directed mutagenesis kit, XL 1 Blue competent cells 
Thermofisher scientific, Roskilde, Denmark 
NUNC 1.8 ml cryo tubes. 
Vical Inc., San Diego, CA, USA 
VR1012 retroviral plasmid vector 
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VWR International Lutterworth, Leicestershire, UK 
22 mm x 22 mm coverslips 
Weber Scientific International Ltd., Lancing, Sussex, UK 
Haemocytometer 
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2.2 Buffers 
  Gel loading buffer (10x): 60% glycerol, 0.25% bromophenol blue 
  HEPES Buffered Saline (HBS) 2x: 50 mM HEPES, 250 mM NaCl, 1.5 mM NaHPO4; 
pH 7.2 
  LB agar: 1 % bactotryptone, 0.5% yeast extract, 1% NaCl, 7% agar 
  Luria Bertani (LB) medium: 1% bactotryptone, 0.5% yeast extract, 1% NaCl, 
pH 7.4 
  L broth: 1% bactotryptone, 0.5% yeast extract, 0.5% NaCl; pH 7.0 
  MACS buffer: 2 mM EDTA, 0.5% BSA in PBS; pH 7.2 
  PBAz: 1% bovine serum albumin (BSA) and 0.1% sodium azide in PBS 
  PBSA: 1% bovine serum albumin (BSA) in PBS 
  PBST: 0.1% Tween
® 20 in PBS 
  Phosphate buffered saline (PBS) 10x: 137mM NaCl, 27mM KCl, 1.5mM KH2PO4, 
10.2mM Na2HPO4; pH 7.4 
  SOC medium: LB broth, 0.04% glucose, 10 mM MgSO4, 10 mM MgCl2 
  TBE (10x): 1.25 M Tris, 27mM EDTA, 0.4 M boric acid 
  TE buffer: 10 mM Tris.HCl pH 8.0, 1 mM EDTA 
  Versene: 0.6 mM EDTA with 0.002% phenol red in PBS 
  RBC lysis buffer: 0.88% NH4Cl, 10 mM; pH 7.4 
 
Other buffers provided within kits are indicated in methods. Chapter two 
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2.3 Cell culture 
 
All cell culture work was performed employing aseptic techniques with sterile 
equipment and reagents inside a laminar flow hood. 
 
2.3.1 Plasma and PBMC collection 
Blood samples were collected from FIV sero positive samples submitted to the 
Companion Animals Diagnostic Services at the University of Glasgow.  Blood 
samples were centrifuged at 2000 rpm for 10 minutes and the plasma fractions 
were dispensed in 200  l aliquots and stored at  80ºC until required.  To collect 
peripheral blood mononuclear cells (PBMCs), the remainders of blood samples 
were diluted in 1 ml PBS, transferred to a 30 ml universal container containing 
20 ml pre warmed RBC lysis buffer, incubated at room temperature until the 
solution  became  clear  (approximately  10  minutes)  and  then  centrifuged  at 
1000 rpm for  5 minutes.  Supernatant was removed and cells  were washed 
twice with PBSA buffer and pelleted in 1.5 ml eppendorf tubes.  PBMCs were 
either used fresh for co cultivation and virus isolation or stored frozen at  80ºC 
until required for molecular analyses. 
 
2.3.2 Cell lines 
All cells used in this study were grown at 37ºC under 5% CO2 in a humidified 
atmosphere.  To initiate growth of specific cell line, cells were recovered from 
frozen  in  liquid  nitrogen,  thawed  rapidly  at  37ºC  and  washed  in  10  ml  of 
warmed culture medium to ensure complete removal of the DMSO within the 
freezing mix.  The appropriate medium was then used to resuspend the cells 
which were transferred into culture flasks and maintained for a period of time 
sufficient to allow full recovery prior to experimental use or manipulation. 
 
2.3.2.1 MYA 1 
The lymphoblastoid IL 2 dependent MYA 1 cell line (Miyazawa et al., 1989b) 
was  grown  in  RPMI  1640  medium  supplemented  with  10%  heat  inactivated 
foetal  bovine  serum  (FBS),  25  mM  HEPES,  2  mM  L glutamine,  50   M  2 
mercaptoethanol, 100 IU/ml penicillin, 100  g/ml streptomycin, and 100 IU/ml Chapter two 
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human recombinant interlukin 2 (IL 2).  Generally, cultures were subcultured 1 
in  2  at  confluence  so  that  cell  concentrations  of  5x10
5  to  10
6  per  ml  were 
maintained. 
 
2.3.2.2 CLL CD134 
This cell line was derived from cells isolated from a canine chronic lymphocytic 
leukaemia  that  were  transduced  with  a  retroviral  vector  expressing  feline 
CD134.  Feline CD134 expressing cells were enriched twice using magnetic cell 
sorting  (section  2.3.4).    Cells  grow  in  suspension  and  were  routinely 
subcultured every 3 4 days by dilution (1:10) into fresh culture medium.  Cells 
were  maintained  in  RPMI  1640  medium  supplemented  with  10%  heat 
inactivated FBS, 25 mM HEPES, 2 mM L glutamine, 50  M 2 mercaptoethanol, 
100 IU/ml penicillin, and 100  g/ml streptomycin, and selected with 400  g/ml 
Geneticin 418. 
 
2.3.2.3 HEK293T 
Human  embryonic  kidney  cells  stably  expressing  the  SV40  large  T antigen, 
known as 293T cells (DuBridge et al., 1987), were grown in DMEM with high 
glucose  (4.5  g/l)  supplemented  with  10%  heat  inactivated  FBS,  2  mM  L 
glutamine,  1  mM  sodium  pyruvate,  100  IU/ml  penicillin,  and  100   g/ml 
streptomycin, and selected with 400  g/ml Geneticin 418.  Cells were typically 
grown in 75 cm
2 flasks.  For serial passage, the growth medium was removed 
and confluent cell monolayers were washed with 5 ml PBS to remove all traces 
of serum that contains trypsin inhibitor, then treated with 2 ml 10% trypsin in 
versene (2 ml 0.25% trypsin EDTA in 20 ml versene) and incubated at 37ºC for 
5 10 minutes.  Once the cell layer had detached, cells were washed with 5 ml 
of fresh medium, centrifuged at 1000 rpm for 5 minutes, resuspended in fresh 
medium and subcultured at a ratio of 1 in 5. 
 
2.3.3 Cell staining for flow cytometry 
Cells were regularly  examined for the expression of both CD134 and CXCR4 
receptors.  10
6 cells were pelleted in a 5 ml polystyrene tube by centrifugation 
at 1000 rpm for 5 minutes and culture medium was removed.  Cell pellets were 
re suspended in 10  l of 100 mg/ml anti CD134 (7D6) or anti CXCR4 antibody Chapter two 
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(Ab) and stored in the dark at 4ºC for 30 minutes.  The cells were then washed 
in 2 ml PBAz buffer to remove unbound Abs.  Bound Ab was detected following 
incubation  with  Phycoerythrin  (PE) conjugated  rabbit  anti mouse  IgG  for  15 
min in the dark at room temperature.  Finally, cells were washed again and re 
suspended in 1 ml PBAz. 
Samples were analysed using a Coulter Epics LX MCL FACScan (Beckman Coulter 
Inc., Fullerton, CA, USA) with a laser at 488 nm and ‘Expo32 v1.2 Cytometry 
List Mode Data Acquisition and Analysis Software’.  Analysis was performed on 
10,000 events. 
 
2.3.4 Magnetic cell sorting 
CLL CD134  cells  (approximately  2x10
7)  were  pelleted  in  a  15  ml  tube  by 
centrifugation at 1000 rpm for 5 minutes and culture medium was removed.  
Cell pellets were re suspended in 100  l anti CD134 (100 mg/ml) and incubated 
at 4ºC for 30 minutes.  After being washed in 1 ml MACS buffer, cells were 
suspended in 20  l goat anti mouse IgG microbeads and incubated at 4ºC for 15 
minutes.    Meanwhile,  a  MACS  column  was  placed  in  the  MACS  magnetic 
Separator  and  500   l  MACS  buffer  was  allowed  to  flow  through  by  gravity.  
Cells were washed in 5 ml MACS buffer and then suspended in 500  l before 
being applied to the column.  The column was washed twice with 500  l MACS 
buffer so that unlabelled cells were washed out and discarded.  The column 
was then removed from the magnet prior to the addition of 1 ml MACS buffer 
and the depleted cells were collected by pressing a plunger into the column.  
Cells were suspended with RPMI 1640 and cultured at 37ºC in 5% CO2.  Receptor 
expression was estimated by flow cytometry (section 2.3.3). 
 
2.3.5 Virus neutralisation assay 
The assay was optimised as described in detail in chapter 3.  Subsequently, 
assays  were  set  up  in  triplicate  wells  of  96 well  flat bottom  tissue  culture 
plates, incubating 25  l of heat inactivated plasmas with 25  l of luciferase 
HIV(FIV)  pseudotype  viruses  (4  tenfold  serial  dilutions  starting  at  1  in  10 
dilution) for 1 h at 37ºC and then adding 50  l of 5x10
5 cell/ml CLL CD134 cells 
(or  1x10
6  MYA 1).    Neutralising  activity  was  determined  after  72  hours  in 
culture, following the addition of 100  l steadylite HTS substrate, by measuring Chapter two 
  43 
the luciferase activity in a 1450 MicroBeta Liquid Scintillation and Luminesence 
Counter (Perkin Elmer).  Data was analysed using SigmaPlot software, version 
8.02.  Percent neutralisation was calculated as follows:  
(No plasma luc activity – plasma luc activity) / no plasma luc activity * 100. 
Empirical cut off values of greater than 80% or 60% were considered as strong 
and moderate neutralisation respectively. 
  
2.3.6 Transient transfection and pseudotype production 
To prepare pseudotypes, 293T cells were transfected with VR1012 expressing 
the  FIV  env  clone  and  a  second  plasmid,  pNL Luc E R
+,
  that  incorporates  a 
luciferase reporter gene.  For transient transfection, 2x10
6 cells were seeded 
into a 10 cm
2 biocoat culture dish in 10 ml complete DMEM medium and grown 
overnight until 60 80% confluent.  Transfection complex was then prepared by 
adding 7.5  g of each of FIV env-expressing VR1012 and pNL Luc E R
+ plasmids 
to 300  l of serum free DMEM and 60  l of SuperFect
® reagent, mixed well and 
left at room temperature for 15 minutes.  The transfection complex was added 
dropwise to the cells and incubated for 3 hours at 37ºC in an atmosphere of 5% 
CO2  before  replacing  the  medium  with  fresh  complete  DMEM.    Cells  were 
washed  with  4  ml  PBS  before  and  after  applying  the  transfection  complex.  
Cells were then grown for 48 72 hours at 37ºC in an atmosphere of 5% CO2.  
Pseudotype containing media were collected in 15 ml tubes and centrifuged at 
2000 rpm for 10 minutes or passed through a 0.45  m syringe operated filter 
and each pseudotype titre was measured before stocks were aliquoted in cryo 
tubes and stored at  80ºC until required. 
To produce a large batch of GL8 pseudotype, 293T cells were transfected using 
the calcium phosphate co precipitation method.  Accordingly, 5x10
6 cells were 
seeded into 15 cm
2 culture dishes in 20 ml complete DMEM and grown overnight 
to  80%  confluency.    On  the  day  of  transfection,  15   g  of  each  of  VR1012 
expressing GL8 env and pNL Luc E R
+ plasmids were mixed in a 30 ml universal 
tube and the volume was brought to 4 ml by adding 0.01 M Tris HCl buffer (pH 
8).    Then  560   l  of  2M  CaCl2  was  added  slowly  and  the  mix  was  shaken 
vigorously  for  15  seconds.    Keeping  continuous  mixing  by  air bubbling  the 
mixture, 4.5 ml 2x buffer HBS was carefully added.  The complex DNA/CaPO4 
was incubated 30 minutes at 37ºC and added dropwise to the cells.  The cells Chapter two 
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were incubated overnight at 37ºC in 5% CO2 and then the medium was replaced 
with 20 ml fresh complete DMEM, before being incubated at 37ºC in 5% CO2 for 
48 hours.  Pseudotype containing medium was collected in a 50 ml tube and 
centrifuged at 2000 rpm for 10 minutes.  The luciferase titre was measured 
before  pseudotypes  were  aliquoted  in  cryo tubes  and  stored  at   80ºC  until 
required. 
 
2.3.7 Virus isolation 
Fresh PBMC (section 2.3.1) were washed and co cultivated with 2x10
6 MYA 1 
cells in 5 ml complete RPMI 1640 in a 25 cm
2 culture flask and observed for 
cytopathic  effect.    Once  cytopathic  effect  was  evident  (cell  swelling, 
syncytium formation and cell death) the culture was tested for p24 production 
by  FIV  antigen  ELISA  (section  2.3.8).    Antigen  (p24)  positive  cultures  were 
centrifuged at 1000 rpm for 5 minutes and supernatants were aliquoted and 
stored at  80ºC until required.  Cells were washed in PBS and either used fresh 
for DNA extraction or stored at  80ºC until required. 
Virus  could  also  be  isolated  by  infecting  CLL CD134  cells  with  1  ml  of  p24 
positive tissue culture supernatant or 200  l of plasma, as described above. 
 
2.3.8 FIV p24 antigen detection 
To confirm successful isolation of the virus, FIV antigen ELISA kits were used in 
accord with the manufacturer’s instructions.  Briefly, 200  l cell free culture 
fluid  was  incubated  with  20   l  sample  treatment  solution  in  an  anti FIV 
antibody coated well for 30 minutes at room temperature.  This allows viral 
lysis and FIV p24 capture.  The solution was then aspirated off and the well 
washed  thoroughly  with  PBST  buffer  before  200   l  of  anti FIV  Horseradish 
Peroxidase (HRP) conjugate was added and incubated for 15 minutes before a 
second wash step.  Then 200  l of chromagen substrate was added and left for 
30  minutes.    Stop  solution  (100   l)  was  added  and  the  absorbance  was 
measured  at  650  nm  using  a  spectrophotometer.    All  incubations  were 
conducted at room temperature.  For each test, positive and negative controls 
(provided with the kit) were tested in parallel, the difference in absorbance 
between  the  positive  and  negative  being  ≥  0.500.    The  assay  cut off  was 
estimated as the negative control absorbance plus 0.150 Chapter two 
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2.3.9 Cryogenic preservation and storage 
To create frozen cell stocks, cells were grown in 225 cm
2 flasks and, when 
confluent, they were pelleted by centrifugation at 1000 rpm (800 rpm for MYA 
1 cells) for 5 minutes and re suspended in a solution containing 70% complete 
medium, 20% heat inactivated FBS and 10% dimethylsulphoxide (DMSO).  Cells 
were  aliquoted  into  cryo tubes,  each  containing  10
7  logarithmically  growing 
cells,  properly  labeled,  placed  in  a  cryo freezing  container  (Nalgen,  USA) 
jacketed with propan 2 ol and frozen at  80ºC overnight before being placed in 
the vapour phase of liquid nitrogen for long term storage. Chapter two 
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2.4 Molecular biology 
 
2.4.1 DNA Extraction 
QIAamp DNA Blood Mini Kits were used to extract DNA from PBMCs and cultured 
cells.  All extractions were performed in a room designated for Category 2 
work (pre PCR room).  Precautions were taken to avoid cross contamination 
between samples, including cleaning the bench thoroughly, placing samples in 
multiple racks, keeping sufficient space between samples in the same rack, 
using  aerosol barrier  pipette  tips,  changing  pipette  tips  between  all  liquid 
transfers and regular glove changes during each procedure. 
As per the manufacturer’s instructions, up to 10
7 cells were suspended in 200 
 l  PBS  and  then  added  to  20   l  proteinase  K  (0.15  mg/ml)  in  a  1.5  ml 
eppendorf tube, before the addition of 200  l lysis buffer (AL) (all buffers and 
components supplied with kit).  The lysate was mixed using a vortex for 15 
seconds  and  then  incubated  at  56ºC  for  10  minutes;  then  200   l  of  100% 
ethanol was added prior to mixing for 15 seconds using a vortex.  The solution 
was transferred to a QIAamp Mini spin column and centrifuged at 8000 rpm for 
1  minute.    The  column  was  washed  twice  with  500   l  AW1  and  AW2 
respectively and placed on a clean 1.5 ml eppendorf tube and centrifuged at 
13000 for 1 minute.  DNA was then eluted in 50 – 100  l buffer EB and used 
immediately  in  PCR  (section  2.4.2)  after  quantification  (section  2.4.11),  or 
aliquoted and stored at  20ºC until required. 
 
2.4.2 Polymerase chain reaction  
Polymerase chain reactions (PCR) were performed in a PCR workstation with 
laminar  flow  under  conditions  designed  to  prevent  cross  contamination.  
Reagents  and  DNA  samples  were  stored  at   20ºC  and  defrosted  at  room 
temperature.  Equipment was sterilised under UV light for 10 minutes before 
the  work  commenced  and  was  kept  separate  from  that  used  for  other 
techniques within the laboratory. 
Conditions were altered according to the requirements of the PCR product, in 
order to optimise the purity and efficiency.  The plasmid pBR GL8 Mya, which Chapter two 
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contains one full length GL8 genome, and distilled water were included in each 
batch of samples as positive and negative controls respectively.  All PCR were 
performed  using  a  GeneAMP  PCR  system  9700  Thermocycler  (Applied 
Biosystems).  FIV env genes were amplified from genomic DNA (gDNA) using the 
following PCR systems. 
 
2.4.2.1 Phusion high fidelity polymerase kit 
The following conditions were used in a 2 round nested protocol:  
The first round mixture contained 4  l high fidelity (HF) Buffer (supplied in the 
kit), 0.16  l 25 mM dNTPs, 1  l (10 mM stock) primers, 0.8 l DMSO, 0.2  l (1U) 
Phusion  Polymerase, 0.2 1.2   g  purified  gDNA  and  nuclease free  water to a 
total volume of 20  l.  First round thermocycling conditions were as shown in 
Table 2.1a. 
The second round mixture contained 4  l HF Buffer, 0.16  l 25 mM dNTPs, 1  l 
(10 mM stock) primers, 0.6  l DMSO, 0.2  l (1U) Phusion polymerase, 2  l first 
round PCR product and nuclease free water to a total volume of 20  l.  Second 
round thermocycling conditions were as shown in Table 2.1b. 
 
Table 2.1a. 
 
Cycle step  Temperature  Time  Number of cycles 
Initial denaturation  98ºC  2 minutes  1 
Denaturation  98ºC  10 seconds 
Annealing  58 64ºC  30 seconds 
Extension  72ºC  90 seconds 
35 
Final extension  72ºC  10 minutes  1 
Hold  4ºC  ∞  1 
 
Table 2.1b. 
Cycle step  Temperature  Time  Number of cycles 
Initial denaturation  98ºC  1 minute  1 
Denaturation  98ºC  10 seconds 
Annealing  64 68ºC  30 seconds 
Extension  72ºC  75 seconds 
30 
Final extension  72ºC  10 minutes  1 
Hold  4ºC  ∞  1 Chapter two 
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Table  2.1.    Thermocycling  conditions  for  polymerase  chain  reaction  using 
phusion high fidelity polymerase kit, (a) shows the first round and (b) shows 
the second round. 
 
2.4.2.2 Hot start KOD high fidelity polymerase kit 
PCR reactions contained 2  l 10x buffer, 2  l 2 mM dNTPs, 1  l (10 mM stock) 
primers,  1.2   l  MgSO4,  1   l  DMSO,  0.4   l  (1U)  KOD  polymerase,  0.2 1.2 g 
purified gDNA and nuclease free water to a total volume of 20  l.  PCR was 
performed under the conditions described in Table 2.2.  Primers used to clone 
and sequence the FIV env genes are shown in Table 2.3. 
 
Cycle step  Temperature  Time  Number of cycles 
Initial denaturation  95ºC  2 minutes  1 
Denaturation  95ºC  20 seconds 
Annealing  69ºC  10 seconds 
Extension  70ºC  13 minutes 
35 
Final extension  70ºC  10 minutes  1 
Hold  4ºC  ∞  1 
Table 2.2.  Thermocycling conditions for polymerase chain reaction using Hot 
start KOD high fidelity polymerase kit. Chapter two 
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5’￿ 3’ sequence  Name  Description 
of use 
Binding site 
(GL8–antisense) 
GTCGACTGGCAGGTAAGTAGAGA
GCTCTTTGC  5340Sal1   env cloning  5244   5275 
GCGGCCGCCATCATTCCTCCTCTT
TTTCAG  XG8Not1   env cloning  8812   8841 
GGATGAGTGACGAAGATTGGCAG  AF2  PCR 
amplification  5233   5255 
CCTTGTAACCAAGTATCTACTC  AnaSeqR   env 
sequencing  7126   7147 
TATTATTGGCA(AG)TTGCAATCTA
C(AC)TTATC  2F2  PCR 
amplification  6183   6211 
TGTAATCAACG(CT)TTTGT(AG)TC
TCCTTACAG  1F4  PCR 
amplification  5892   5920 
CCAATA(AC)TCCCAGTCCACCCTT  1R4  PCR 
amplification  9103   9124 
GGGTCGACACCATGGCAGAAGGG
TTTGCAGCA  G8Sal1F   env cloning  6256   6285 
GGGCGGCCGCCATCATTCCTCCTC
TTTTTCAGAC  G8Not1R   env cloning  8810   8843 
AGACTTTACAAAGACTCGCTATGT
TGGC  1F5  PCR 
amplification  5830   5857 
CTATGAAAATAGAGGACC  JAPSeqF  Confirm 
mutagenesis  7789 – 7806* 
CCTCAAAGGGAAGAAATCAGCTCA  XR2  PCR 
amplification  8869   8892 
CTGGGTTATACCAATTTCTTAAG  V6RSeq   env 
sequencing  7967   7999 
GGTGTGGAGATTGTTGGAATTTAA
TG  AF1  PCR 
amplification  5782   5807 
GCTAACATAACATGAATAGC  1790SeqR   env 
sequencing  8097   8116 
CATCCTAATTCTTGCATAGC(AG)A
AAGCG  AySeqR   env 
sequencing  8330   8357 
AACCTAACCTTTGCAATGAGAAGT  V3R   env 
sequencing  7527   7550 
GTATCTGTGGGAGCCTCAAGG  AR1  PCR 
amplification  9352   9380 
TTTTTTGGGATTGTTGGGC  550SeqF   env 
sequencing  6841   6859 
Table 2.3.  Oligoneucleotides used in env gene cloning and sequencing, a brief 
description of use and their binding sites based on the 5’ sequence of GL8 
virus.   
* sequence based on TOT1 sequence. 
 
 Chapter two 
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2.4.3 DNA gel electrophoresis 
PCR products or digested DNA samples (section 2.4.5) were examined by gel 
electrophoresis to ensure correct ligation of constructs, to isolate a plasmid 
vector  or  to  separate  and  identify  PCR  products.    A  0.8%  agarose  gel  was 
prepared by mixing agarose with 1x TBE buffer and heating until the agarose 
had melted, then 1  l of ethidium bromide (10 mg/ml) was added and the gel 
was poured into trays with the appropriately sized comb.  The gel was left to 
set before immersion in 1x TBE buffer in a horizontal gel tank.  Samples were 
mixed with 10x DNA loading buffer and loaded alongside a 1 Kb ladder to assess 
the fragment sizes and gel were electrophoresed at 100 V / 75 mA for 40 60 
minutes.  DNA fragments were visualised under UV transillumination (Syngene 
Bio  Imaging,  Cambridge,  UK)  and  photographed;  otherwise  DNA  bands  were 
excised and gel purified (section 2.4.4). 
 
2.4.4 DNA purification from agarose gels 
DNA was visualised under UV transillumination (UltraViolet Products Inc., San 
Gabriel, CA, USA).  Appropriate DNA fragments were excised from the gel using 
a clean scalpel blade and purified using the QIAquick gel extraction kit as per 
the manufacturer’s instructions.  Briefly, DNA gel fragments were dissolved in 
buffer QG for 10 minutes at 50ºC (all buffers and components supplied with 
kit).  One gel volume of propan 2 ol was added and the solution transferred to 
a  QIAquick  column  and  spun  at  13000  rpm  for  1  minute.    The  column  was 
washed using buffer PE and DNA was eluted in 50  l buffer EB. 
 
2.4.5 Restriction endonuclease digestion 
Restriction digests of DNA were performed before PCR fragments and purified 
plasmid DNA were sub cloned, in order to ensure successful ligation.  Digests 
were usually prepared in a final volume of 20  l, containing 2  l buffer and 
restriction enzymes as directed by the manufacturer.  Restriction enzymes and 
DNA concentration were adjusted, assuming that 1 U of the enzyme is capable 
of completely digesting 1  g of DNA in 1 hour at the appropriate temperature.  
Enzyme  was  occasionally  added in excess,  based on  the purity  of  the  DNA.  
Purified PCR products or plasmid DNA were double digested with NotI and SalI.  Chapter two 
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Reactions  were  incubated  at  37ºC  for  a  minimum  of  1  hour  before  being 
examined by DNA gel electrophoresis (section 2.4.3). 
 
2.4.6 DNA ligations 
Ligated constructs were generated by ligating NotI SalI double digested PCR 
fragments  into  plasmid  vector  using  T4  DNA  ligase.    For  each  construct,  a 
typical ratio of 1:3 of vector to PCR product was used in a volume of 20  l 
containing 1  l of ligase and 2  l of the supplied buffer.  The reaction was 
incubated at 15ºC approximately for 16 hours.  The  ligation reactions were 
transformed as detailed in section 2.4.8.  The remainders were stored at  20ºC. 
 
2.4.7 Preparation of antibiotic agar plates 
LB agar was autoclaved and allowed to cool prior to the addition of kanamycin 
as a selection antibiotic at the final concentration of 30  g/ml.  The medium 
was mixed gently and approximately 25 ml poured into 10 cm
2 petri dishes.  
The dishes were left to allow the agar to set at room temperature before being 
either  used  or  stored  at  4ºC.    Unused  plates  were  disposed  of  two  weeks 
following preparation. 
 
2.4.8 Transformation 
E.Coli DH5α supercompetent cells or XL 1 Blue supercompetent cells stored at 
 80ºC  were  thawed  on  ice  and  aliquoted  in  40   l  amounts  into  pre chilled 
plastic 14 ml Falcon round bottomed tubes.  DNA ligations were diluted in TE 
buffer (pH 7.5) at 1:5 and then 4  l (0.5 1  g) was added to the cells and 
incubated on ice for 30 minutes.  The cells were then subjected to a heat 
shock at 42ºC for 45 seconds, incubated on ice for 2 minutes and then 400  l of 
SOC medium was added and cells were incubated for one hour at 37ºC in a 
shaking incubator at 225 rpm.  The mixture was spread onto two agar plates 
(section 2.4.7).  Plates were then incubated for 24 48 hours at 30ºC, to allow 
slow bacterial growth because of the instability of the primary FIV env genes.  
Colonies  were  picked  from  the  plates  and  cultured  as  described  in  section 
2.4.9.  For long term storage, 812  l of bacterial culture were mixed with 188 
 l of 80% sterile glycerol in a cryo tube and stored at  80ºC. Chapter two 
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2.4.9 Small scale DNA preparation 
Starter  cultures  were  generated  by  inoculating  4  ml  L broth  containing 
kanamycin (30  g/ml) with a single bacterial colony.  This was placed in a 
shaking incubator (200 rpm) at 30ºC for 24 hours before 1.5 ml of the bacterial 
culture were transferred into a clean 1.5 ml eppendorf tube.  The bacteria 
were pelleted by centrifugation at 3000 rpm for 5 minutes and plasmid DNA 
was  extracted  using  the  QIAprep  Mini Prep  Kit  according  to  manufacture’s 
guidelines, as follows: 
The bacterial pellet was re suspended in 250  l buffer P1 and the cells lysed by 
the addition of 250  l buffer P2 (all buffers and components supplied with kit).  
The resulting lysate was neutralised with 350  l of buffer N3 to precipitate any 
unwanted chromosomal DNA.  Precipitated chromosomal DNA was removed by 
centrifugation at 13,000 rpm for 10 minutes and the supernatant was applied 
to a QIAprep spin column.  The column was washed with 500  l buffer PB, and 
then 750  l buffer PE.  DNA was eluted in 50  l buffer EB and was analysed by 
digestion with the appropriate restriction endonucleases (section 2.4.5). 
 
2.4.10 Large scale DNA preparation 
To achieve greater amounts of purified DNA, PureLink HiPure Filter Plasmid 
Maxiprep kit was used according to the manufacturer’s instructions.  Briefly, 2 
ml of the starter culture was used to inoculate a 200 ml LB culture containing 
30  g/ml kanamycin in a conical flask and grown for 24 48 hours at 30ºC in a 
shaking incubator at 200 rpm.  Bacterial cultures were spun at 5000 rpm using 
a Beckman Coulter JA10.500 rotor (Galway, Ireland) for 10 minutes at 4ºC, and 
the  resulting  supernatant  was  discarded.    The  bacterial  pellet  was  re 
suspended in 10 ml of chilled buffer R3 and lysed with 10 ml buffer L7 (all 
buffers and components supplied with kit).  The lysate was incubated at room 
temperature for 5 minutes and then neutralised by 10 ml buffer N3 in order to 
precipitate  any  unwanted  chromosomal  DNA.    Meanwhile,  a  HiPure  Filter 
column was equilibrated by adding 30 ml buffer EQ1 into the filter cartridge, 
placed  inside  the  column.    The  lysate  was  then  passed  through  the  filter 
cartridge into the column.  The filter was removed and the column was washed 
with 50 ml of buffer W8.  DNA was eluted in 15 ml buffer E4 in a clean 50 ml 
centrifuge  tube,  precipitated  by  adding  10.5  ml  isopropan 2 ol  and  spun  at Chapter two 
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3500 rpm for 30 min at 4ºC.  The DNA pellet was washed with 1.5 ml 70% 
ethanol, transferred to a 1.5 ml eppendorf tube and centrifuged at 13000 rpm 
for 5 min.  The supernatant was carefully removed and the DNA pellet was air 
dried prior being resuspended in 500  l buffer TE and transferred to a fresh 
eppendorf tube.  DNA was quantified, aliquoted, and stored at  80ºC. 
 
2.4.11 DNA quantification 
Quantification of DNA samples was performed by measuring the absorbance of 
a  1:200  dilution  of  the  sample  at  a  wavelength  of  260  nm  to  give  a 
spectrophotomeric  measurement  of  the  amount  of  ultraviolet  radiation 
absorbed by DNA bases.  An absorbance at 260nm (OD260 value) of 1 unit was 
assumed to correspond to 50  g/ml of double stranded DNA. 
DNA concentrations were calculated using the following formula: 
Sample concentration = OD260 X dilution factor (200) X 50 ( g/ml) 
The OD280 value of each sample was also measured to assess the purity of the 
DNA solution.  A DNA solution with OD260/OD280 ratio of 1.8 represents a pure 
preparation.  Values between 1.7 and 2.0 were considered sufficiently pure. 
 
2.4.12 DNA sequencing of PCR products 
Purified PCR products were sequenced using the Big Dye Terminator V1.1 kit.  
The  reaction  mixture  consisted  100   g/ l  purified  DNA,  0.32   l  sequencing 
primers (10 mM stock), 4  l sequencing buffer, 2  l sequencing enzyme and 
nuclease free water to a total volume of 20  l.  Cycling conditions were as 
shown in Table 2.4. 
 
Cycle step  Temperature  Time  Number of cycles 
Initial denaturation  96ºC  1 minute  1 
Denaturation  96ºC  10 seconds 
Annealing  50ºC  5 seconds 
Extension  60ºC  4 minutes 
25 
Hold  4ºC  ∞  1 
Table 2.4.  Thermocycling conditions for sequencing. 
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Sequencing reactions were then purified using the following procedure.  The 
volume of each reaction was adjusted to 100  l by adding 80  l sterile distilled 
water  and  the  mixes  were  transferred  to  1.5  ml  eppendorf  tubes.    To 
precipitate DNA, 200  l 100% ethanol and 1  l 3M sodium acetate were added, 
the solutions were mixed well and then incubated at  70ºC for 30 minutes.  
Tubes were centrifuged at maximum speed for 10 minutes and supernatants 
were  discarded.    DNA  pellets  were  washed  with  200   l  70%  ethanol  and 
centrifuged again at maximum speed for 10 minutes.  The supernatants were 
carefully removed and DNA pellets were air dried, re suspended in 20  l buffer 
Hi Di, transferred to a 0.2 ml 96 well PCR plate and covered with a stratum.  
Sequencing  was  performed  using  the  ABI3700  automated  capillary  array 
sequencer.    Raw  chromatograph  data  were  analyzed  using  ‘Contig  Express’ 
sequence analysis software within the Vector NTI suite of programs. 
 
2.4.13 Multiple alignments and phylogenetic analysis 
Nucleotide  sequence  analysis  was  performed  on  a  651  nucleotide  fragment 
spanning  the  V3 V5  region  of  the  FIV  env  gene.    The  generated  consensus 
sequence  comprised  sequences  of isolates included  in  the  study,  as  well  as 
reference sequences.  Multiple alignments were performed using the ClustalX 
(version 2.0.1)(Larkin et al., 2007) and BioEdit (version 7.0.9.0) applications, 
followed  by  manual  adjustment  to  maximise  similarities.    Alignments  were 
translated  and  the  resulting  amino  acid based  alignments  were  used  as  an 
exact  guide  for  re positioning  of  improper  gapping,  particularly  where 
sequences  differed  in  length.    DNA  distance  matrices  were  calculated  with 
DNADIST from the PHYLIP software package (version 3.68, 2008)(Felsenstein, 
1989) using the F84 model and an empirical transition/transversion ratio of 2.  
Phylogenetic  trees  were  constructed  by  the  neighbour joining  method.  
Robustness of the tree was evaluated by bootstrap analysis on 1000 replicates 
to assess the support at each of the internal nodes of the neighbour joining and 
minimum evolutionary trees.  To compare different measures, additional trees 
were created by the maximum likelihood using DNAML with the substitution 
model of HKY85, assuming two rates of variability along the alignment. Amino 
acid  alignments  were  analysed  with  PROTDIST  to  create  distance  matrices 
based on the Dayhoff PAM model prior to constructing the neighbour joining Chapter two 
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tree.  The phylogenetic trees were committed for final editing and graphical 
representation using MEGA 4 (Tamura et al., 2007). 
 
2.4.14 Site directed Mutagenesis 
The QuickChange II site directed mutagenesis kit was used to induce mutations 
in  the  FIV  env  gene.    According  to  the  manufacturer’s  protocol,  a  50   l 
reaction contained 50 ng of DNA (VR1012 plasmid carrying FIV env gene), 125 
ng of each of the primers, 10 × Pfu reaction buffer, 1  l of dNTP mix (0.2  M), 
and 2.5 U PfuUltra
® high fidelity DNA polymerase.   
Reactions were cycled under the cycling conditions described in Table 2.5. 
 
Cycle step  Temperature  Time  Number of cycles 
Initial denaturation  95ºC  30 seconds  1 
Denaturation  95ºC  10 seconds 
Annealing  50ºC  1 minute 
Extension  68ºC  13 minutes 
12 18 
Hold  4ºC  ∞  1 
Table 2.5.  Thermocycling conditions for site directed mutagenesis PCR. 
 
The product was treated with 1 l (10U) DpnI endonuclease at 37ºC for 1 hour, 
in order to digest the methylated parental DNA template.  DpnI treated DNA 
was then transformed into XL1 Blue Supercompetent
® cells, and the env gene 
was sequenced to confirm the mutation.  Primers sequences are detailed in 
Table 2.6. Chapter two 
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Primer sequence (5’ ￿ 3’)  Description of use 
CAAATGGAACTGATAATAGTAAGACAAAAATG
GCATGCCCTGAG  
F primer, to induce 6 bp insertion 
AAGACA (Arg & Thr) in V5 
CTCAGGGCATGCCATTTTTGTCTTACTATTAC
AGTTCCATTTG 
R primer, to induce  
6 bp insertion in V5 
GTGACATTTCAGTGTCACAGAACACAAAGTCA
ATC 
F primer, to induce 
substitution Gln￿His in V3 
GATTGACTTTGTGTTCTGTGACACTGAAATGT
CAC 
R primer, to induce  
substitution (Gln￿His) in V3 
GATATTTGAATTGTAATTGTACAAATGGAACT
GAT 
F primer, to induce 
substitution Ser ￿Asn in V5 
ATCAGTTCCATTTGTACAATTACAATTCATATA
TC 
R primer, to induce 
substitution Ser ￿Asn in V5 
CAAATGGAACTGATAATAGTAAGAAAATGGCA
TGCCCTGAG 
F primer, to induce 3 bp 
insertion AAG (Arg) in V5 
CTCAGGGCATGCCATTTTCTTACTATTACAGT
TCCATTTG 
R primer, to induce  
3 bp insertion in V5 
GTACAAATAGCACAGTATACAGTGATACTAAA
ATGAC 
F primer, to induce substitution 
NGNDN ￿ DNSDT in V5 
GTCATTTTAGTATCACTGTTATCTGTGCTATTT
GTAC 
R primer, to induce substitution 
NGNDN ￿ DNSDT in V5 
CAAGGAAAAGTAAGTATATCATTATGTC  F primer, to reinstate PNGS in 
V1/V2 analogue 
GACATAATGATATACTTACTTTTCCTTG  R primer, to reinstate PNGS in 
V1/V2 analogue  
GGATGTCATAGAAACAAAAGCCAATTTCATGA
TG 
F primer, to induce 
substitution Asn￿Lys in C3 
CATCATGAAATTGGCTTTTGTTTCTATGACAT
CC 
R primer, to induce 
substitution Asn￿Lys in C3 
Table 2.6.  Oligonucleotides used in mutagenesis in this research, with a brief 
description of use. 
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3 The development and optimisation of an in vitro assay 
to detect virus neutralising antibodies 
 
3.1 Introduction 
It  is  generally  accepted  that  it  will  be  important  for an effective  lentiviral 
vaccine to elicit neutralising antibodies (NAbs).  Therefore, it is important to 
develop an assay that is robust, sensitive, quantitative and reproducible, in 
order  to  monitor  adequately  neutralisation  breadth  and  potency  and  to 
compare the efficacy of candidate FIV immunogens. 
The first neutralisation assays to be developed for FIV used a Crandell feline 
kidney (CrFK) cell based assay system (Fevereiro et al., 1991; Siebelink et al., 
1995b; Tozzini et al., 1992) because infection with isolates adapted for growth 
in CrFK cells produced syncytia that could be enumerated.  Using CrFK based 
assays,  it  was  demonstrated  that  sera  collected  from  naturally  and 
experimentally infected cats in the United States and Europe contained NAbs.  
Subsequently  it  was  shown  that  assays  employing  CrFK adapted  isolates 
detected  antibodies  that  bound  a  linear  neutralisation  site  within  the  third 
hypervariable (V3) region of the FIV envelope (Env) (Lombardi et al., 1993).  
During adaptation for growth in CrFK cells, an E to K mutation within V3 was 
observed (Siebelink et al., 1995a; Verschoor et al., 1995) and, consequently, 
CrFK based neutralisation assays emphasised the role of antibodies directed at 
the V3 region of Env. 
CrFK adapted  primary  isolates  such  as  GL8  were  poorly  cross neutralised  by 
antibodies raised against the laboratory adapted isolate FIV PET (Osborne et 
al., 1994; Talbott et al., 1989).  A survey of plasma samples from naturally 
infected  cats  demonstrated  that  primary  viruses  with  the  reactivity  of  GL8 
were common (Osborne et al., 1994) and it was necessary to develop other 
neutralisation assay formats that did not require prior adaptation of primary 
isolates to CrFK cells.  When assays were developed using IL2 dependent T cell 
lines, viruses resisted neutralisation by sera with high titres of NAbs on CrFK 
based neutralisation assays (Baldinotti et al., 1994), suggesting that regions of 
Env other than V3 could be targets also for NAbs.  Subsequently other lymphoid 
cell based assays have been developed using the IL 2 dependant cell lines MBM Chapter three 
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(Baldinotti et al., 1994; Del Mauro et al., 1998) and MYA 1 (Inoshima et al., 
1998). 
For  HIV,  a  number  of  neutralisation  assays  has  been  developed  to  detect 
antibodies elicited by either potential vaccine immunogens or following natural 
infection and two assay formats have emerged.  The “gold standard” utilises 
primary  peripheral  blood  mononuclear  cells  (PBMCs)  as  the  target  cell  and 
uncloned primary clinical (field) isolates.  In this assay system, freshly isolated 
PBMCs are stimulated with phytohemagglutinin (PHA) and cultured with IL 2 
before infection in the presence or absence of test antibodies.  The endpoint 
measure is the inhibition of viral infection based on the detection of HIV p24 
antigen  in  the  culture  fluids.    The  main  limitation  of  this  system  is  the 
differential  susceptibility  of  PBMCs  to  infection,  which  affects  the 
reproducibility of the assay system (Brown et al., 2005). 
An  alternative  assay  format  utilises  pseudotyped  viruses,  generated  by  co 
transfection of an env  and rev deleted HIV backbone, together with the env 
clone  of  interest;  the  resulting  pseudotypes  are  then  used  to  infect  a 
transformed cell line expressing the appropriate viral receptors, such as TZM 
bl, a genetically engineered HeLa cell clone that expresses CD4, CXCR4 and 
CCR5  and  contains  a  Tat responsive  reporter  gene  encoding  the  firefly 
luciferase  enzyme  (Platt  et  al.,  1998;  Wei  et  al.,  2002).    This  pseudotype 
based assay has proved to be robust and highly reproducible (Mascola et al., 
2005; Li et al., 2005).  Other advantages of this system include: shorter assay 
length (2 3 days compared to 4 6 days for the PBMC based system) and no cell 
cell  transmission  (Brown  et  al.,  2005).    However,  it  has  also  been 
demonstrated  more  recently  that  primary  cell based  assays  and  pseudotype 
virus assays may each reveal different, distinct patterns of cross neutralisation 
(Brown et al., 2008). 
Developing  a  reliable  virus  neutralisation  assay  (VNA)  to  detect  neutralising 
antibodies is complex; there are many variables requiring standardisation and 
optimisation,  including  the  cell  substrate,  cell  count,  prior  cell  adsorption, 
virus titre, antibody dilution, virus dose and antibody incubation times, length 
of culture incubation, the inclusion of complement, volumes of components 
added and the endpoint measured. Chapter three 
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It was proposed that, using this assay, it would be possible to measure the NAb 
response generated in vivo, both in naturally infected cats and in vaccinates, 
in  order  to  help  evaluate  the  efficacy  of  potential  vaccines.    In  addition, 
antibodies  that  enhance  viral  infectivity  may  be  detected.    This  chapter 
describes studies undertaken to develop and optimise a novel, luciferase based 
neutralisation assay employing viral pseudotypes bearing FIV Envs in order to 
detect FIV NAbs.   Chapter three 
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3.2 Methods 
 
3.2.1 Plasma adsorption to remove anti cellular antibodies 
Plasma samples were adsorbed with CLL CD134 cells before being used in the 
neutralisation  assay,  using  the  method  described  in  Tozzini  et  al.  (1992).  
Briefly, plasma samples were heat inactivated at 56ºC for 30 minutes and ten 
fold serial dilutions starting at 1 in 5 were prepared in complete RPMI.  An 
equivalent  volume  containing  5x10
5  CLL CD134  cells  was  added  to  each 
dilution, so the final dilution of 1 in 10 is maintained, and incubated at 4ºC for 
one hour with continuous shaking.  Cells were removed and adsorbed plasmas 
were added to 1.5 ml eppendorf tubes containing a pellet of 5x10
5 of CLL 
CD134  cells.    Tubes  were  incubated  at  37ºC  for  one  hour  on  a  shaker.  
Adsorbed plasmas were removed to fresh 1.5 ml eppendorf tubes and the assay 
was conducted according to the standard protocol. 
 
3.2.2 Effect of hypotonicity on neutralisation sensitivity 
Non ionic distilled water was used to prepare hypotonic solutions of growth 
media, according to the method used by Russell (1978), resulting in a series of 
solutions containing 10%, 25%, 50%, 75%, and 100% RPMI 1640.  Plasma samples 
were  diluted  in  each  of  the  hypotonic  solutions,  and  25   l  of  each  plasma 
dilution were tested in the neutralisation assay. 
 
3.2.3 CD134 receptor blocking assay 
Dilutions of the anti CD134 monoclonal antibody 7D6 were prepared, starting 
from 1.2  g/ml in complete RPMI.  Equivalent volumes containing CLL CD134 
cells  (10
6  /ml)  were  added  to  each  dilution  of  monoclonal  antibody  and 
incubated at 4ºC for one hour with occasional shaking.  Fifty  l of cells were 
added to the equivalent volume of plasma/pseudotype mixture into a 96 well 
culture plate and subsequent steps of the assay were followed according to the 
normal protocol.  Cells treated in parallel with anti CD8 antibody served as 
negative controls. Chapter three 
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3.2.4 Immunoglobulin separation 
Immunoglobulins from enhancing plasma samples were purified using Protein A 
Sepharose  beads.    The  beads  were  washed  twice  with  10  volumes  of  PBS 
containing  Complete  Protease  Inhibitors,  before  being  suspended  in  the 
enhancing plasma and incubated at 4ºC overnight with rotation.  The beads 
were carefully pelleted following centrifugation at 2000 rpm for 5 minutes, and 
the supernatant carefully removed and transferred to a fresh 1.5 ml eppendorf 
tube.  The beads were then washed twice with 10 volumes of PBS containing 
protease inhibitors and immunoglobulins were eluted using 0.1M citrate pH 3.  
The eluate was dialysed overnight against an isotonic solution (PBS), and the 
eluted immunoglobulins were tested for neutralising activity. 
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3.3 Results 
 
3.3.1 Optimisation of virus neutralisation assay (VNA) 
A  luciferase based  neutralisation  assay  was  designed  to  detect  NAbs  with 
activity  against  FIV.    Figure  3.1  shows  a  cartoon  depicting  the  major  steps 
involved in the standard assay.  HIV(FIV) luciferase pseudotypes based on an 
env   and  rev deleted  HIV  pNL Luc E
  R
   plasmid  (Conner  et  al.,  1995),  and 
carrying  a  luciferase  reporter  gene  were  prepared  as  described  in  section 
2.3.6, bearing a series of FIV Envs.  Serial dilutions of each test plasma were 
incubated with HIV(FIV) pseudotype for an hour in 96 well culture plates in 
order to permit neutralisation of the pseudotype to proceed.  Following the 
addition  of  substrate  cells  and  incubation  for  two  to  three  days,  non 
neutralised pseudotype was quantified by measuring the luciferase activity of 
each well.  The percent neutralisation was calculated with reference to control 
wells which contained no plasma, and plasmas were classified as for HIV, as 
strongly  neutralising  (≥80%),  moderately  neutralising  (60 79%),  and  weakly 
neutralising 40 59%).  Various parameters were examined as described in the 
following sections. Reproducibility was ascertained with the low error bars of 
the raw data of luciferase activity counts (see Appendix 3). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1.  Cartoon depicts the steps of the neutralisation assay. 
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3.3.1.1 Effect of cell substrate on neutralisation 
For productive infection to occur, FIV utilises the chemokine CXCR4 as a co 
receptor in addition to the primary receptor CD134.  The MYA 1 cell line, a 
feline lymphoblastoid, IL 2 dependent cell line, has been utilised previously in 
FIV neutralisation assays.  However, its low expression of CXCR4 (~10%), slow 
growth,  sensitivity  to  manipulation,  and  IL 2  dependency are all  considered 
limitations for the use of this cell line for routine neutralisation assays.  As an 
alternative and to overcome these limitations, the cell line CLL CD134, derived 
from a canine chronic lymphocytic leukaemia and transduced with feline CD134 
was tested (Willett et al., 2008).  Prior to use, the cells were enriched for 
CD134 expression on two occasions (as described in section 2.3.4) and selected 
using Geneticin 418, and high expression of CD134 (over 99%) was maintained 
over 50 passages (Table 3.1).   
 
Percent expression 
Passages # 
CXCR4  CD134 
4  99.50  99.75 
8  99.07  99.59 
14  98.96  98.85 
22  99.42  99.53 
32  99.87  99.82 
38  99.81  99.79 
52  99.37  99.79 
60  74.58  99.11 
Table 3.1.  Expression of CD134 and CXCR4 receptors on CLL CD134 cell line 
with passage number over a 30 week period.  Both CD134 and CXCR4 receptor 
expression was maintained over 99% over 50 passages. 
 
CLL CD134 is an IL 2 independent, easily manipulated and robust cell line, with 
a high growth rate compared to MYA 1; as a result higher luciferase activity 
was observed in CLL CD134 compared to MYA 1 cells (Figure 3.2).   
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Figure  3.2.    Infection  of  MYA 1  and  CLL CD134  cell  lines  with  a  panel  of 
HIV(FIV) pseudotypes.  B2542, M2, and TM2 are subtype B strains; PET KKS, 
GL8, and PPR are subtype A strains; CPG 41 is subtype C strain; and 425, 827, 
556, and 182309 are primary subtype A strains.  A similar pattern of infectivity 
was  seen  but,  in  general,  higher  luciferase  activity  was  observed  following 
infection of CLL CD134 compared to MYA 1 cells.  Each column represents the 
mean (n=3) +/  SEM. Chapter three 
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Next, the CLL CD134 concentration was optimised using two HIV(FIV) luciferase 
pseudotypes, bearing Envs of GL8 and CPG 41.  The optimum concentration 
was found to be within the range of 2x10
5 – 5x10
5 per ml, equivalent to 10
4 – 
2.5x10
4 cells per well (Figure 3.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3.3.    Comparison  of  different  CLL CD134  cell  concentrations.    The 
luciferase activity was compared when different concentrations of CLL CD134 
cells  were  infected with a constant  dose  of  HIV(FIV)  luciferase  pseudotype, 
bearing the Env of either GL8 or CPG 41.  Each column represents the mean 
(n=3) +/  SEM. 
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3.3.1.2 Titration of pseudotype luciferase activity 
As described in chapter two, pseudotyped viruses were produced comprising 
HIV structural proteins, bearing FIV Envs and carrying the luciferase reporter 
gene (HIV(FIV)luc).  The minimum pseudotype titre result in a reproducible, 
productive infection was determined by titrating the GL8 pseudotype, using a 
constant concentration of strongly neutralising plasma.  The % neutralisation 
remained  stable,  or  was  only  slightly  reduced,  with  a  pseudotype  titre  of 
2x10
5,  but  dramatically  changed  at  pseudotype  titres  lower  than  4.5x10
4, 
indicating that below this titre, pseudotypes were not sufficiently abundant to 
produce a reliable infection.  The assay reproducibility was greatly improved at 
pseudotype titres of 10
6 or greater (Figure 3.4).   
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Figure 3.4.  Pseudotype titration.  The GL8 pseudotype was five fold serially 
diluted starting from 1.6x10
7 and then tested against homologous neutralising 
plasma, Q253, diluted at 1 in 10.  Each point is derived from the mean (n=3) 
+/  SEM of luciferase activity counts. Chapter three 
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3.3.1.3 Other variables 
Optimisation  of  the  virus  neutralisation  assay  involved  testing  additional 
variables, including the incubation periods.  It was shown that an incubation 
period of one hour prior to addition of the substrate cells was sufficient for 
neutralisation of the HIV(FIV) pseudotypes.  Shorter incubation periods may not 
allow sufficient time for neutralisation, and longer incubation periods at 37ºC 
led to reduced luciferase activity (data not shown).  The second incubation 
time  was  dependent  on  the  growth  rate  of  the  substrate  cells,  since  cells 
would overgrow the assay plate wells if the incubation was too long.  As shown 
in Table 3.2, CLL CD134 cells grow well for the first three days after being set 
up in fresh medium, whereas the growth rate declined dramatically after the 
fourth day.  It was concluded that a three day incubation period, using a final 
cell concentration of 1.5x10
5 cells per well, was optimal. 
 
Days  Percent growth rate 
First  179 
Second  190 
Third  188 
Fourth  138 
Fifth  39 
 
Table 3.2.  Growth curve for CLL CD134 cells.  It was observed that cells grow 
actively during the first three days following subculture; however, the growth 
rate declined dramatically after day 4 when cells became over confluent. 
 
Next, the inclusion of a plasma adsorption step was examined.  Thirty nine 
plasma samples from vaccinated cats, and twenty nine plasma samples from 
naturally  or  experimentally  infected  cats  were  adsorbed  against  uninfected 
CLL CD134 cells, prior to being tested for neutralisation activity in order to 
remove antibodies recognising cellular antigens that could have the potential 
to affect the detection of NAbs in vitro, as reported by Tozzini et al. (1992). 
No  significant  differences  were  detected  in  the  neutralisation  activity  of 
plasmas before and after adsorption, as shown in Figure 3.5.  It was concluded 
that  there  was  insufficient  evidence  to  include  plasma  adsorption  routinely 
prior  to  conducting  virus  neutralisation  assays  on  plasmas  from  naturally 
infected cats. Chapter three 
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Figure  3.5.    The  effect  of  plasma  pre adsorption  on  sensitivity  to 
neutralisation.  Plasma samples from experimentally infected cats (A411, A413, 
A414, A415, A416   see appendix 4) were adsorbed prior to being tested for 
neutralising activity in order to remove antibodies recognising cellular antigens 
which could potentially affect the detection of NAbs in vitro.  Samples were 
taken at 32 weeks post infection.  Each point is derived from the mean (n=3) 
+/  SEM of luciferase activity counts. Chapter three 
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Consistent with other protocols for the detection of HIV NAbs, plasma samples 
were  heat  inactivated  at  56ºC  for  30  minutes  in  order  to  inactivate 
complement  before  dilutions  were  incubated  with  the  HIV(FIV)  pseudotypes 
(Derby et al., 2006; Kraft et al., 2007).  However, there was no evidence that 
complement played a significant role as non heat inactivated plasma samples 
displayed a similar neutralisation pattern to untreated samples (Figure 3.6).  
Nevertheless, a heat inactivation step was included for consistency, in order to 
cancel any potential effects of complement and other labile proteins in viral 
lysis, allowing a direct comparison with previously published studies (Fevereiro 
et al., 1993). Chapter three 
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Figure  3.6.    Comparison  of  neutralisation  activity  with  and  without  heat 
inactivation of plasma samples from four experimentally infected cats, A411 & 
A413, which were infected with PET, and A414 & A415 which were infected 
with GL8.  Samples were taken at post mortem at 48 weeks post infection.  
Each point is derived from the mean (n=3) +/  SEM of luciferase activity counts. 
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Russell  (1978)  reported  a  method  in  which  the  neutralisation  of  feline 
leukaemia virus (FeLV) was potentiated when plasma samples were diluted in a 
mixture containing 50% hypotonic solution and 50% culture medium.  A similar 
methodology  was  applied  using  weakly  neutralising  plasmas,  and  a  slight 
potentiation of neutralisation at 50% RPMI (and 50% non ionised distilled water) 
was observed in some of the plasmas tested (Figure 3.7).  Given the lack of 
compelling  evidence  for  a  significant  improvement  in  the  neutralisation 
sensitivity  afforded  by  this  approach,  the  use  of  hypotonic  diluent  was  not 
pursued further in FIV neutralisation assay development. 
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Figure  3.7.    The  effect  of  hypotonic  solution  on  FIV  neutralisation.    Four 
plasma samples from naturally infected cats, 294787, 205270, and 171505 were 
diluted 1 in 10 in RPMI adjusted to be hypotonic by dilution in water as shown 
and the effect on neutralising activity was measured.  Each point is derived 
from the mean (n=3) +/  SEM of luciferase activity counts. 
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3.3.2 Time course of NAb production 
Anti FIV  antibodies  can  be  detected  as  early  as  6  weeks  post  infection  in 
experimentally infected cats (Hosie  et al., 1998).  Similarly,  seroconversion 
can typically be detected between 2 and 4 weeks of HIV infection (Sierra et 
al., 2005; Pantaleo et al., 1993).  However, it takes longer for a NAb response 
to  mature  and  in  order  to  estimate  the  time  required,  sequential  samples 
collected from an experimentally infected cat at 23, 26, 32 & 37 weeks post 
challenge  were  examined.    The  results  demonstrated  that  NAbs  were 
generated between 26 and 32 weeks post infection (Figure 3.8).  Subsequent 
assays used the strongly neutralising plasma sample A416. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8.  The development of NAb response.  Sequential samples collected 
from cat (A416) experimentally infected with a molecular clone of homologous 
GL8 were tested and NAbs were first detected 32 weeks post infection. Each 
point is derived from the mean (n=3) +/  SEM of luciferase activity counts. 
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3.3.3 Variation in NAb response amongst viral isolates 
HIV(FIV) luciferase pseudotypes bearing the Envs of the GL8, PPR (Phillips et 
al., 1990), B2542 (Diehl et al., 1995a) and CPG 41 (Diehl et al., 1995b) isolates 
of  FIV  were  tested  for  neutralisation  by  plasma  from  a  cat  experimentally 
infected with the GL8 isolate of FIV.  GL8 is a representative UK isolate (Hosie 
et al., 2000; Dunham et al., 2006a), belonging to subtype A (see chapter 4), 
while PPR, B2542 and CPG 41 were isolated in the US and belong to subtypes A, 
B, and C, respectively.  The pattern of neutralisation observed with a strongly 
neutralising plasma sample collected from a cat experimentally infected with 
GL8  varied  dramatically  amongst  the  pseudotypes,  as  shown  in  Figure  3.9.  
While the GL8 pseudotype was strongly neutralised at 1 in 10 plasma dilution 
by its homologous plasma, B2542 was only weakly neutralised.  A similar profile 
was achieved by plasma samples from naturally infected cats (data not shown).  
Furthermore, enhancement rather than neutralisation was observed for both 
B2542 and CPG 41.  The enhancement was dose dependent, being most marked 
at  lower  dilutions  of plasma.    Such a  spectrum  of  activities  displayed  by a 
plasma sample, from neutralisation to enhancement of infection, indicates the 
major challenge faced in FIV vaccine development, since ideally an effective 
and safe vaccine should protect against a wide range of primary isolates with 
no adverse effects such as enhancement of infection. Chapter three 
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Figure 3.9.  Plasma A416 neutralised a pseudotype bearing the homologous GL8 
Env but enhanced infection with pseudotypes bearing the heterologous PPR and 
CPG 41 Envs (appendix 4). Subtype classification between parentheses. 
 
3.3.4 In vitro enhancement of FIV infection 
Steps  were  taken  to  investigate  further  the  enhancement  phenomenon 
whereby, on occasions, increased luciferase activity was observed in wells in 
which  pseudotypes  were  incubated  with  heterologous  plasma  samples 
compared to “no plasma” control wells.  One possible mechanism for antibody 
mediated  enhancement  was  via  T cell  activation  mediating  upregulation  of 
CD134,  the  primary  receptor  for  FIV  (Shimojima  et  al.,  2004),  and  the  co 
receptor CXCR4.  Accordingly, we attempted to block the enhancement effect 
using  antibody  7D6  recognising  CD134.    As  shown  in  Figure  3.10,  the 
enhancement  of  CPG 41  infection  displayed  by  plasma  samples  A411  and 
170338  was  blocked  by  the  addition  of  increasing  doses  of  antibody  7D6 
(starting concentration 600ng/ml).  In contrast, enhancement was not blocked 
by an isotype matched control antibody recognising CD8.  It was concluded, 
however,  that this  reduction  occurred  by blocking  viral  entry, since plasma 
170305  was  not  enhancing  but  showed  a  similar  pattern  of  reduction  in 
luciferase  activity.    Concentrations  of  7D6  greater  than  600  ng/ml  did  not 
result in further reduction of the enhancement. 
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Figure  3.10.    CD134  blocking.    This  assay  aimed  to  block  enhancement  by 
preventing the activation of the primary (CD134) at a 1:10 plasma dilution.  A.) 
Luciferase activity (counts per minute) with 1:5 dilutions of 7D6.  Anti CD8 was 
used as a negative control.  B.) Percent blocking values. Each point represents 
the mean (n=3) +/  SEM. 
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To  test  whether  the  enhancement  was  antibody mediated,  antibodies  were 
separated from other soluble factors within a representative enhancing plasma 
(A411) using either protein A Sepharose or Sepharose G25 as a control.  The 
eluted  fractions  were  tested  for  the  ability  to  neutralise  the  CPG 41 
pseudotype.  It was demonstrated that only the fraction eluted from protein A 
Sepharose and whole plasma enhanced infection (Figure 3.11), confirming that 
the enhancement was antibody mediated.  Furthermore, when a panel of anti 
FIV Env monoclonal antibodies was tested, it was observed that incubation with 
vpg67,  a  monoclonal  antibody  targeting  the  V3  loop  of  FIV,  also  led  to 
enhancement of infection with the GL8 and TM pseudotypes (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3.11.    Enhancement  is  antibody mediated.    Immunoglobulin  was 
separated  from  enhancing  plasma  using  protein  A Sepharose  (Eluted  Abs).  
Eluted antibodies enhanced infection whereas the fraction that could not be 
eluted from protein A Sepharose (SPA) and the eluate from Sepharose G25 with 
no Protein A attached (G25 elution) did not enhance infection, suggesting that 
enhancement was antibody dependent. Each point is derived from the mean 
(n=3) +/  SEM of luciferase activity counts. 
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Plasma  Q253  was  identified  as  having  strongly  neutralising  activity  against 
pseudotypes  bearing  the  GL8  Env.    To  investigate  the  mechanism  of 
enhancement  observed  with  the  anti FIV  Env  antibody  vpg67,  a  series  of 
dilutions of plasma Q253 in RPMI were set up, each containing 2  g/ml of the 
anti FIV  Env  monoclonal  antibody  vpg67.    Enhancement  of  infection  in  the 
presence of monoclonal antibody vpg67 was observed only in the absence of 
NAb, i.e. at the highest dilutions of the neutralising plasma Q253 (Figure 3.12).  
Therefore it is likely that an immunogen which induces high titres of broadly 
cross neutralising antibodies may overcome the effect of enhancing antibodies. 
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Figure  3.12.    Strong  neutralisation  overcomes  the  enhancement.    Strongly 
neutralising plasma is titrated against the GL8 pseudotype in the presence of a 
constant  concentration  of  an  enhancing  antibody  (vpg67),  showing  that 
enhancement occurs at plasma dilutions greater than 1 in 10000. Each point is 
derived from the mean (n=3) +/  SEM of luciferase activity counts. Chapter three 
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3.4 Discussion 
A robust assay for the detection of FIV NAbs is highly desirable, to understand 
more  fully  the  humoral  immune  response  in  naturally  infected  cats  and  to 
determine  the  potential  value  of  candidate  vaccine  immunogens,  either 
experimentally or in clinical trials.  Here we developed and optimised a highly 
reproducible FIV neutralisation assay using pseudotypes bearing FIV Envs and 
carrying a luciferase gene.  The pseudotyped viruses were efficiently produced 
by HEK293T cells transfected with the HIV pNL Luc E
  R
  expression plasmid.  
Assay  variable  parameters  were  optimised  and  adjusted  for  robustness  and 
reproducibility. 
The  luciferase  based  assay  is  likely  to  replace  PBMC  assays  which  utilise 
uncloned  viruses  produced  in  PBMCs.    Both  assays  are  based  on  similar 
principles, measuring reductions in virus infectivity, but the former has the 
advantage of being more reliable and robust, using shorter assay periods and 
excluding cell cell transmission. 
One application for the luciferase based assay for FIV NAbs is likely to be in 
testing vaccine efficacy.  While the aim of vaccination against FIV infection is 
to protect cats from virus challenge, it has been observed that some immune 
responses  elicited  by  vaccination  may  result  in  deleterious  responses  that 
actually enhance viral pathogenicity in immunised animals (Hosie et al., 1992; 
Karlas et al., 1999; Osterhaus et al., 1996; Giannecchini et al., 2002; Wang & 
Teng, 1994; Richardson et al., 2002).  The induction of such immune responses 
must be avoided in the production of efficacious and safe vaccines. 
Generally  speaking,  lentiviral  vaccine based  enhancement  has  been  well 
known;  several  lentiviral  vaccines  enhanced  rather  than  decreased 
susceptibility  to  challenge  (Willett  et  al.,  1997b),  with  vaccinated  subjects 
showing enhanced levels of viraemia, more rapid disease progression and often 
increased  disease  severity  compared  to  control  subjects  (Montefiori  et  al., 
1996).    Such  outcomes  are  of  major  concern  for  vaccine  development, 
illustrated  by  the  failure  in  September  2007  of  the  clinical  trial  of  an 
adenovirus based HIV 1 vaccine (Fauci, 2007). Chapter three 
  79 
Enhancement of viral infection is speculated to be immune mediated, mainly 
through the Fc receptor or the complement receptor (Fust, 1997; Robinson, Jr. 
et al., 1988; Perno et al., 1990; Wu et al., 1995).  It has been demonstrated 
that  antibody dependent  enhancement  of  HIV l  infection  occurs  via  IgG  Fc 
receptors on monocytes, and that enhancement was blocked by the presence 
of  a  potent  ligand  for  Fc  receptors  (Takeda  et  al.,  1988).    Other  immune 
mediated  enhancement  mechanisms  can  be  attributed  to  dendritic  cells 
(Izquierdo Useros et al., 2007), soluble CD4 (Sullivan et al., 1995), or perhaps 
other, as yet undefined, soluble factors. 
Indeed, the enhancement phenomenon does not appear to be solely vaccine 
mediated; in this study enhancing plasmas were identified from naturally and 
experimentally  infected  cats.    The  finding  that  vaccinated  cats  showed 
enhanced viraemia compared to control cats could be attributed to the fact 
that the immune system of vaccinated cats has encountered the immunogen 
earlier  than  that  for  control  cats,  resulting  in  an  earlier  and  enhancing 
response.  Antibodies generated early in infection are not neutralising.  We 
observed that in an experimentally infected cat, NAbs required several months 
to mature and, in the absence of NAbs, antibody mediated enhancement may 
occur. 
Antibody mediated  enhancement  has  been  described  in  vitro  (Fust,  1997; 
Sullivan, 2001).  Enhanced infection after viral challenge was established in 
naïve cats following the passive transfer of plasma from vaccinated cats; such 
findings indicated that enhancement was antibody mediated (Siebelink et al., 
1995c).  In this chapter it was observed that the enhancement was attributable 
to  the  immunoglobulin  fraction  of  an  enhancing  plasma  sample,  confirming 
that  enhancement  is  likely  to  be  antibody mediated.    The  mechanism  of 
enhancement is not known, but it has commonly been assumed that enhancing 
antibodies promote viral attachment and subsequent internalisation by acting 
as adaptors between viral particles and Fc or complement receptors on target 
cell  membranes,  or  that  enhancing  antibody  binds  to  Env,  mimics  the 
interaction with the primary receptor and allows the direct interaction with 
the  co receptor  (Trischmann  et  al.,  1995;  Thomas  et  al.,  2006;  Takada  & 
Kawaoka, 2003).  However, further investigations are required to understand 
more fully the exact mechanism of enhancement. Chapter three 
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The  data  described  in  this  chapter  were  consistent  with  the  epitope, 
recognised by the enhancing monoclonal antibody vpg67, being sited within the 
V3 loop.  Indeed, the V3 V5 region was predicted previously to include epitopes 
for enhancing antibodies, and thus was deleted from a recombinant protein 
tested in a vaccine trial (Huisman et al., 2004).  Nonetheless, enhancement 
occurred, indicating that epitopes for enhancing antibodies are not confined to 
this  region.    Indeed,  epitopes  for  enhancing  antibodies  were  identified 
previously  in  other  domains  within  HIV 1  Env  (Robinson,  Jr.  et  al.,  1990), 
including an epitope in the transmembrane glycoprotein gp41 (Takeda et al., 
1992).    Moreover,  monoclonal  antibodies  directed  against  the  principal 
immunodominant domain may enhance infection (Eaton et al., 1994).  Hence, 
enhancing  epitopes  may  be  distributed  throughout  Env,  and  it  may  not  be 
feasible  to  locate  and  exclude  all  enhancing  epitopes  for  the  purpose  of 
designing the ideal safe and effective vaccine.  However, when the significance 
of enhancing antibodies was assessed in the presence of NAbs in this study, it 
was  observed  that  NAbs  can  efficiently  block  viral  infection,  even  in  the 
presence  of  enhancing  antibodies.    Therefore  it  appears  that  enhancement 
cannot occur when a strong neutralising response has been induced. 
The  complex  neutralisation  profile  displayed  by  the  plasma  sample  that 
strongly neutralised the GL8 pseudotype but enhanced infection with the PPR 
and  CPG 41  pseudotypes  may  be  attributed  to  the  fact  that  this  plasma 
contained  both  neutralising  and  enhancing  antibodies.    While  it  strongly 
neutralised its homologous pseudotype, it appeared to lack sufficient potency 
to neutralise a broader range of genetically distinct pseudotypes; these were 
unlikely to share common neutralisation epitopes and therefore NAbs effective 
against GL8 Env were not effective against PPR or CPG 41 Env and, accordingly, 
enhancement occurred. 
In  light  of  these  findings,  and in  terms  of  vaccine  development,  it appears 
more  feasible  to  identify  common  neutralising  epitopes,  and  to  solve  the 
spatial  structure  that  renders  such  epitopes  exposed  to  the  host’s  immune 
system, rather than to identify and delete epitopes for enhancing antibodies.  
Accordingly, more extensive investigations were directed towards identifying 
key components capable of inducing broad NAb responses against FIV and the 
results of these investigations are presented in the following chapters. Chapter four 
4 Phylogenetic subtyping in the United Kingdom 
 
4.1 Introduction 
Like other retroviruses, FIV has high mutation rate, mainly due to the error 
prone  reverse  transcriptase  (Shankarappa  et  al.,  1998);  accordingly,  diverse 
viral variants emerge continually.  Since the env gene is the key determinant of 
viral  diversity  amongst  FIV  strains  (Olmsted  et  al.,  1989),  FIV  phylogenetic 
studies have focussed mainly on env sequences.  According to the nucleotide 
sequence diversity of the V3 V5 region of env, FIV is classified currently into 
five distinct phylogenetic subtypes, designated A to E (Pecoraro et al., 1996; 
Sodora  et  al.,  1994);  subtypes  A  and  B  are  the  most  commonly  occurring 
worldwide (Martins et al., 2008).  Furthermore, similar to HIV 1, several inter 
subtype  FIV  recombinants  have  been  recognised  in  natural  populations 
following  co infection;  inter subtype  recombinants  A/B,  A/C  and  B/D  have 
been identified (Hayward & Rodrigo, 2008; Bachmann et al., 1997). 
Phylogenetic studies on FIV sequences have revealed significant heterogeneity 
(up  to  30%)  in  the  sequence  of  the  env  gene  of  FIV  isolates  worldwide 
(Burkhard  &  Dean,  2003),  similar  to  that  estimated  for  HIV 1  (Rong  et  al., 
2007b).  Subtype A isolates are common in Australia, New Zealand, western 
United States, South Africa and northwestern Europe (Steinrigl et al., 2009; 
Kann et al., 2006a; Kann et al., 2007; Kann et al., 2006b; Bachmann et al., 
1997).    Subtype  B  isolates  have  been  identified  in  the  central  and  eastern 
United States, central Europe, Brazil and eastern Japan (Pistello et al., 1997; 
Nishimura et al., 1998; Sodora et al., 1994; Kakinuma et al., 1995; Steinrigl & 
Klein, 2003; Martins et al., 2008).  Subtype C has been recognised in Canada, 
New Zealand and southeast Asia (Nakamura et al., 2003; Reggeti & Bienzle, 
2004; Uema et al., 1999; Hayward et al., 2007).  Finally, subtypes D and E are 
infrequent but were identified originally in southwestern Canada and Japan, 
and  Argentina,  respectively  (Pecoraro  et  al.,  1996;  Nishimura  et  al.,  1998) 
(Figure 1.1). 
Such heterogeneity in env gene sequence poses problems for the design of a 
broadly  protective  vaccine.    It  has  been  reported  previously  that  effective Chapter four 
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protection  was  obtained  following  a  homologous  FIV  challenge  using  an 
inactivated whole virus vaccine, although, despite the relative success of Fel 
O Vax against heterologous subtype B isolates (Pu et al., 2005), protection did 
not extend to a heterologous challenge (Dunham et al., 2006a).  Such different 
outcomes highlight the impact of genetic diversity on vaccine strategies against 
FIV and the importance of assessing the genetic diversity of local subtypes for 
vaccine  development,  or  before  introducing  a  commercial  vaccine  to  a 
particular geographical area.  Furthermore, identification of the predominant 
strains  in  a  particular  region  is  necessary  in  order  to  develop  appropriate 
reagents  for  the  molecular  diagnosis  of  FIV  infection  (Hosie  et  al.,  2002; 
Leutenegger et al., 1999). 
Based on the strains previously isolated in the UK, there is a general agreement 
that all UK strains of FIV belong to subtype A.  Nonetheless, there have not 
been any phylogenetic studies conducted describing accurately the strains of 
FIV  circulating  within  the  UK.    This  phylogenetic  study  was  conducted  to 
investigate the distribution of UK FIV subtypes, based on the sequence of the 
V3 V5 region of env, examining 45 novel sequences from the UK and including 
one sequence from of the Republic of Ireland and another from Jersey. Chapter four 
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4.2 Methods 
 
4.2.1 Blood samples, PBMC collection and DNA extraction 
Blood  samples  were  examined  from  47  FIV  sero positive,  naturally  infected 
domestic cats (Felis catus).  The blood samples were collected over the period 
from  April  2007  to  August  2008  and  had  been  submitted  to  the  Companion 
Animals Diagnostic Services at the University of Glasgow for the diagnosis of 
FIV, either because the cat was sick or for screening purposes.  The remainders 
of blood samples were centrifuged at 2000 rpm for 10 minutes and the plasma 
was removed and stored at  80
oC.  Peripheral blood mononuclear cells (PBMCs) 
were collected as described in section 2.3.1.  Approximately 10
7 PBMC were 
used  directly  for  DNA  extraction  using  QIAamp  DNA  Blood  Mini  Kit  (Qiagen, 
West Sussex, UK), as described in section 2.4.1. Chapter four 
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4.3 Results 
 
4.3.1 The sample population 
In total, 47 left over clinical blood samples were examined from cats that had 
been  infected  naturally  with  FIV;  the  cats  were  either  pets  or  stray  cats 
waiting  to  be  re homed  from  animal  protection  shelters.    Samples  were 
submitted from across the UK; the majority originated from southern Scotland, 
England or Wales but one sample came from Jersey (171069) and another from 
the Republic of Ireland (179200) (Figure 4.1).  The majority of the cats (35 of 
47) were male (74%), a finding that is consistent with other studies (Hayward 
et  al.,  2007;  Reggeti  &  Bienzle,  2004),  and  likely  to  be  associated  with 
aggressive  social  behaviour  in  males  increasing  the  risk  of  transmission  via 
biting (Natoli et al., 2005).  The ages were known for only 34 of the 47 cats 
and these ranged from 6 months to 16 years, with only 3 cats less than 1 year 
of age.  The infected cats were likely at different stages of infection, with 
clinical  signs  ranging  from  asymptomatic  to  symptomatic;  clinical  signs 
recorded  on  the  submission  forms  included  lethargy,  pyrexia,  anaemia, 
stomatitis, gingivitis, upper respiratory tract infections, urinary tract infections 
and central nervous system disorders (Table 4.1). 
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Figure 4.1.  Distribution of FIV isolates included in the study.  This map shows 
the locations of the veterinary practices where blood samples were collected 
from FIV infected cats and sent to the University of Glasgow for the diagnosis 
of FIV infection. 
 Chapter four 
Strain  Location  Age  Gender  Health Status  Clinical Signs  Subtype 
170003  Essex  2 3 years  Male  NK  NK  A 
170141  Kent  12 years  Male  NK  NK  A 
170186  Norfolk  15 years  Male  Sick  anaemia  A 
170305  Suffolk  NK  Female  NK  NK  A 
170338  Essex  11 years  Male  Sick  NK  A 
170415  Lincolnshire  Adult  Male  NK  covered in scabs and scars  A 
170418  London  1 year  Male  NK  NK  A 
170488  Kent  4 years  Male  NK  pale   poor condition  A 
170617  London  Adult  Female  Sick  NA  A 
170719  London  9 years  Male  Sick  anaemia   dehydration  A 
171025  London  2.5 years  Male  NK  NK  A 
171069  Jersey  NK  Male  Healthy  No aparant lesion  A 
171070  Worcestershire  8 years  Male  Sick  ulcerative pharyngitis   A/C 
171101  London  6 months  Male  Sick  alopecia  A 
171163  Leicester  9 months  Female  Sick  cyclical pyrexia  A 
171169  Cornwall  1.5 years  Female  Healthy  slight conjunctivitis  A 
171170  Lancashire  Adult  Male  Healthy  No aparant lesion  A 
171175  Norfolk  16 years  Female  Sick  upper respiratory tract signs  A 
171265  Nottinghamshire  NK  Male  Healthy  No aparant lesion  A 
171270  Cheshire  3 years  Male  Healthy  No aparant lesion  A 
171303  Norfolk  Adult  Male  Sick  NK  A 
171358  Lanark  16 years  Male  Sick  persistant non regenerative anaemia   
leucopenia  A 
171532  Cumbria  5 years  Male  Sick  recurrent gingivitis/ stomatitis   A 
171700  Hull  NK  Male  NK  NK   A 
171781  Norfolk  10 years  Male  Sick  anorexia   recurrent gingivitis  A 
171810  Lancashire  NK  Female  Sick  change of coat colour  A Chapter four 
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171812  Norfolk  5 years  Male  Healthy  No aparant lesion  A 
171838  Glasgow  1.5 years  Female  Sick  dullness – stopped eating   A 
172325  London  12 years  Female  NK  NK   A 
172458  Wirral  4 years  Male  Sick  gingivitis   stomatitis  A 
172506  Hull  10 years  Male  Sick  NK   A 
172527  Glasgow  9 years  Female  sick  ataxia   A 
172532  Essex  NK  Male  NK  NK  A 
178586  Manchester  5 years  Female  Sick  severe gingivitis  A 
178721  Lancashire  4 5 years   Male  Sick  large abscess on side of face  A 
179200  Dublin / Ireland  10 years  Male  Sick  weight loss   lethargy   fever  A 
179288  Lancashire  3 years  Male  Sick  mild gingivitis   neck lesions  A 
179297  Norfolk  8 years  Male  Healthy  No aparant lesion  A 
179369  Hertfordshire  Adult  Male  NK  NK  A 
179466  Worcestershire  5 years  Male  NK  NK  A 
180115  Dewsbury  12 years  Female  sick  mucopurulent ocular + nasal discharges 
  stomatitis   bilateral conjunctivitis 
A 
180140  London  Adult  Male  Healthy   No aparant lesion  A 
180260  Denbigh  10 years  Male  NK   NK  A 
180638  Durham  > 2 years  Male  sick  severe periodontitis   swollen and lysed 
jaw bones 
A 
182309  Hull  9 years  Male  sick  loss of appetite   halitosis  A 
182455  Bridgend  NK  Female  NK   NK  A 
206394  Kent  11 years  Male  sick  Urinary tract infection   A 
 
         Table 4.1.  Details of the naturally FIV infected cats included in the study.  NK: Not known Chapter four 
4.3.2 Phylogenetic Analysis of naturally occurring UK isolates of FIV 
An unrooted neighbour joining phylogenetic tree was generated based on a 651 
nucleotide alignment of the V3 V5 region of the env gene, comprising 47 novel 
sequences  from  naturally  occurring  isolates  of  FIV  together  with  reference 
sequences from subtypes A, B, C, D and E (Figure 4.2).  The tree demonstrated 
that  all  the  novel  sequences,  with  the  exception  of  171070,  cluster  within 
subtype  A  with  a  bootstrap  value  of  99%,  while  171070  was  classified  as 
belonging  to  subtype  C,  albeit  with  low  bootstrap  support  (36%).    Sequences 
within subtype A were grouped on a branch from which two sequences (179200 
and 179297) emerged as a separate group.  This demonstrated that both the Irish 
and British sequences (179200 and 179297), in spite of originating from different 
geographical  areas  (Table  4.1),  were  closely  related.    Consistent  with  the 
phylogenetic  distance  between  FIV  isolate  179200  and  the  other  subtype  A 
isolates, a pseudotype bearing the 179200 FIV Env was not highly susceptible to 
neutralisation  by  a  subtype  A  cross neutralising  plasma.    Subsequently  the 
neutralisation resistance of 179200 was found to be associated with a mutation 
in C3 V4 domain (see section 6.2.5).  These data highlight the role of the V3 V5 
region of Env as a target for neutralisation.   
The  genetic  distance  between  any  two  sequences  within  subtype  A  ranges 
between  0.0  and  0.272  (between  171810  and  179297),  while  the  maximum 
difference  in  base  composition  bias  per  site  (Kann  et  al.,  2006b)  is  1.86 
(between 171810 and 179200).  The pairs 180140, 180115; 182455 and 179288; 
171536 and 171069 have similar V3 V5 sequences, despite having being isolated 
from geographically distinct locations (Figure 4.1), in England and the island of 
Jersey.  Each sample of these three pairs had been collected and manipulated 
on different days; hence any possibility of sample mix up or cross contamination 
was  highly  unlikely.    The  average  evolutionary  divergence  within  subtype  A 
sequences,  which  refers  to  the  number  of  base  substitutions  per  site  from 
averaging over all sequence pairs based on the pairwise analysis, was calculated 
as 0.091 using the MEGA 4 software (Tamura et al., 2007); this value was lower 
than the divergence for other subtypes described in previous studies (Duarte & 
Tavares, 2006; Sodora et al., 1994), indicating that isolates within subtype A 
may be less genetically heterogeneic compared to other FIV subtypes. 
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Figure  4.2.    An  unrooted 
neighbour joining 
phylogenetic tree from 651 
nucleotides  of  the  V3 V5 
region  of  env.    Bootstrap 
values  based  on  1,000 
replications  are  shown  at 
the  nodes.    The  tree  was 
constructed using Kimura’s 
two parameter  model  and 
includes  the  47  novel 
sequences  as  well  as 
representative  sequences 
from subtypes A, B, C, D, 
and E.  Branches are shown 
in  red  for  subtype  A 
reference  sequences,  blue 
for  subtype  B  reference 
sequences,  green  for 
subtype  C  reference 
sequences,  pink  for 
subtype  D  reference 
sequence,  and  brown  for 
subtype  E  reference 
sequences. 
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A Maximum likelihood tree (Figure 4.3) was also constructed in order to confirm 
the consistency of subtyping.  The tree was similar to the neighbour joining tree, 
with  the  exception  that  171070  did  not  cluster  with  subtype  C  isolates.    To 
investigate further the inconsistent subgroup assignment of 171070, a minimum 
evolutionary  tree  was  constructed  and  this  showed  a  similar  pattern  as  the 
maximum likelihood tree (data not shown).  Because it could not be assigned to 
a  particular  subtype,  the  171070  sequence  was  submitted  for  recombination 
analysis. 
Given its importance as a target for neutralisation, the V3 V5  env sequences 
were  translated  in  order  to  calculate  a  neighbour joining  tree  based  on  the 
amino  acid  sequence.    The  tree  was  not  significantly  different  from  the 
nucleotide based  trees,  but  demonstrated  also  that  171070  did  not  cluster 
within any of the subtypes (Figure 4.4).   Chapter four 
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Figure 4.3.  Maximum likelihood 
tree based on a 651 nucleotide 
alignment  of  V3 V5  env  gene.  
The  tree  was  generated  using 
DNAML  with  the  substitution 
model of HKY85. 
 pbar02
 pbar03
 pbar07
 pbar01
 pady02
 TI1
 TI3
 TI4
 TI2
C
 boy03
 mtex03
 glwd03
 brny03
 M3
 M2
 AICO2
 Lp9
B
 Lp24
 Lp20
 Lp3
E
D  OKA01D
?  171070
 179297
 179200
 172325
 171175
 172532
 171810
 171812
 170338
 180260
 171170
 171270
 172458
 170141
 180638
 170186
 172506
 171536
 171069
 SAP03
 178721
 172527
 206394
 171838
 sam01
 zepy01
 tt09
 hnky12
 171169
 171303
 171101
 170305
 182455
 179288
 170719
 170003
 170488
 178586
 170418
 171781
 UK14
 180140
 180115
 182309
 171700
 179466
 171025
 179369
 171265
 171358
 171163
 170617
 170415
A
0.05Chapter four 
  92 
 
 
 
Figure  4.4.    Phylogenetic  tree  inferred  by  neighbour joining  from  amino  acid 
sequence.  Tree was generated from an alignment of 217 amino acids including 
the UK sequences and reference sequences from all subtypes A E. Chapter four 
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4.3.3 Recombination analysis 
The  sequence  of  171070  env  was  examined  for  possible  recombination  using 
SimPlot  (Lole  et  al.,  1999).    Software  analysis  confirmed  that  171070  is  a 
recombinant of subtypes A and C, with a putative breakpoint approximately 260 
nt from the start of the env sequence (Figure 4.5).  Phylogenetic trees were 
constructed  based  on  the  criteria  of  minimum  evolution  for  the  sequences 
before and after the putative breakpoint and indicated that the 5’ moiety of the 
sequence clustered within subtype A, whereas the subtype assignment of the 
second moiety was not clear (Figure 4.6).  Interestingly, plasma from cat 171070 
significantly  neutralised  a  pseudotype  bearing  the  subtype  C  Env  CPG 41, 
whereas  a  pseudotype  bearing  the  subtype  A  GL8  Env  was  not  neutralised, 
suggesting that the major neutralisation determinant is more likely to be located 
within the subtype C sequence of the strain, i.e.  within the V4 V5 region (Figure 
4.7). 
 
 
Figure 4.5.  Bootscan analysis of env V3 V5 from 171070.  Bootscanning analysis 
was performed using a window of 200 nucleotides and a step of 20 nucleotides, 
by the neighbour joining algorithm based on the Kimura two parameter model 
and 1000 bootstrap replicates.  Strain 171070 was used as a query in the analysis 
and the subtype A E reference sequences used in the phylogenetic analysis were 
used as reference groups for the bootscan. Chapter four 
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Figure 4.6.  Recombination analysis of the A/C recombinant 171070.  Minimum 
evolutionary  trees  based  on  the  nucleotide  sequence  of  (A)  5’  terminus  to 
putative  breakpoint  sequence  (B)  breakpoint  to  the  end  of  the  sequence.  
Bootstrap frequencies are shown at the main nodes. Chapter four 
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Figure  4.7.    Neutralisation  profile  of  plasma  171070  against  GL8  and  CPG 41 
pseudotypes.    A.)  Luciferase  activity  (counts  per  minute)  with  successive 
dilutions of TOT1 serum (dilution factor 1/10, 1/100, 1/1000 and 1/10,000, no 
serum=∞).  B.) Percent neutralisation relative to no serum control.  Each point 
represents the mean (n=3) +/  SEM. 
B 
A Chapter four 
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4.4 Discussion 
Nucleotide  sequences  of  the  V3 V5  region  of  the  env  gene  have  been  used 
extensively  in  the  genetic  subtyping  of  FIV  strains  as  well  as  in  molecular 
epidemiology studies.  Although there is general agreement that the FIV isolates 
circulating within the UK are assigned exclusively to subtype A (Hosie et al., 
2009), this is the first phylogenetic study to have been performed in the UK.  
The results of the current study, based on the sequence of 45 naturally occurring 
isolates  of  FIV  from  across  the  UK,  confirm  that  subtype  A  predominates.  
However, isolate 171070, was identified as an A/C recombinant.  The cat from 
which 171070 was isolated was a feral cat that had been adopted in a suburb 
near a sea port, raising the possibility that the cat had originated from, and 
perhaps become infected, outside the UK. 
It  is  possible  that  recombination  arose  via  PCR mediated  recombination.  
However,  this  highly  unlikely  in  this  case,  since  PCR mediated  recombination 
occurs  in  heterogeneous  genetic  populations  and  in  this  study  all  the  UK 
sequences appear to belong to subtype A.  Furthermore, the high fidelity DNA 
polymerase used to amplify the env gene has a low error rate and overcomes 
many of the limitations of Taq polymerase (Gilje et al., 2008). 
Hence it appears likely that this is the first isolation of a subtype C isolate of FIV 
from  the  UK  or  Western  Europe.    Reviewing  the  database  containing  FIV 
sequences from Eastern Europe confirmed that no sequences had been recorded 
from this region.  The finding that plasma 171070 cross neutralised CPG 41, a 
subtype  C  isolate,  but  none  of  the  subtype  A  isolates  tested  may  be  highly 
significant,  suggesting  that  171070  Env  contains  a  cross neutralisation 
determinant in a location beyond the putative breakpoint, i.e. within the V4 or 
V5 regions. 
The  V3 V5  region  of  Env  has  been  shown  to  play  a  significant  role  in  viral 
neutralisation for both FIV and HIV 1 (Lombardi et al., 1993; Draenert et al., 
2006; Bendinelli et al., 2001).  The neutralisation resistance by 179200 to the 
cross neutralising plasma due to a mutation at the start of V4 loop confirms that 
the V3 V5 region (see chapter six), which has been examined in FIV phylogenetic 
studies, is a vital target for neutralising antibodies.  Furthermore, the ability of 
171070  plasma  to  cross neutralise  a  subtype  C  FIV  is  consistent  with  the Chapter four 
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existence of a neutralisation determinant in the V4 loop or further downstream, 
since its apparently recombinant homologous strain shares sequence homology 
with subtype C isolates between the V4 region and the 3’ end of the env gene.  
Therefore phylogenetic subtyping based on the V3 V5 region of env are likely to 
be important for vaccine development.   
In conclusion, this study has demonstrated that FIV subtype A, if not exclusively 
the circulating subtype, predominates in the UK.  Further characterisation of the 
genetic diversity of FIV investigating a greater number of isolates may provide 
more information about whether subtype A is the only subtype circulating within 
the UK, since an A/C recombinant isolate has been recognised, albeit from a cat 
of unknown origin. Chapter five 
5 Neutralisation of FIV by antibodies targeting the V5 
Loop of Env 
 
5.1 Introduction 
The induction of an effective humoral response against lentiviral infection is a 
key element in the immunological control of the disease and the primary target 
for neutralising antibodies is the viral envelope glycoprotein (Env) (Binley et al., 
2004; Wei et al., 2003; Frost et al., 2005).  The FIV Env varies by up to 30% 
amongst the FIV subtypes (Hosie & Beatty, 2007) and thus the preparation of an 
immunogen capable of inducing broadly neutralising antibody responses against 
such diverse isolates of FIV would be of great value to the development of an FIV 
vaccine.    Further,  the  development  of  a  vaccine  against  FIV  would  have 
implications extending beyond veterinary medicine; FIV is the only non primate 
lentivirus which induces AIDS like symptoms in its natural host and as such is a 
valuable  animal  model  for  both  prophylactic  and  therapeutic  studies  for  HIV 
(Okada et al., 1994; Elder et al., 1998; Bendinelli et al., 1995).  Moreover, cats 
have the advantage of being easier to breed and have shorter life cycles than 
other  animal  models  currently  used  for  HIV  research  (Miller  et  al.,  2000; 
Desmaris et al., 2005). 
Previous studies showed that vaccination with whole inactivated vaccines or DNA 
vaccines  can  protect  cats  against  challenge  with  either  low  virulence/ 
homologous strains of FIV, but not against virulent/heterologous primary strains 
(Hosie et al., 1995).  A vaccine capable of protecting cats against infection with 
a wide range of virulent primary isolates remains a challenge, primarily because 
of  the  limited  number  of  conserved  neutralisation  epitopes  that  have  been 
identified and the failure to present such epitopes appropriately in vaccines.  
Steric  factors  may  render  neutralisation  epitopes  inaccessible  to  neutralising 
antibodies (NAbs) (Chiarantini et al., 1998; Labrijn et al., 2003) while most of 
the  antibodies  generated  by  vaccination  may  be  directed  against  non 
neutralising epitopes (Dhillon et al., 2007; Richman et al., 2003).  Accordingly, 
the  identification  of  conserved  determinants  for  neutralisation  will  be  an 
important advance in the design of the next generation of FIV vaccines. Chapter five 
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Understanding  the  biological  basis  for  the  induction  of antibodies  with  broad 
neutralising  activity  is  pivotal  to  the  development  of  efficacious  lentiviral 
vaccines  and  to  the  generation  of  vaccines  that  will  protect  against  a  broad 
range of primary isolates.  Encouraging results have indicated that it is possible 
to protect cats against challenge with primary FIV isolates depending on their 
regional  distribution.    By  vaccinating  cats  with  a  whole  inactivated  vaccine 
based  on  the  subtype  B  Pisa  M2  strain,  cats  were  protected  from  natural 
challenge  with  subtype  B  isolates  of  FIV  (Pistello  et  al.,  1997).    It  has  been 
suggested that subtype B isolates may be more ancient and accordingly more 
host adapted  (Bachmann  et  al.,  1997),  hence  they  may  be  more  readily 
neutralisable by the host humoral response.  In contrast, while subtype A viruses 
display similar levels of non synonymous mutations, such viruses display half as 
many synonymous site mutations, suggesting a more recent spread and lower 
level  of  host virus  adaptation  (Bachmann  et  al.,  1997).    As  the  major  FIV 
subtypes are restricted in their global distribution, it has been proposed that it 
may  be  necessary  to  design  several  regional  vaccines  rather  than  a  single 
worldwide protective vaccine (Steinrigl & Klein, 2003). 
In this study, we investigated the observation that a subtype B strain resisted 
neutralisation  by  its  homologous  serum.    By  applying  targeted  mutagenesis 
across the env gene, we identified the V5 loop as the primary determinant of 
escape from neutralisation and localised the primary determinant to a lysine 
threonine (K T) motif.  Additional subtype B strains bearing the same motif were 
also sensitive to neutralisation.  Furthermore, incorporation of these residues 
into a neutralisation resistant subtype B strain rendered the virus more sensitive 
to  neutralisation,  confirming  the  mono specificity  of  the  neutralising  serum.  
These data indicate that the functional neutralising response in natural infection 
with FIV may be highly specific and that immune evasion in vivo may stem from 
the mutation of as few as two amino acids in the V5 loop. Chapter five 
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5.2 Methods 
 
5.2.1  Blood  samples  and  collection  of  peripheral  blood  mononuclear  cells 
(PBMC) and sera 
All blood samples were collected from five naturally infected cats from three 
different regions of Japan (isolate NG4 originated in Isikawa, KNG1 and KNG2 
from Kanagawa and TOI1 and TOT1 from Tokyo).  Four of the cats, KNG1, NG4, 
TOT1,  and  TOI1  were  apparently  healthy  and  displaying  no  clinical  signs 
(analogous to the asymptomatic stage of HIV infection) whereas one cat, KNG2, 
presented with severe gingivostomatitis (analogous to the symptomatic stage of 
HIV infection).  PBMC were fractionated from 5 ml of heparinised whole blood by 
centrifugation  over  Ficoll Paque  density  separation  medium  (GE  Healthcare, 
Little Chalfont, U.K.).  Sera were aliquoted and stored at  80ºC prior to use in 
neutralisation assays. Chapter five 
5.3 Results 
 
5.3.1 Phylogenetic analysis 
An unrooted neighbour joining phylogenetic tree was generated based on 651 
nucleotides spanning the env V3 V5 sequence from the five isolates included in 
the study, as well as reference sequences from subtypes A, B, C, D and E.  The 
phylogenetic tree (Figure 5.1) demonstrated that the five Japanese isolates were 
genetically related and clustered within subtype B with a bootstrapping support 
of 100%.  KNG1 and TOT1 were highly similar at the nucleotide level and indeed 
had identical V3 V5 amino acid sequences (100% identity) and clustered together 
on a single tree branch (Figure 5.1). 
 Chapter five 
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Figure 5.1.  Midpoint rooted neighbour joining tree of the FIV V3 V5 env gene 
sequence.  The tree shows the five Japanese sequences included in the study (in 
red typeface) as well as reference sequences from subtypes A, B, C, D, and E.   
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5.3.2  Cats  show  different  NAb  responses  to  homologous  and  heterologous 
strains 
Sera  from  cats  KNG1  and  TOI1  showed  no  evidence  of  neutralising  activity 
against any of the pseudotypes tested (except moderate neutralisation of KNG2) 
including those bearing their homologous Envs and serum from cat KNG2 showed 
no neutralising activity against the KNG1, NG4 or TOT1 pseudotypes, moderate 
neutralising activity against the KNG2 pseudotype and weak neutralising activity 
against the TOI1 pseudotype (Table 5.1).  In contrast, sera from cats NG4 and 
TOT1 showed strong neutralising activity against pseudotypes expressing Envs of 
the heterologous KNG1, TOT1 and TOI1 strains, and moderate responses against 
pseudotypes expressing the Env of strain KNG2.  The pseudotype expressing the 
NG4 Env resisted neutralisation by four heterologous sera and showed only weak 
neutralising activity against its homologous serum (Table 5.1).  Although KNG1 
and  TOT1  shared  similar  env  sequences  (97%  similarity),  they  did  not  induce 
similar humoral immune responses in their respective hosts. 
 
Serum    
Pseudotype  KNG1  KNG2  NG4  TOT1  TOI1 
KNG1   7   12  86  99   78 
KNG2  67  71  73  64  61 
NG4  4  25  46   31   15 
TOT1   31   48  80  99   57 
TOI1  15  41  98  96   8 
Table  5.1.    Percent  neutralisation  values  (at  1:10  serum  dilution)  for  five 
HIV(FIV) pseudotyped viruses tested against homologous and heterologous sera 
for  neutralisation,  neutralising  activity  is  categorised  as  weak  (40 59%, 
highlighted in green), moderate (60 79%, highlighted in yellow) or strong (80 
100%, highlighted in orange).  Negative values indicate in vitro enhancement of 
infection and are not significant.   
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5.3.3 Escape from homologous neutralisation by NG4 
NG4 was only weakly or resisted neutralisation by the two cross neutralising sera 
NG4 and TOT1 respectively.  The finding that NG 4 was only weakly neutralised 
by its homologous serum, a serum that cross neutralised the other four viruses, 
may have indicated the evolution in vivo of a neutralisation escape mutant that, 
at the time of sampling, was the dominant species in the periphery since five 
independent Env clones for each virus were sequenced, all of which gave rise to 
identical V5 amino acid sequences (data not shown).  However, as blood samples 
from cat NG4 at earlier time points in infection were not available, it was not 
possible to identify earlier strains which would most likely have contributed to 
the generation of the NAbs.  However, given the similarity between the five 
subtype B isolates, sites of amino acid divergence from the consensus sequence 
that  were  identified  in  NG4  would  be  likely  to  contribute  to  the  relative 
resistance of this strain to neutralisation by its homologous serum (Figure 5.2).  
Accordingly,  these  non synonymous  residues  were  targeted  by  site directed 
mutagenesis in an attempt to render NG4 more sensitive to neutralisation by its 
homologous serum.  Initially, Env was mutated at the V3 loop, a known target 
for  neutralising  antibody  (Osborne  et  al.,  1994;  Lombardi  et  al.,  1993).    A 
glutamine residue (377) was substituted with a histidine (Q377H), resulting in a 
net increase in the charge of the V3 loop.  However, the Q377H mutation did not 
render NG4 more sensitive to neutralisation (Figure 5.3).  Next, the NG4 Env was 
mutated at the crown of the predicted V5 loop (Figure 5.2), targeting serine 
residue 550 (S550N), creating a potential site for N linked glycosylation.  When 
tested against its homologous serum, the S550N mutant did not show enhanced 
sensitivity  to  neutralisation  (Figure  5.3,  WT  =  46%  neutralisation  at  1  in  10 
dilution;  S550N  =  38%  at  1  in  10  dilution),  indicating  that  the  absence  of 
asparagine  550  alone,  and  ablation  of  the  predicted  site  for  N linked 
glycosylation did not contribute to the escape from neutralisation by homologous 
serum.  The NG4 Env was then mutated within the V5 loop with the insertion of 
two amino acids, lysine and threonine, at positions 556 and 557 (S556(KT)557K).  
Interestingly, this mutation rendered NG4 sensitive to neutralisation, with strong 
neutralising activity (98%) observed at 1:10 dilution (Figure 5.3A,B).  Moreover, 
the  S556(KT)557K  insertion  also  rendered  NG 4  sensitive  to  the  broadly 
neutralising TOT1 serum (Figure 5.3C,D) indicating that despite the independent 
origins  of  the  two  viruses,  both  cats  responded to  infection  by targeting V5.  Chapter five 
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Next, we asked whether the increase in polarity afforded by the inserted lysine 
residue  contributed  to  the  formation  of  the  neutralising  determinant.    An 
S556(K)557K mutant was prepared in which only a lysine residue was inserted.  
The  NG4  S556(K)557K  mutant  was  tested  against  NG4  serum  and  showed  an 
intermediate  pattern  of  neutralisation  (Figure  5.3)  indicating  that  while  the 
lysine residue was clearly important, the additional threonine residue enhanced 
the  formation  of  the  neutralising  determinant.    These  data  emphasise  the 
dominance of V5 in the neutralisation of FIV and are consistent with a hypothesis 
whereby the broadly neutralising NG4 serum selected for mutant viruses in the 
host animal bearing a deletion in V5. Fold neutralisation was calculated based on 
the mean (n=3) of the luciferase activity of no plasma control relative to that for 
each plasma dilution. Fold neutralisation was used to clarify the image when 
relatively strong neutralisation is obtained.  
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Figure 5.2.  Schematic structural model of the FIV SU protein illustrating the 
location  of  the  Q377H  mutation  in  V3,  and  the  V5  loop.    Inset  displays  a 
comparison of the sequence from the five study strains KNG1, KNG2, TOI1, TOT1 
and NG4, and the reference strain TM2 (Genbank: M59418).  
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Figure  5.3.    Neutralisation  of  wild  type  (WT)  NG4  and  NG4  mutants  by 
homologous serum (A,B) and by TOT1  serum (C,D).  A,C.  Luciferase activity 
(counts  per  minute)  with  successive  dilutions  of  NG4  serum  (dilution  factor 
1/10,1/100,  1/1000  and  1/10,000,  no  serum=∞).    B,D.    Fold  neutralisation 
relative to no serum control.  Each point represents the mean (n=3) +/  SEM. 
C 
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5.3.4 Neutralisation sensitivity of KNG2 
Of the five isolates studied, KNG2 was the most divergent at V5.  In comparison 
with the other strains, KNG2 was moderately sensitive to neutralisation by all 
the  sera  tested,  including  the  NG4  and  TOT1  sera  that  showed  strong 
neutralising activity against KNG1, TOT1 and TOI1.  Based on our finding that 
NG4  could  be  rendered  sensitive  to  neutralisation  by  a  single  change  in  the 
amino acid sequence of the V5 loop, we asked whether the partial resistance of 
KNG2  was  conferred  by  its  divergent  V5  loop.    Firstly,  a  KNG2  mutant  was 
prepared bearing a DN556KT mutation targeting the same residues shown earlier 
to confer neutralisation sensitivity upon NG4.  The DN556KT mutation did not 
display improved sensitivity to neutralisation relative to the wild type.  Since the 
sequence of KNG2 diverged from the consensus at 7 amino acids (Figure 5.5), we 
considered  that  the  context  of  the  mutation  may  have  been  important  for 
formation  of  the  epitope.    Accordingly,  the  V5  loop  was  mutated  in  stages 
towards identity with the (highly sensitive) KNG1 and TOT1 sequences; initially a 
5  amino  acid  change  was  created  (553NGNDN558→553DNSDT558)  followed  by 
the  full  mutation  (551STNGNDNKMT558→551GTDNSKTKMA558).    Both  KNG2 
mutants were then tested for sensitivity to neutralisation by the TOT1 serum.  
The  551STNGNDNKMT558→551GTDNSKTKMA558  variant  was  neutralised 
efficiently by the TOT1 serum while the 553NGNDN558→553DNSDT558 mutant 
showed an intermediate sensitivity (Figure 5.4).  The conversion of KNG2 from 
neutralisation resistant to neutralisation sensitive by changing the sequence of 
V5 to a sequence similar to the neutralisation sensitive KNG1 and TOT1 strains is 
consistent with V5 being a primary determinant of neutralisation sensitivity and 
the specificity of the neutralising sera. Chapter five 
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Figure 5. 4.  Conferral of neutralisation sensitivity to KNG2 by V5 loop transfer.  
A.)  Luciferase  activity  (counts  per  minute)  with  successive  dilutions  of  TOT1 
serum (dilution factor 1/10, 1/100, 1/1000 and 1/10,000). Each point represents 
the mean (n=3) +/  SEM. B.) Fold neutralisation relative to no serum control.   
 
A 
B Chapter five 
  111 
The results of this study indicate the importance of V5 to antibody mediated 
neutralisation of FIV.  While anti V5 antibodies can neutralise primary isolates of 
FIV very efficiently, the virus appears able to escape neutralisation readily by 
mutating V4.  What then are the prospects for designing an FIV vaccine that 
induces broadly neutralising antibodies targeting V5? A comparison of published 
V5 sequences (Figure 5.5) would suggest that the V5 region has highly conserved 
structural  features  such  as  the  cysteine  residues  at  533,  546,  548  and  561 
(numbering as in KNG1&2, TOI1 and TOT1, Figure 5.5).  However, the region 
between cysteine residues 548 and 561 appears to be remarkably flexible in its 
ability to tolerate amino acid substitutions, glycosylation (potentially O and N 
linked) and length polymorphisms, suggesting that it is under pressure to vary 
from  the  host  immune  response.    The  relative  conservation  of  the  region 
between  cysteines  533  and  548  may  indicate  that  this  region  is  either 
inaccessible  or  structurally  constrained,  perhaps  through  interactions  with 
adjacent  regions  of  Env.    If  possible,  targeting  the  humoral  response  to  this 
region may induce more broadly neutralising antibodies. 
 
Figure 5.5.  Amino acid alignment of the V5 region from diverse FIVs.  Within the 
framework of the predicted loop bounded by cysteines 533 and 561 (numbering 
as in KNG1&2,TOI1 and TOT1), extensive variation is evident, the majority of 
which resides between cysteine residues 548 and 561. Chapter five 
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5.4 Discussion 
In this chapter, it was demonstrated that the V5 loop of FIV Env is a primary 
target  for  virus  neutralising  antibodies.    Although  previous  studies  in  vitro 
indicated  that  the  V3  loop  was  a  major determinant  for  virus  neutralisation, 
subsequent  studies  revealed  that  the  significance  of  antibodies  targeting  this 
region to the neutralising response had been over emphasised by the cellular 
substrate  used  to  quantify  neutralisation.    Formerly,  assays  were  based  on 
inhibiting infection of CrFK cells with “CrFK adapted” strains of virus.  Prior to 
measuring neutralisation in this system, the challenge virus had to be selected 
for  growth  in  CrFK  cells,  thereby  selecting  for  viruses  that  were  capable  of 
CD134 independent infection through a direct interaction with CXCR4 (analogous 
to CD4 independent infection with HIV).  The V3 loop plays a critical role in the 
FIV  Env CXCR4  interaction;  accordingly,  CrFK based  assays  exaggerated  the 
importance of neutralising antibodies binding this region.  Subsequent studies 
revealed that when primary (non CrFK adapted) isolates were assayed on IL2 
dependent T cells, the correlation between the efficiency of virus neutralisation 
and the response to V3 was diminished.  This study extended previous studies 
that indicated that in biologically relevant in vitro systems, the variable loops 
V4 and V5 appear to be the major targets for effective neutralising antibodies.  
Moreover, it was found that in polyclonal sera from infected cats, deletion of as 
few as two amino acids from V5 converted a virus from a strongly neutralised to 
a weakly neutralised or neutralisation resistant phenotype.  Each of the isolates 
described in the current study were confirmed as CD134 dependent, by plating 
the viral pseudotypes on target cells expressing CD134.  No evidence of CD134 
independent  infection  via  CXCR4  alone  was  detected  (data  not  shown), 
confirming that the isolates were primary and not cell culture adapted. 
Amongst the variable regions in FIV Env, V5 appears to be highly polymorphic 
between  strains,  with  variations  in  amino  acid  sequence,  glycosylation,  and 
extended stretches of serine and threonine residues being common.  These data 
suggest that there is a selective pressure within the host for variation in V5, 
consistent  with  escape  from  an  effective  immune  response.    That  minimal 
variation in V5 is sufficient to either reduce substantially or ablate completely 
the  neutralising  capacity  of  the  host  humoral  response  is  of  concern  for  the 
design of effective FIV vaccines.  How then are we to elicit broadly neutralising Chapter five 
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antibodies in vivo? Clearly, the V4 and V5 loops are exposed and immunogenic 
and  antibodies  targeting  these  regions  neutralise  virus.    However,  it  would 
appear that these regions may represent little more than a decoy for the virus, 
presenting the immune system with an easy target for neutralising antibodies.  
By the time functional neutralising antibodies develop, viral variants that can 
escape the mono specific serum may have evolved already in vivo.  The solution 
to  this  dilemma  would  appear  to  lie  in  the  identification  of  framework 
determinants in Env that induce antibodies that are broadly active, refocusing 
the immune response by either silencing the immunodominant (but ultimately 
ineffectual) determinants in V4 and V5, or by presenting them in a such a way as 
to  induce  antibodies  that  recognise  structures  or  motifs  that  are  difficult  or 
impossible for the virus to vary. 
Previous studies have demonstrated the importance of V5 in virus neutralisation 
(Pistello et al., 2003b; Siebelink et al., 1995a).  V5 was mapped using synthetic 
peptides for a possible linear epitope based on the sequence of the 19k1 560 
strain  (Siebelink  et  al.,  1995a),  and  demonstrated  that  a  single  mutation  at 
position  560  may  be  involved concurrently  with  another  mutation  at  483  (V4 
loop) in one or more conformational epitopes; but no linear epitope was mapped 
in V5.  Further, two independent mutations have been reported that resulted in 
the  creation  of  potential  N linked  glycosylation  sites  in  V4  (K481N)  and  V5 
(S557N) and which contributed to the conversion from a neutralisation sensitive 
to neutralisation resistant phenotype (Giannecchini et al., 2001b; Pistello et al., 
2003b).    In  comparison,  the  conversion  from  a  weakly  neutralised  or 
neutralisation resistant to a strongly neutralised phenotype described herein was 
mediated by mutation of V5 alone.  The V5 loop of FIV Env is highly variable 
among isolates.  Variation occurs not only within the amino acid sequence but 
also in the length of the central region (up to 14 residues) towards the end of 
the loop formed by disulfide bond linkage, indicating that this particular region 
may play a significant role in viral evolution and escape from neutralisation.  It 
is  notable  that  the  length  polymorphisms in this region are  attributable  to  a 
reiteration of codons encoding serine and threonine residues.  Threonine and 
serine  have  hydroxyl  side  chains  and  may,  potentially,  undergo  O linked 
glycosylation.  It is generally believed that due to their small molecular size, O 
linked oligosaccharides have only minor effects on the formation of the glycan 
shield  on  HIV  Env  compared  to  N linked  oligosaccharides.    However,  these Chapter five 
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oligosaccharides usually have diverse structures with no common carbohydrate 
core  and  it  is  difficult  to  predict  how  efficient  they  may  be  in  shielding 
neutralisation epitopes, especially when there are several adjacent molecules 
(Bernstein et al., 1994).  Moreover, X ray crystallography studies on HIV 1 gp120 
showed that glycosylation may have significant effects on the conformational 
stability of Env as well as an indirect effect on more distant sequences along the 
secondary  structure.    This  in  turn  would  affect  the  interaction  between  the 
epitope  and  neutralising  antibodies,  rendering  epitopes  less  accessible  for 
antibody binding (Huang et al., 1997). 
In  conclusion,  we  identified  a  neutralisation  determinant  in  the  FIV  V5  loop 
which  is  associated  with  the  conversion  of  strongly  neutralised  to  weakly 
neutralised or neutralisation resistant strains.  The determinant was apparently 
linear and involved at least 10 amino acids (GTDNSKTKMA) within the V5 region, 
a  highly  variable  region  amongst  FIV  strains.    The  identification  of  this 
neutralisation determinant will inform vaccine design in the future in order to 
induce more potent neutralising antibody responses. Chapter six 
6 Identification of neutralising antibodies in clinical samples 
 
6.1 Introduction 
There are many similarities between the clinical manifestations and progression 
of disease with FIV and HIV infections; following the acute phase of infection, 
which  lasts  a  few  weeks,  infected  subjects  enter  the  asymptomatic  phase.  
During this phase virus replication is minimal in PBMCs and the immune response 
develops and matures (Stebbing et al., 2004; English et al., 1994).  Both humoral 
and cell mediated immune responses have roles in restraining the virus at this 
stage of infection. 
It has been documented that, several months after sero conversion, HIV infected 
individuals  develop  NAbs  effective  against  the  homologous  challenge  strains, 
commonly named autologous NAbs (aNAbs) (Sather  et al., 2009; Frost  et al., 
2005).    An  inverse  correlation  between  the  presence  of  NAbs  and  disease 
manifestation has been well documented in HIV 1 infection, where progression 
of infection to clinical AIDS is dependent on viral evasion of antibody mediated 
neutralisation  (Kwong  et  al.,  2002).    Moreover,  sera  from  long  term  non 
progressors  (LTNPs)  contain  high  titres  of  NAbs  and  more  frequently  develop 
stronger neutralising responses compared to short term progressors (Cao et al., 
1996), highlighting the protective role of humoral immunity. 
The continuous emergence of new viral variants in response to immune pressure 
reduces the efficacy of NAbs (Mahalanabis et al., 2009; Bunnik et al., 2008).  
Although it is an additive challenge for the immune system to respond to a highly 
heterogeneic population or viral quasispecies, such viral heterogeneity broadens 
the  scope  of  NAb  recognition  such  that  even  heterologous  strains  may  be 
neutralised  in  some  LTNPs  (Simek  et  al.,  2009).    Factors  involved  in  the 
generation of broad NAbs have not yet been well defined but may include the 
virulence of the infecting strain and the initial viral load that is established, 
quasispecies complexity, the status of the host immune system, as well as other 
factors (Balfe et al., 2004; Krachmarov et al., 2006). 
A  small  proportion  of  sera  from  HIV infected  individuals  may  contain  cross 
neutralising antibodies, usually after two years of sero conversion (Kraft et al., Chapter six 
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2007; Moore & Trkola, 1997).  Broad NAb responses are well developed in LTNPs, 
whereas NAbs titres are usually low in rapid disease progressors (Pilgrim et al., 
1997;  Carotenuto  et  al.,  1998).    It  is  therefore  reasoned  that  NAb  impede 
disease progression, and that a decline in HIV specific antibody responses often 
predicts a poor prognosis (Cecilia et al., 1999).  For FIV, little is known about 
the ability of infected cats to either mount a NAb response or develop NAbs that 
may cross neutralise either related or unrelated primary strains of FIV. 
The variable (V) loops of Env play a key role in viral evasion from NAbs, shielding 
conserved epitopes that would be targets for neutralisation (Etemad Moghadam 
et  al.,  1999).    For  example,  the  V1/V2  region  in  HIV 1  occludes  important 
conserved  epitopes  such  as  the  co receptor  binding  site  (Krachmarov  et  al., 
2005; Pinter et al., 2004).  The V3 loop of HIV 1 is considered to be a principal 
neutralising determinant (Moore & Trkola, 1997) and is involved in co receptor 
binding and determines cell tropism (Sundstrom  et al., 2008; Cormier  et al., 
2001; Hoffman & Doms, 1999).  The role of the V4 and V5 loops in neutralisation 
resistance  is  unclear  but  it  is  thought  that  these  regions  impact  upon  Env 
conformation and glycan packing (Wei et al., 2003).  For both FIV and HIV 1, 
mutations in the V4 loop alter the viral neutralisation profiles (Bendinelli et al., 
2001; Kinsey et al., 1996). 
This chapter describes studies undertaken using the remainders of blood samples 
collected from cats naturally infected with FIV.  Plasma samples were screened 
for NAbs against a representative primary UK isolate of FIV, GL8.  Subsequently, 
samples  which  strongly  neutralised  GL8  were  tested  against  other  isolates  to 
assess  the  breadth  of  cross reactivity.    Furthermore,  viral  pseudotypes  were 
constructed bearing the Envs of novel primary isolates and these pseudotypes 
were tested for susceptibility to neutralisation by homologous plasma as well as 
the broadly neutralising plasma samples that were identified.  It was possible to 
estimate the proportion of naturally infected cats that had developed NAbs and 
to assess the cross reactivity of these NAbs, thereby providing an insight into the 
ability of the feline immune system to generate effective responses against FIV.  
As a result of these studies, a neutralisation epitope was identified in the C3 V4 
domain Chapter six 
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6.2 Methods and Results 
 
6.2.1 Description of the sample population  
Plasma  samples  were  collected  from  345  FIV  sero positive, naturally  infected 
cats that have been submitted to the the Companion Animals Diagnostic Service 
at the University of Glasgow. Samples were tested for the presence of antibodies 
against FIV using an immunofluorescence assay (IFA).  Information included on 
the sample submission forms such as the age, sex, health status, and clinical 
signs of the cats is presented in Appendix 2. 
 
The cats’ ages ranged from 5 months to 18 years but many ages were either 
unknown or estimated by the cats’ veterinarians.  Many of the FIV infected cats 
were  held  in  cat  protection  shelters,  strays  awaiting  adoption,  or  were  free 
roaming.  Cats within these groups are at greater risk of FIV infection, according 
to epidemiological studies (Courchamp & Pontier, 1994).  The FIV infected cats 
in this study were five times more likely to be male than female, consistent with 
previous studies which demonstrated that males were at a higher risk of FIV 
infection  due  to  their  more  aggressive  nature  (Natoli  et  al.,  2005).  
Approximately  one  third  of  the  cats  displayed  no  clinical  signs  and  were 
apparently healthy.  However, not all cats had been examined thoroughly by 
veterinarians and so this proportion may have been  over estimated.  Clinical 
signs  recorded  for  the  sick  cats  included  weight  loss,  dullness,  anorexia, 
vomiting,  inappetance,  malaise,  lethargy,  pyrexia,  anaemia,  jaundice, 
keratitis/uveitis,  upper  respiratory  tract  (URT)  signs,  stomatitis/gingivitis, 
neurological signs and enlarged lymph nodes.   
 
6.2.2 Identification of NAbs against HIV(GL8)  
The remainders of 345 samples that tested positive for FIV were screened for 
NAbs  against  the  HIV(GL8)  pseudotype,  since  GL8  has  been  shown  to  be 
representative of primary FIV strains in the UK (Dunham et al., 2006a).  As the 
aim of the study was to estimate the proportion of cats naturally infected with 
FIV that develop NAbs, samples were tested subsequently for the ability to cross 
neutralise other pseudotypes.  Since the plasma samples were collected from 
clinical cases, the time of FIV infection was unknown and clinical staging based Chapter six 
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on  the  signs  recorded  on  the  submission  forms  was  unlikely  to  be  accurate.  
Since  older  cats  may  have  been  infected  for  longer,  we  examined  the  data 
collected  from  214  cats  of  known  age  to  determine  whether  older  cats  had 
higher levels of NAbs (Figure 6.1).  The neutralisation profiles from these cats 
ranged from slight enhancement to strong neutralisation, with no relationship 
evident  between  age  and  cross neutralisation  of  the  GL8  pseudotype.    For 
example, plasma sample 179028 (collected from an 11 year old male cat with 
clinical  signs  including  chronic  gingivitis)  only  poorly  neutralised  the  GL8 
pseudotype (28% neutralisation at a plasma dilution of 1 in 10), whereas plasma 
sample 171838 (belonging to an 18 month old male cat) was strongly neutralising 
(90% neutralisation at a plasma dilution of 1 in 10).  Furthermore, the latter 
plasma from the younger cat displayed strong cross neutralising activity against 
pseudotypes expressing Envs from a panel of primary isolates (see section 6.2.6). 
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Figure 6.1.  The relationship between age and levels of FIV NAb.  Plasma samples 
from  cats  of  known  ages  were  screened  against  HIV(GL8).    Values  for  % 
neutralisation (at a 1:10 dilution of plasma) are shown in relation to the cats’ 
ages. Chapter six 
  119 
It was observed that 30 of the 345 plasma samples examined (8.7%) strongly (i.e.  
≥ 80% at a 1 in 10 dilution) neutralised HIV(GL8).  The samples containing NAb 
were collected from cats aged between 18 months and 14 years (Table 6.1).  
Hence  it  was  concluded  that  8.7%  of  plasma  samples  collected  from  cats 
naturally  infected  with  FIV  contained  NAbs  against  the  heterologous  primary 
isolate  GL8.    It  is  likely  that  the  proportion  of  cats  with  NAbs  against  their 
homologous isolates may have been greater but, nevertheless, it appears that, 
as for HIV 1 infected individuals (Beirnaert et al., 2001), NAbs generated during 
natural infection are not commonly detected in FIV infected cats. 
 
Number  Age 
(years)  % Neutralisation  Number  Age 
(years)  % Neutralisation 
169248  7  92  179035   NK  92 
169422  9  92  180644  10  85 
169630  12  92  180779   NK  84 
170141  12  93  180871  1  86 
170305  NK   83  181380  8  95 
170338  11  85  181516   NK  85 
170764  12  81  181650  8  81 
170777  13  84  181793  12  97 
170962  8  81  203126   NK  99 
170973   NK  89  203135  4  97 
171806  8  87  203179  NK   98 
171838  2  90  205687  10  80 
172279  12  97  206394  14  95 
172532   NK  100  209971  3  80 
178639  10  99  210101  10  83 
Table 6.1.  Identification of plasma samples that strongly neutralised (≥ 80%) 
HIV(GL8).  Values shown represent % neutralisation at a 1:10 dilution of plasma.  
Cats’ ages are also shown where known; NK: not known. 
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6.2.3 Identification of samples containing broadly neutralising antibodies 
The 30 plasma samples containing NAbs that strongly neutralised GL8 (Table 6.1) 
were tested next for the ability to neutralise HIV(FIV) pseudotypes bearing Envs 
from primary isolates such as PPR and CPG 41.  Selected samples are shown in 
Table  6.2.    Next,  samples  displaying  broad  cross reactivity  were  tested  also 
against  pseudotypes  bearing  Envs  from  a  panel  of  primary  isolates.    Three 
samples exhibited broad neutralising antibody activity against most or all of the 
pseudotypes  tested  (Table  6.3),  representing  10%  of  the  plasma  samples 
containing NAbs.  Unfortunately there was insufficient sample available from cat 
171838 to test more pseudotypes; this sample contained high levels of broadly 
NAbs against the majority of pseudotypes tested and is discussed later in this 
chapter. 
 
Pseudotype  Plasma 
GL8  PPR  CPG 41 
169630 (17)  87  99  86 
203135  97  99  82 
203179  98  60  ND 
203292  95  99  99 
209971  80  74  ND 
210101  83  100  21 
Table  6.2.    Screening  plasma  samples  for  broad  neutralisation.    The  values 
shown represent the % neutralisation at a 1 in 10 dilution of plasma.  Samples 
which strongly neutralised GL8 were subsequently tested against the pseudotype 
bearing the Env of PPR, a subtype A strain isolated in the USA.  Samples which 
strongly or moderately neutralised PPR were further tested against the CPG 41 
pseudotype, a subtype C strain isolated in the USA.  Values for plasma 169630 
(17) are recorded for the sample collected 17 months after the first sample. 
ND: not done Chapter six 
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Plasma  Pseudotype  Subtype 
178639  206394  171838 
180638  A  99  90  83 
171838  A  ND  99  99 
180260  A  96  96  97 
182309  A  100  100  98 
180140  A  90  97  93 
178721  A  99  97  99 
179200  A  83  97  16 
206394  A  83  93  89 
KNG2  B  96  99  ND 
TM2  B  99  99  ND 
GL8  A  99  95  90 
B2542  B  99  99  ND 
CPG 41  C  96  99  ND 
PPR  A  98  99  ND 
0425  A  99  96  ND 
M2  B  93  100  ND 
0827  A  99  95  ND 
1419  A  95  96  ND 
Leviano  B   ND  100  ND 
Table  6.3.    The  identification  of  broadly  neutralising  plasmas.    Values  of  % 
neutralisation at plasma dilutions of 1:10 are shown.  B2542, M2, KNG2, Leviano 
and TM2 are subtype B strains; PET KKS, GL8, and PPR are subtype A strains; 
CPG 41 is subtype C strain; and 425, 1419, 827, 556, 180638, 171838, 180260, 
180140, 178721, 179200, 206394 and 182309 are primary subtype A strains (also 
see appendix 4).  ND: not done. 
 
 
6.2.4 The development of NAb with time following natural infection 
In  order  to  monitor  the  development  of  immunity  as  infection  proceeds,  we 
examined  sequential  plasma  samples  collected  from  naturally  infected  cats.  
However, few sequential samples were obtained as a large number of the FIV 
infected cats had been euthanised following diagnosis.  Follow up samples were 
obtained  from  nine  FIV  infected  cats  as  a  part  of  an  undergraduate  student 
project.  These samples were collected at intervals of between 10 months and 
18 months after the first sample collection and the sample pairs were tested for 
the presence of NAb against GL8.  As shown in Table 6.4, in general the follow 
up  samples  showed  either  little  change  in  neutralisation  (or  even  decreased Chapter six 
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neutralisation)  in  the  later  samples.    It  had  been  speculated  that  the  NAb 
response  would  mature  as  infection  proceeds;  however  the  results  did  not 
confirm this hypothesis.  For example, although cat 171505 showed an increase 
in neutralising activity after 15 months (neutralisation increased from 40% to 80% 
at a 1:10 dilution of plasma), the follow up sample from cat 172279 showed only 
moderate  neutralisation  although  the  earlier  sample  had  been  strongly 
neutralising (neutralisation decreased from 97% to 61%).  Cat 181809 also showed 
reduced neutralising efficacy in the follow up sample (neutralisation decreased 
from 68% to 21%).   
The  most  likely  explanation  for  the  reduction  in  neutralisation  observed  in 
follow up samples from cats 172279 and 181809 is that both cats had progressed 
to the late stage of infection; the former had chronic stomatitis and laryngeal 
swelling, and the latter was lethargic, pyrexic, inappetant, and slightly ataxic.  
Perhaps  these  two  cats  were  terminally  ill  and  their  immune  systems  were 
failing  at  the  time  of  the  follow up  sampling.    Other  samples  did  not  show 
significant changes in neutralising ability, perhaps because insufficient time had 
elapsed  between  samplings  to  permit  the  maturation  of  cross reactive  NAbs.  
Plasma from cat 169630 displayed a strong NAb response against GL8 at both the 
first sampling as well as at the follow up, 17 months later.  Furthermore, the 
follow up  sample  showed  broader  NAb  activity,  with  stronger  neutralising 
activity  against  CPG 41  (neutralisation  increased  from   7%  to  86%)  (data  not 
shown).  Therefore, it appeared that, in this cat, the NAb response had matured 
in both efficacy and breadth during the 17 month period between samplings. 
 
Plasma number  First sample  Follow up  Time interval 
(months) 
169630  92  87  17 
172279  97  61  14 
169421  43  14  18 
170003  48  33  16 
172471  30  29  13 
169244  15  35  18 
181809  68  21  10 
170901  79  62  15 
171505  40  80  15 
Table 6.4.  The effect of time on NAb maturation.  Values show % neutralisation 
at a 1:10 dilution for plasma samples tested against HIV(GL8). Chapter six 
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6.2.5 Neutralisation of homologous pseudotypes by clinical samples  
In  order  to  assess  the  neutralisation  of  field  isolates  by  their  homologous 
plasmas, pseudotypes were prepared bearing the Envs of primary field isolates 
from naturally infected cats.  The env genes of these primary field isolates were 
cloned and HIV(FIV) pseudotypes were constructed, using the methods described 
in Section 2.3.6.  Eight viable pseudotypes were prepared, bearing the Envs of 
171838,  179200,  178721,  182309,  180638,  180140,  180260,  and  206394.    As 
shown  in  Table  6.5,  plasma  samples  from  cats  171838,  182309,  and  206394 
strongly neutralised (>80% neutralisation at 1:10 dilution of plasma) pseudotypes 
bearing  their  homologous  Envs,  while  the  remaining  plasmas  only  weakly 
neutralised or did not neutralise their homologous pseudotypes.  While plasma 
samples  from  cats  171838  and  206394  contained  NAbs  that  cross  neutralised 
strongly  (>90%)  the  GL8  pseudotype,  plasma  from  cat  182309  only  weakly 
neutralised GL8 (34%).     
 
Plasma  Homologous 
pseudotype 
a 
GL8 
pseudotype
 b 
206394  93  95 
171838  99  90 
178721  29  45 
179200  38  41 
180140  53  63 
180260   30  23 
180638   4   13 
182309  83  34 
Table  6.5.    The  ability  of  plasma  samples  from  8  naturally  infected  cats  to 
neutralise pseudotypes bearing either a.) homologous or b.) GL8 Env.  Values 
shown are % neutralisation at 1:10 plasma dilution. 
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6.2.6 Characterisation of a broadly neutralising plasma  
Plasma collected from the 18 month old cat 171838 contained NAb that showed 
strong cross reactivity (>80% neutralisation) against the GL8 pseudotype and 7/8 
pseudotypes bearing the Envs of novel primary isolates (Table 6.3 and Figure 
6.3).    In  order  to  investigate  the  factors  that  may  have  contributed  to  the 
induction of this broad NAb response, the sequence of the env gene cloned from 
MYA 1  cells  co cultivated  with  PBMC  from  cat  171838  was  compared  to  the 
proviral env sequence amplified directly from PBMCs.  It was striking that these 
two  env  sequences  displayed  significant  differences  in  amino  acid  sequence 
(Figure 6.2), suggesting that perhaps cat 171838 was infected with a diverse FIV 
quasispecies.   
 
 
Figure 6.2.  Sequence diversity of 171838 Env.  Amino acid sequences of Env 
171838 cloned from virus recovered from MYA 1 co cultivated with the cat’s own 
PBMC (171838 clone), compared to the sequence of the provirus cloned directly 
from PBMC (171838 provirus).  The V3, V4 and V5 loop sequences are located 
between the arrows as shown. 
 
6.2.7 The identification of a neutralising epitope in the C3 V4 region of Env 
Plasma from cat 171838 neutralised all pseudotypes bearing the Envs of primary 
strains that were prepared in this project, with the exception of the pseudotype 
bearing the Env of 179200 (Figure 6.3).  Unfortunately, no follow up samples 
were  available  from  cat  171838  as  the  cat  was  euthanised  following  the 
diagnosis of FIV infection and therefore further tests could not be conducted. 
V3 
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Figure 6.3.  Plasma from cat 171838 was broadly neutralising.  Plasma from cat 
171838 was tested for the ability to neutralise a panel of HIV(FIV) pseudotypes 
bearing the Envs of eight naturally occurring UK isolates (see key), showing % 
neutralisation.  All pseudotypes except 179200 were strongly neutralised (>80% 
at 1:10 plasma dilution). Each point is derived from the mean (n=3) +/  SEM of 
luciferase activity counts. Chapter six 
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Since 179200 resisted neutralisation by the broadly neutralising plasma 171838, 
the Env amino acid sequence of 179200 was compared with sequences derived 
from other env clones encoding Envs that were susceptible to neutralisation by 
plasma  171838  (Figure  6.4).    We  looked  for  evidence  of  sequence  variation 
within the variable loops, especially for amino acid substitutions which changed 
the polarity and/or net charge of the domains, as well as substitutions resulting 
in  the  creation  or  deletion  of  potential  N linked  glycosylation  sites  (PNGS).  
PNGS  are  covalently  attached  to  aspargine  residues  identified  within  the 
following sequence: N X S/T, where N is aspargine, X is any amino acid except 
proline, S is Serine, and T is Threonine.  Using these criteria, a number of unique 
substitutions were identified in Env 179200.  Firstly, a PNGS close to the start of 
the V4 region of Env, at aspargine 447, was ablated (Figure 6.4).  This PNGS was 
conserved in most of 47 naturally occurring strains that were sequenced as part 
of this project (see Appendix 1), as well as in strains from subtypes A,B,C, D and 
E.
* 
 
 
Figure 6.4.  Amino acid sequence of wild type and mutant variants of 179200.  
This  region  of  C3 V4  sequence  shows  that  the  179200  Env  contains  a  unique 
KKTQ motif located between residues 447 and 450.  The 179200 mutant variant 
contains the sequence NKSK, similar to the other Envs. 
 
Accordingly, a mutant variant Env of 179200 was prepared, repairing the deleted 
PNGS  (179200 K447N),  and  an  HIV(FIV)  pseudotype  bearing  the  179200 K447N 
mutant Env was tested for sensitivity to neutralisation by plasma 171838.  It was 
                                                 
* GenBank accession numbers for strains that retain the PNGS at N 447 are as follows.  Subtype 
A:  U02403  (hnky12);  U02410  (sam01);  U02413  (tt09);  U02417  (zepy01);  NC001  (Petaluma); 
AB010404  (SAP03);  X57002  (Swiss  Z1).    Subtype  B:  U02418  (brny03);  U02419 (boy03);  U02420 
(glwd03)  U02422  (mtex03);  D84497  (Lp9);  AB010397  (AICO2).    Subtype  C:  AB016025  (TI1); 
AB016026  (TI2);  AB016027  (TI3);  AB016028  (TI4);  U02392  (pady02).    Subtype  D:  AB010400 
(OKA01D).  Subtype E: D84496 (Lp3); D84497 (Lp9); D84498 (Lp20); D84500 (Lp24). 
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observed  that  the  K447N  mutation  alone  did  not  render  179200  sensitive  to 
neutralisation  (neutralisation  of  16%  was  observed  for  the  wild type  179200 
pseudotype compared to 23% for the 179200 K447N mutant at a 1:10 dilution of 
plasma 171838).  The mutation was then extended to include the threonine 449 
and glutamine 450 residues, constructing a mutant with a sequence similar to 
the  remaining  sequences  (the  WT  sequence  447KKTQ450  was  mutated  to 
447NKSK450), and an HIV(FIV) pseudotype bearing the 447NKSK450 mutant Env 
was  tested  for  susceptibility  to  neutralisation  by  plasma  171838.    The 
447NKSK450  mutant  pseudotype  was  neutralised  strongly  by  plasma  171838 
compared  to  the  wild type  pseudotype  (Figure  6.5a).    It  was  concluded, 
therefore,  that  the  four  amino  acid  sequence  447KKTQ450  rather  than  the 
absent PNGS had an important role in rendering the 179200 Env neutralisation 
resistant.    Subsequently,  the  likelihood  of  N linked  glycosylation  occurring  at 
position 447 was calculated using NetOGlyc 3.1 software (Julenius et al., 2005); 
the  results  obtained  by  applying  the  full  sequence  of  env  were  found  to  be 
minimal (<50%), consistent with our observation.  The 447NKSK450 mutant was 
tested also for susceptibility to neutralisation by the homologous plasma from 
cat  179200.    The  results  showed  no  improvement  in  neutralisation  sensitivity 
(Figure  6.5b),  suggesting  that  plasma  179200  did  not  contain  mature  NAbs.  
Furthermore,  no  significant  differences  in  neutralisation  sensitivity  were 
observed when the neutralisation of the wild type 179200 Env was compared 
with the neutralisation of the 447 NKSK 450 mutant of 179200 Env, using the 
broadly neutralising plasma 206394 (Table 6.6).  Pseudotypes bearing both Envs 
were strongly neutralised. Chapter six 
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Figure 6.5.  Neutralisation of pseudotypes bearing the Env of wild type (WT) 
179200  or  its  mutant  (179200  mutant)  by  A.)  the  heterologous  broadly 
neutralising plasma 171838 and B.) the homologous plasma 179200. Each point is 
derived from the mean (n=3) +/  SEM of luciferase activity counts. Chapter six 
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Plasma  179200 WT  179200 mutant 
179200  38  39 
171838  16  90 
206394  99  97 
Table  6.6.    Summary  of  %  neutralisation  of  wild  type  and  mutant  179200 
pseudotypes by homologous plasma and two broadly neutralising plasma samples 
tested at 1:10 dilution of plasma. 
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6.3 Discussion 
In this chapter the generation of NAbs in response  to naturally occurring FIV 
infection  was  investigated.    It  was  demonstrated  that  out  of  eight  plasma 
samples,  two  (171838  and  206394)  have  shown  strong  neutralising  activity 
against  pseudotypes  bearing  homologous  or  heterologous  Envs.    Furthermore, 
one  plasma  sample  (182309)  strongly  neutralised  a  pseudotype  bearing  the 
homologous 182309 Env but not the pseudotype bearing the GL8 Env (Table 6.5).  
In HIV 1 infected subjects, in whom the time of infection was more accurately 
determined, it has been shown that aNAbs were generated in almost all infected 
subjects a few months after sero conversion (Gray et al., 2007; Li et al., 2006).  
It is possible, therefore, that the proportion of plasma samples from FIV infected 
cats  containing  NAbs  may  have  been  greater  if  follow  up  samples  had  been 
available from cats at later stages of infection.  However, it was not possible to 
determine  the  time  of  infection  since  all  the  cats  studied  were  naturally 
infected.    It  is  possible  that  NAbs  may  not  be  detectable  early  after  sero 
conversion, as has been demonstrated for HIV 1 infection (Moog et al., 1997). 
It is likely that the generation of aNAbs is less important than the induction of 
broadly  NAbs;  certainly,  in  terms  of  vaccine  development,  an  effective 
immunogen must be capable of inducing a broad neutralising response.  The data 
presented  in  this  chapter  demonstrated  that  cats  with  broadly  cross reactive 
NAbs are not common (less than 3% of samples tested).  Similarly, it has been 
shown that sera capable of neutralising a diverse panel of HIV 1 viruses are not 
common (Kraft et al., 2007; Li et al., 2007).  An investigation of the specificities 
of these broadly NAbs may reveal neutralisation determinants that are conserved 
amongst viral isolates and between subtypes.   
As  the  NAb  response  matures  with  time,  in  terms  of  potency  and  breadth, 
follow up plasma samples were collected from FIV sero positive cats at intervals 
of between 10 months and 18 months after the first sample collection.  While no 
significant improvement was observed in neutralisation potency in most samples 
tested, it was shown that one follow up plasma sample (plasma 171505 collected 
15  months  after  the  first  sample)  was  able  to  strongly  neutralise  GL8.    This 
finding may suggest that a smaller proportion of plasma samples contain NAbs 
against  FIV  compared  to  HIV 1;  alternatively  it  may  require  longer  for 
heterologous NAbs against FIV to mature.  Moreover, one of two plasmas which Chapter six 
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strongly neutralised GL8 (169630) showed a broader response after follow up, 
strongly neutralising CPG 41 (86%) and PPR (99%) in addition to GL8 (Table 6.2), 
whereas the other plasma (172279) showed no increase in the breadth of cross 
reactivity  (data  not  shown).    However,  plasma  169630  did  not  neutralise 
pseudotypes from primary UK isolates, suggesting that the cross reactivity of the 
neutralising response was still limited. 
Plasma  sample  171838  displayed  strong  cross neutralising  activity  against 
pseudotypes expressing the Env of GL8 as well as a panel of Envs from novel 
primary isolates.  As cat 171838 was young, it was possible that this cat had 
become infected from its dam in utero; however the case history of the cat was 
not  available  and  therefore  the  route  and  timing  of  infection  could  not  be 
confirmed.  Other factors that may have affected the development of broadly 
NAbs in this cat included the virulence of the transmitted virus, the viral load 
and divergence of the evolved quasispecies. 
In order to analyse further the cross reactivity of plasma 171838, a potential 
sequence motif was identified as conferring neutralisation resistance to the Env 
of  one  of  the  novel  field  isolates.    Previous  studies  have  indicated  that  the 
variable loops V4 and V5 appear to be major targets for effective neutralising 
antibodies and that substitution of a single amino acid in either or both loops 
may  alter  the  phenotypic  characteristics  of  neutralisation  for  primary  FIV 
isolates  (Bendinelli  et  al.,  2001;  Siebelink  et  al.,  1995a).    Here,  we  have 
demonstrated that a motif containing at least four amino acids (KKTQ) over the 
C3 V4 region contributed to the resistance of the 179200 Env to neutralisation by 
plasma 171838, rather than the loss of a PNGS within the same region. 
The V4 loop of the HIV 1 Env has been shown to be highly variable, with the 
variability involving the numbers and locations of PNGSs (Belair et al., 2009).  
Furthermore,  enormous  sequence  variability  within  the  V4  loop  of  simian 
immunodeficiency virus (SIV) has been associated with rapid disease progression 
in macaques (Rivera Amill et al., 2007).  Moreover, the C3 V4 region in HIV 1 is 
considered to be a major target for NAbs (Moore et al., 2008).  Indeed, it has 
been shown that mutations within the a2 helix of C3, which is located in the 
outer domain of gp120, were associated with resistance to neutralisation (Rong 
et al., 2007b).  It has been speculated that the a2 helix plays a role in viral Chapter six 
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evasion  from  NAbs  and  may  participate  in  the  maintenance  of  the  tertiary 
structure of the gp120 outer domain or the quaternary structure of the trimer 
(Rong et al., 2007a; Gnanakaran et al., 2007). 
 Chapter seven 
7 Analysis of broad neutralisation 
 
7.1 Introduction 
Although an effective vaccine was developed shortly after the initial isolation of 
swine influenza, vaccination against persistent lentiviral infections represents a 
more significant challenge.  Although the human immunodeficiency viruses (HIV) 
have been recognised for decades, such infections cannot yet be controlled by 
vaccination.  A major obstacle to the development of an effective HIV vaccine is 
the  resistance  of  primary  viral  isolates  to  antibody mediated  neutralisation 
(Wyatt et al., 1998).  Similarly, for FIV, it was reported in chapter six that only a 
small proportion of plasma samples from naturally infected cats contained virus 
neutralising  antibodies  (NAb).    The  studies  described  in  the  present  chapter 
were designed to investigate mutations arising within the envelope glycoprotein 
of FIV that affected the induction of NAb. 
It  is  debatable  whether  NAb  play  a  major  role  in  the  clearance  of  the 
immunodeficiency virus infections; it requires several months for the humoral 
immune response to mature, whereas cell mediated immunity requires only a 
few weeks (Koup et al., 1994).  It has, however, been proven that sterilising 
immunity  against  FIV,  HIV 1  or  SHIV  can  be  achieved  through  passive 
immunisation with sera containing NAb (Shibata et al., 1999; Hohdatsu et al., 
1993; Mascola et al., 2000).  Furthermore, in most experimental animal model 
systems  of  viral  infection,  T cell  based  vaccines  alone  have  been  unable  to 
prevent infection by providing sterilising immunity (Shiver et al., 2002; Wilson et 
al., 2006).  It is thus believed that a successful vaccine must elicit high titres of 
broadly NAbs in addition to cell mediated immune responses (Walker & Burton, 
2008; Chakrabarti et al., 2002; Schulke et al., 2002). 
Shortly  after  infection,  antibodies  recognising  the  viral  envelope  glycoprotein 
(Env) can be detected, although none have neutralising activity (Stamatatos et 
al., 2009; Richman et al., 2003); it takes the NAb response several months to 
mature.  At this stage of infection, the generated NAbs are extremely limited in 
both potency and breadth, and are highly isolate specific, that is neutralisation 
is restricted to the homologous isolate (Li et al., 2006; Richman et al., 2003).  
Later  in  infection,  a  small  proportion  of  plasmas  cross neutralises  various Chapter seven 
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isolates to varying degrees (Kraft et al., 2007; Li et al., 2007; Stamatatos et al., 
2009).  Both neutralising and non neutralising antibodies contribute to a high 
proportion (up to 5%) of total immunoglobulin in some HIV infected individuals 
later in infection (Binley et al., 1997). 
Env is the target of neutralising antibodies; however, it is poorly immunogenic 
(Kolchinsky et al., 2001) and evolves rapidly in response to immune pressure and 
selection, such that neutralisation determinants continuously diminish with time 
post  infection.    Furthermore,  the  masking  of  variable  loops  on  conserved 
epitopes, such as the primary and co receptor binding sites, the occlusion of 
protein surfaces through trimer formation, the glycan shield formed by extensive 
N linked  glycosylation,  and  the  use  of  a  two receptor  entry  mechanism  all 
contribute to the poor immunogenicity of Env (Koch et al., 2003; Chackerian et 
al., 1997).  In particular, the co receptor binding site is exposed only transiently 
following the conformational change that is triggered by the engagement of the 
primary receptor (Willett et al., 2009), minimising the time during which the 
binding site may be recognised by the immune system. 
Env is heavily glycosylated, such that carbohydrate comprises a great proportion 
of its molecular weight, estimated as more than 50% in HIV 1 (Leonard et al., 
1990; Geyer et al., 1988).  N linked glycosylation of Env plays a shielding role 
and is essential for the correct folding of Env (Land & Braakman, 2001).  It has 
been proposed that carbohydrate forms a glycan shield which creates a fluid  
like  shelter  overlying  the  neutralising  epitopes,  thereby  protecting  the  virus 
from the host immune system (Wei et al., 2003).  It has been speculated that 
potential  N linked  glycosylation  sites  (PNGSs)  maintain  the  integrity  of  the 
glycan shield.  Since Env evolves in response to pressure exerted by NAbs, new 
PNGSs  may  be  initiated  or  deleted  throughout  the  sequence  of  Env.    It  has, 
however,  been  demonstrated  that  numerous  PNGSs  are  highly  conserved 
amongst  viral  isolates,  indicating  that  specific  glycans  may  be  vital  for  the 
integrity and conformation of Env, while simultaneously masking key targets for 
NAb (Cheng Mayer  et al., 1999).  A proposed mechanism of HIV escape from 
NAbs  is  that  the  repositioning  of  glycosylation  sites  across  the  Env  sequence 
limits recognition by NAbs but does not affect the ability of Env to interact with 
the primary and co receptors (Wei et al., 2003). Chapter seven 
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This  chapter  describes  the  examination  of  plasma  samples  from  field  cats 
containing broadly NAbs, identified and described in chapter six.  An isolate, 
prepared from the PBMC of a cat which had generated a broadly neutralising 
plasma, lacked a conserved PNGS in the V1/V2 loop homologue.  Therefore the 
effect  of  repairing  this  PNGS  was  investigated,  utilising  HIV(FIV)  pseudotypes 
bearing modified Envs to assess susceptibility to neutralisation.  Understanding 
the mechanism of cross neutralisation and the generation of broadly neutralising 
antibodies could provide valuable insights for Env based lentivirus immunogen 
design and facilitate the development of novel immunisation protocols. Chapter seven 
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7.2 Results 
 
7.2.1 Broad neutralising activity is rare in FIV infected cats 
As reported in chapter six, a panel of over 300 plasma samples collected from 
naturally  infected  cats  was  screened  to  detect  NAb  against  the  HIV(FIV) 
pseudotype bearing the GL8 Env pseudotype.  The majority of the samples either 
did not neutralise or only weakly neutralised (<60%) the GL8 pseudotype that 
was used for screening (see Appendix 2).  However, two plasma samples were 
identified (namely 178639 and 206394) that neutralised strongly (>80%) not only 
GL8 but all pseudotypes tested (Table 7.1), representing 0.67% of the plasma 
samples examined. 
 
% Neutralisation  % Neutralisation 
Env  Subtype  Origin 
178639  206394 
Pseudotype  Subtype  Origin 
178639  206394 
180638  A  UK  99  90  GL 8  A  UK  99  95 
171838  A  UK  99  99  B 2542  B  USA  99  99 
180260  A  UK  96  96  CPG 41  C  USA  96  99 
182309  A  UK  100  100  PPR  A  USA  98  99 
180140  A  UK  90  97  425  A  UK  99  96 
178721  A  UK  99  97  M2  B  Italy  93  100 
179200  A  UK  83  97  827  A  UK  99  95 
206394  A  UK  83  93  1419  A  UK  95  96 
KNG2  B  Japan  96  99  Leviano  B  Brazil  90  100 
TM 2  B  Japan  99  99  LLV B  B  Africa  51   16 
Table 7.1.  Percent neutralisation values for 178639 and 206394 plasmas at 1 in 
10 dilution using a panel of 19 HIV(Env) pseudotyped viruses.  The Env subtypes 
and country of origin are shown. 
 
Plasma 178639 was collected from a 10 year old cat that was terminally ill (and 
was  euthanised  shortly  after  FIV  infection  was  diagnosed),  whereas  plasma 
206394  was  collected  from  a  14  year  old  cat  with  chronic  age related  renal 
problems but was otherwise healthy.  The duration of infection for each cat was 
unknown  as  both  had  been  adopted  from the  feral  population.    Both  plasma 
samples were tested for neutralisation against pseudotypes bearing the Env of 
lion lentivirus B (LLV B) as a control, in order to exclude the possibility that the 
plasmas may have contained substances that were toxic to the substrate cells 
used in the neutralisation assay.  A panel of HIV(FIV) pseudotypes bearing the Chapter seven 
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Envs of 20 FIV isolates, including primary isolates derived from naturally infected 
cats, was used to test the plasma samples for broadly NAb (Figure 7.1).  Since 
the volume of each sample was limited and follow up samples were not available 
from  cat  178639,  it  was  possible  to  isolate  virus  only  from  sample  206394.  
Subsequently,  the  predominant  env  gene  was  cloned  and  HIV(206394) 
pseudotypes were prepared. 
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Figure 7.1.  Neutralisation by HIV(FIV) pseudotypes (denoted by FIV Env genes) 
by successive dilutions of plasma 206394. Each point is derived from the mean 
(n=3) +/  SEM of luciferase activity counts. Chapter seven 
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7.2.2  Pseudotype  bearing  206394  Env  moderately  neutralised  by  non 
homologous plasma samples  
Susceptibility to NAbs is different amongst FIV isolates; for example, primary 
isolates are more refractory to neutralisation compared to laboratory adapted 
isolates.  Consequently, it has been suggested that vaccines based on laboratory 
adapted  isolates  of  FIV  may  fail  to  protect  cats  against  challenge  with  more 
virulent primary isolates (Hosie et al., 1995).  Since plasma 206394 displayed 
broadly neutralising activity, it is conceivable that its homologous isolate was of 
low  virulence  and,  as  a  consequence,  readily  neutralised  by  antibodies  in 
plasmas from genetically related and unrelated isolates.  Hence, neutralisation 
of the HIV(FIV) pseudotype bearing the Env of 206394 was examined, using a 
panel of plasmas collected from cats infected with isolates of FIV from different 
countries.  The results of the luciferase based neutralisation assay showed that 
the pseudotype bearing the Env of 206394 was neutralised strongly by both its 
homologous plasma and plasma 178639, one of the broadly neutralising plasma 
samples identified previously.  In contrast, 4 plasma samples (from cats infected 
with FIV isolates of other subtypes or from different regions) did not neutralise 
206394,  as  shown  in  Table  7.2.    These  results  suggest  that  NAbs  in  weakly 
neutralising plasmas, while neutralising isolates within the same subtype, may 
not target common epitopes, as a result of genetic divergence amongst isolates.  
It was likely that plasma 206394 was broadly neutralising because it contained 
NAbs that targeted key epitope(s) that were conserved amongst isolates across 
the subtypes. 
 
Plasma  Subtype  Country  % Neutralisation 
Petaluma KKS  A  USA  12 
LP20  E  Japan   9 
178639  A  UK  83 
206394  A  UK  93 
171070  AC  UK  41 
TOT 1  B  Japan  51 
Table  7.2.    Neutralisation  of  pseudotype  bearing  206394  Env  by  neutralising 
plasmas  from  cats  infected  with  different  subtypes  of  FIV.    Values  show  % 
neutralisation when plasma samples were tested at 1 in 10 dilutions. Chapter seven 
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7.2.3 Loss of conserved PNGS in V1/V2 homologue of 206394 Env 
Since plasma 206394 contained broadly NAbs that apparently targeted conserved 
epitope(s), the amino acid sequence of 206394 Env was examined in order to 
identify a potential sequence motif in Env that may have led to this significant 
observation.  It was noted that the 206394 Env contained relatively few glycan 
residues and lacked two PNGS in the region analogous to the V1/V2 domain of 
HIV and SIV (Figure 7.2).  One of the PNGS was ablated as a result of the T271A 
mutation, similar to the mutation in the FL4 strain of FIV (from which the Fel O 
Vax  FIV  vaccine  was  derived);  the  other  PNGS  was  absent  as  a  result  of the 
N298S mutation.  This is a unique mutation that has not been encountered in any 
other FIV Env sequence published to date.  Figure 7.3 illustrates the sequence of 
206394 Env compared to the Env sequences of the novel FIV isolates described in 
chapter six, all of which contained the PNGS at residue 298. Chapter seven 
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Figure  7.2.    A  schematic  drawing  of  FIV  Env  showing  the  locations  of  PNGSs 
within variable loops in GL8.  PNGSs 269 and 342 which were ablated in FL4 
(GenBank: NC001), the vaccine isolate, and the PNGS at asparagine 298 that was 
ablated in 206394 are highlighted in circles. 
 
 
 
Figure  7.3.    Amino  acid  sequence  of  V1/V2  homologous  Env  regions  for  the 
pseudotypes tested in this thesis.  The 206394 sequence shows the loss of two 
PNGSs compared to the other sequences (shown within boxes). 
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7.2.4 PNGS at residue 298 affects susceptibility to neutralisation 
Pseudotype 206394 displayed markedly lower luciferase activity on CLL CD134 
cells compared to other pseudotypes tested (Figure 7.4).  In order to investigate 
this phenomenon, the ablated PNGS at residue 298 in Env 206394 was repaired 
using site directed mutagenesis, resulting in the 206394 S298N mutant.  Next, 
the PNGS at this site was eliminated from GL8 Env, resulting in the GL8 N298S 
mutant.  Pseudotypes were prepared bearing the two mutated Envs and it was 
shown that the presence of a PNGS at residue 298 was associated with enhanced 
infectivity,  since  the  luciferase  activity  was  markedly  lower  for  pseudotypes 
bearing Envs in which the PNGS was ablated compared to those containing the 
PNGS (Figure 7.5).  Consistent results were obtained for both pairs of HIV(FIV) 
pseudotypes based on either the GL8 or the 206394 Envs. 
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Figure 7.4.  Comparison of the luciferase activity of the pseudotypes tested in 
this  thesis.    Pseudotypes  were  incubated  with  CLL CD134  cells  in  triplicate.  
Each column represents the mean (n=3) +/  SEM. Chapter seven 
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Figure 7.5.  Comparison of luciferase activity of pseudotypes GL8 and 206394 
with and without the PNGS at residue 298.  The differences in infectivity, as 
indicated  by  luciferase  activity, of  each  pair of  pseudotypes  bearing  WT  and 
variant Envs, indicate that the elimination of the glycan at residue 298 reduces 
viral infectivity.  Each column represents the mean (n=3) +/  SEM. 
 
 
Furthermore,  it  was  observed  that  ablation  of  the  PNGS  at  residue  298  was 
associated with marked enhancement of susceptibility to neutralisation.  When 
the neutralising activity of two broadly neutralising plasmas (178639 and 206394) 
was compared against pseudotypes bearing the Env of either the GL8 wild type 
or its mutant containing an ablated PNGS (GL8 N298S), the pseudotype bearing 
the  GL8 N298S  Env  was  approximately  five  fold  more  susceptible  to 
neutralisation  compared  to  the  pseudotype  bearing  the  wild type  GL8  Env 
(Figure 7.6).  This result could not be reproduced with pseudotypes bearing the 
Env of 206394 as the titre of the pseudotype bearing the 206394 wild type Env 
was too low to give valid results in the neutralisation assay when comparing the 
neutralisation sensitivity of the WT and mutant 206394 Envs (data not shown). Chapter seven 
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In  contrast,  the  elimination  of  two  further  PNGSs,  at  positions  269  and  342 
(located at the predicted stem of the V1/V2 loop homologue) did not improve 
the neutralisation sensitivity of Env; only the elimination of the PNGS at residue 
298  (located  at  the  tip  of  the  V1/V2  loop  homologue)  led  to  enhanced 
susceptibility of GL8 N298S to neutralisation compared to the wild type (Figure 
7.7).  The PNGSs at residues 269 and 342 are missing from the FIV FL4 Env, the 
vaccine isolate, where they are located towards the N  and C terminals of the 
V1/V2 homologue respectively.  The PNGS at residue 298, on the other hand, is 
located at the crown of the loop; hence, a glycan residue at this location may 
serve to mask a conserved epitope on Env.   
A follow up sample was obtained from cat 206394 five months after the first 
sample was collected.  Three Env variants were isolated (by Pawel Beczkowski), 
all of which had reinstated the PNGS at residue 298 (Figure 7.8).  These findings 
are  consistent  with  a  role  for  the  PNGS  at  residue  298  in  escape  from 
neutralisation.   Chapter seven 
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Figure 7.6.  N298S mutation is associated with increased sensitivity of GL8 to 
neutralisation.  GL8 N298S mutant was approximately 5 fold more sensitive to 
neutralisation by broadly neutralising plasmas 206394 and 178639 compared to 
the GL8 WT.  Each point is derived from the mean (n=3) +/  SEM of luciferase 
activity counts. Chapter seven 
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Figure 7.7.  Neutralisation of GL8 wild type and mutants by 206394 plasma.  The 
effect of glycan removal within the V1/V2 loop homologue on the neutralisation 
sensitivity of Env by introducing three separate mutations that eliminated glycan 
residues at positions 269, 298, and 342.  Each point is derived from the mean 
(n=3) +/  SEM of luciferase activity counts. 
 
 
 
Figure 7.8.  Amino acid sequence of the 206394 clones.  206394 clones c5, c7 
and c9 were isolated 5 months after the isolation of the first variant (206394 
c95).  The PNGS at residue 269 was still absent from all 206394 variants whereas 
PNGS  at  residue  298  was  reinstated.    The  sequence  of  GL8  is  shown  for 
comparison. Chapter seven 
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7.3 Discussion 
This  chapter  describes  studies  focussing  on  the  elimination  of an  asparagine 
linked glycosylation site at residue 298 which is sited at the crown of the V1/V2 
loop  homologue  of  FIV  Env  and  is  highly  conserved  amongst  published  FIV 
sequences.  A mutation at this site (N298S) was observed in the Env isolated 
from cat 206394, a cat naturally infected with FIV that had developed broadly 
neutralising antibodies (bNAbs).  The N298S mutation ablated a PNGS and led to 
a  reduction  in  infectivity  of  the  HIV(FIV)  luciferase  pseudotype  bearing  the 
206394 Env, while the same pseudotype was neutralised more readily by both 
the homologous plasma and heterologous plasma from other FIV infected cats.   
As has been well documented for HIV 1 infection, few subjects develop bNAbs 
during  the  course  of  infection  (Beirnaert  et  al.,  2001;  Binley  et  al.,  2008); 
similarly we observed that sample 206394 was amongst only a small proportion 
of plasma samples (0.67%) from cats naturally infected with FIV that contained 
bNAbs.  Identifying the target for such bNAbs is important, having implications 
for the design of effective lentiviral vaccines.   
It  has  been  demonstrated  for  HIV  infection  that  viral  load  and  duration  of 
infection  correlate  with  the  generation  of  a  broadly  cross reactive  humoral 
response (Sather et al., 2009).  However, other factors may contribute to the 
development of a bNAb response, including the virulence of the initial challenge 
virus,  the  strength  of  the  host  immune  response,  the  occurrence  of  super 
infection  or  recombination,  and  quasispecies  diversity.    Although  the 
mechanisms leading to the development of bNAbs are not fully understood, high 
titres of NAbs have been observed in long term HIV 1 non progressors (Cao et 
al.,  1995;  Cao  et  al.,  1996;  Montefiori  et  al.,  1996)  and  bNAbs  have  been 
identified only in non progressors (Carotenuto et al., 1998; Dreyer et al., 1999).  
Since  non progressors  develop  more  potent  and  broader  NAb  responses,  it  is 
likely  that  the  continuous  evolution  of  Env  leads  to  the  recognition  of  more 
epitopes  by  the  immune  system,  thereby  increasing  the breadth  of  the  NAbs 
generated.  Furthermore, the NAb response matures with time, becoming more 
focused on conserved epitopes and thereby increasing the titre of high quality 
NAbs.    Simultaneously,  higher  titres  of  NAbs  are  associated  with  increased 
neutralisation potency.  On the other hand, plasma  samples from patients in 
whom  infection  progresses  contain  a  less  heterogeneous  population  of Chapter seven 
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antibodies, perhaps because the immune system has been exposed to a more 
homogeneous  viral  population,  and  such  plasma  samples  have  a  narrower 
spectrum of neutralising activity. 
It has been shown that viral evolution in response to immune pressure involves 
the addition and repositioning of PNGS within regions sometimes termed “hot 
spots” (Zhang et al., 2004).  The V1/V2 domain of HIV Env has been the subject 
of extensive investigations, since it varies greatly in both amino acid sequence 
and length amongst viral strains (Wang et al., 1995; Fox et al., 1997) and has a 
role as an immunological shield, covering the bridging sheet between the inner 
and outer domains of Env (Kwong et al., 1998) and thereby protecting conserved 
regions of Env such as the primary and co receptor binding sites.  A review of 
the  literature  reveals  that  several  studies  have  investigated  the  removal, 
repositioning, and addition of potential glycosylation sites, or even partial or 
complete deletions of variable loops, in HIV and SIV.  Many of these studies have 
shown that glycosylation often results in the masking of certain neutralisation 
epitopes (Cheng Mayer et al., 1999; Reitter et al., 1998; Stamatatos & Cheng 
Mayer, 1998; Chackerian et al., 1997; Lue et al., 2002).  Nevertheless, not all 
modifications result in an increase in viral susceptibility to neutralisation.   
For example, Saunders et al. (2005) demonstrated that the deletion of the V1 
loop  of  HIV 1  renders  the  virus  more  resistant  to  neutralisation,  and  it  was 
concluded that perhaps deletion of the V1 loop focused the immune response on 
the non functional epitopes of the V2 domain.  Moreover, Gzyl et al. (2004) has 
reported that partial deletion of the V1/V2 loop of HIV 1 Env renders the virus 
less virulent, most likely by redirecting the immune response towards unshielded 
immunodominant epitopes and so broadening NAb responses to Env that cannot 
be afforded by the full removal of the variable domains.  Single and multiple 
alterations in the numbers and locations of PNGSs resulted in variable outcomes.  
While no significant improvements in the immunogenicity of Env were obtained 
with mutants compared to the wild type Envs in some studies (Quinones Kochs 
et  al.,  2002;  Li  et  al.,  2008;  Lue  et  al.,  2002),  other  studies  demonstrated 
significant  roles  for  particular  PNGSs  in  viral  susceptibility  to  neutralisation 
(McCaffrey et al., 2004; Reitter et al., 1998; Li et al., 2008).  Similarly, in this 
study, the PNGS at residue 298 had a major effect on the immunogenicity of FIV Chapter seven 
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Env as well as viral infectivity.  However, no significant effects were observed 
when the PNGS at residues 269 and 342 were reinstated.   
Cheng Mayer  et  al.  (1999)  indicated  that  there  are  highly  conserved  PNGSs 
within the Env of HIV 1 and SIV, and thus a systematic study of these sites may 
be valuable in identifying immunogenic epitopes on Env.  Pinter et al. (2004) 
demonstrated  that  exchanging  the  V1/V2  loops  of  two  Envs  switched  viral 
sensitivity to neutralisation by several polyclonal and monoclonal NAbs directed 
against the V2 region, the V3 loop and the CD4 binding domain and concluded 
that the structure of the V1/V2 domain rather than sequence changes altered 
the neutralisation phenotype.  On the other hand, although shorter V1/V2 HIV 
Env  domains  and  fewer  glycosylation  sites  were  associated  with  higher 
susceptibility to neutralisation, Kraft et al. (2008) demonstrated that neither the 
length,  nor  the  extent  of  glycosylation,  of  the  variable  regions  affected  the 
breadth of the NAbs generated against an immunogen based on a subtype A Env.  
These  findings  indicate  that  neither  the  size  of  the  variable  domain  nor  the 
quantity of PNGS but rather it is their positions within Env that are important in 
shielding immunodominant  determinants  and  controlling  viral  susceptibility  to 
neutralisation.  Hence the removal (or shifting the locations) of key PNGSs, as 
well as exposing localised epitopes, also confers structural changes on the entire 
Env that may increase recognition by NAbs.  Consistent with this hypothesis, the 
elimination of the PNGS at residue 298 in this study may have induced structural 
modifications on Env which led to either the exposure of key determinants in 
other domains to NAbs, or reduced masking of a neutralisation determinant on 
the  V1/V2  domain,  as  was  suggested  following  a  similar  observation  by 
Krachmarov et al. (2006). 
It has been reported by several research groups that, as infection proceeds, the 
NAb  response  matures  in  both  potency  and  breadth  in  response  to  the 
continuously  evolving  virus  (Cecilia  et  al.,  1999;  Binley  et  al.,  2008).    Viral 
evolution  may  involve  the  addition  of  PNGSs,  particularly  where 
immunodominant determinants can be guarded (Zhang et al., 2004).  It appears 
that FIV isolate 206394 evolved in this way, since all 3 of the newly emerged 
variants had evolved by reinstating the PNGS at residue 298 during the 5 month 
period between samplings. Chapter seven 
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The mechanism of induction of bNAbs has always been poorly understood; bNAbs 
occur only rarely in natural infections and their target epitopes on Env have not 
been defined (Sather et al., 2009).  The matter is even more complicated when 
it comes to inducing NAbs following vaccination as vaccine induced NAbs are far 
less potent than NAbs generated in natural infection (Bontjer et al., 2009; Li et 
al., 2008).  It has been suggested that vaccine induced NAbs are more likely to 
target epitopes that are either occluded or do not exist, in native virus (Derby et 
al., 2007). 
Promising results were achieved recently following immunisation with a mutant 
HIV Env lacking a single PNGS; the mutant induced stronger NAbs against both 
the mutant and wild type variants (Li et al., 2008).  In order to evaluate the 
effect of the elimination of the PNGS at residue 298 in the FIV Env, it would be 
interesting to determine the efficacy of an FIV immunogen containing the N298S 
mutation  in  inducing  NAbs  in  cats.    Moreover,  following  the  identification  of 
PNGSs  within  Env  that  are  conserved  amongst  published  FIV  sequences, 
particularly  those  located  in  the  V1/V2  homologue,  it  should  be  possible  to 
evaluate the contribution of each PNGS to FIV neutralisation by a process of 
systematic mutation.  In this way it may be possible to understand more fully the 
effect of each glycan on Env immunogenicity and viral infectivity.  Subsequently 
it may be possible to engineer an immunogen in which one or more PNGSs are 
eliminated, in order to generate an immunogen capable of inducing bNAbs. 
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8 Final Discussion 
 
The principal aim of this project was to investigate the role of NAb in immunity 
to infection with FIV.  Having developed a robust assay to detect NAb, bNAbs 
were identified in clinical samples collected from naturally infected cats and 
studies were conducted to address the mechanisms which may have led to the 
generation of such NAbs. 
Other issues tackled during this project included an investigation of immune 
mediated  enhancement  of  FIV  infection,  a  description  of  the  FIV  strains 
circulating in UK cats by generating phylogenetic trees based on the genetic and 
amino  acid  variation  of  Env  and  an  analysis  of  Env  sequences  derived  from 
several primary strains of FIV and identifying critical mutations in variable loops 
which  altered  viral  sensitivity  to  NAbs.    As  a  result  of  this  project,  a  major 
question arose: what impact would these observations have on vaccine design 
for FIV and HIV? 
 
8.1 Impact of FIV studies on HIV vaccine design 
The value of FIV as a model for HIV has been discussed in detail in Section 1.8.  
In addition, a commercial vaccine for FIV has been developed and has shown 
promise,  protecting  cats  against  challenge  with  heterologous  as  well  as 
homologous strains (Pu et al., 2005).  The comparative success in developing a 
protective vaccine against FIV has not, however, been coupled with a similar 
success  for  HIV  vaccine  development,  raising  the  concern:  are  FIV  vaccine 
studies relevant to HIV vaccine design? 
In considering this question it is important to recognise that the Fel O Vax FIV 
vaccine  does  not  induce  protective  immunity  against  challenge  with  virulent 
primary strains such as GL8 (Dunham et al., 2006a), an isolate which is likely to 
be representative of naturally occurring isolates transmitted in the field.  Given 
this limitation to the success of the Fel O Vax FIV vaccine, the relatively sparse 
information available related to its capacity to induce protection, and the as yet 
unidentified  mechanism  of  protection,  current  investigations  in  terms  of 
designing the ideal vaccine for either FIV or HIV are still at a relatively early 
stage.    Another  significant  factor  is  that  the  Fel O Vax  FIV  vaccine  is  an Chapter eight 
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inactivated vaccine and therefore a similar approach cannot be reproduced for 
HIV  vaccine  trials  for  safety  reasons,  since  HIV  is  the  causative  agent  of  an 
incurable human disease.  Only limited success has been observed using other 
approaches to FIV vaccination, such as subunit or DNA vaccines (Hosie et al., 
1996; Leutenegger et al., 1998; Dunham et al., 2002); such approaches are more 
likely to be implemented for HIV vaccine development but success against FIV 
challenge has been very limited and has not, to date, exceeded that for HIV 
trials. 
In spite of there being differences between HIV and FIV, with the latter being a 
feline specific  virus,  having  a  different  route  of  transmission  and  host cell 
receptor  usage  system,  the  two  viruses  share  many  similarities  in  terms  of 
biological  properties,  genome  organisation,  the  general  structure  of  Env,  the 
pathogenesis of infection and mechanisms of evasion from host immunity.  As a 
result, FIV is a good candidate for the purpose of designing a highly effective 
lentiviral  vaccine  and  provides  a  challenge  system  in  which  it  is  possible  to 
dissect the mechanisms by which broadly neutralising responses may be induced 
in a natural host model system. 
 
8.2 The development of regional vaccines 
Since Env, the target for neutralisation, displays immense diversity (which can 
reach 30% and 35% between subtypes for FIV and HIV 1, respectively (Burkhard & 
Dean, 2003; Binley et al., 2004), it has been proposed that it may be necessary 
to  develop  regional  vaccines  that  are  each  based  on  the  sequence  of  the 
predominant circulating viruses in particular regions or countries, at least as a 
preliminary controlling measure (Pistello et al., 1997; Steinrigl & Klein, 2003). 
In order to achieve this goal, the subtype of the strains circulating in particular 
regions  or  countries  must  first  be  identified.    For  example,  it  has  been 
demonstrated that circulating FIV strains belong to subtype B in Italy (Pistello et 
al., 1997), subtypes A and B in Germany and Austria (Steinrigl & Klein, 2003), 
subtype B in Portugal (Duarte et al., 2002), subtype A predominates in Australia 
(Kann et al., 2006b), subtypes A and C in New Zealand (Hayward & Rodrigo, 
2008), subtype C in both Taiwan and Vietnam (Uema et al., 1999; Nakamura et 
al., 2003), subtype A in South Africa (Kann et al., 2006a) subtypes A and C in 
Canada (Reggeti & Bienzle, 2004), subtype B in Brazil (Martins et al., 2008), and Chapter eight 
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subtype E in Argentina (Pecoraro et al., 1996).  In chapter four of this thesis it 
was shown, based on the sequence of the V3 V5 region of Env for over 45 viruses 
collected from cats across the UK, that subtype A is the predominant FIV subtype 
in the UK. 
There is some evidence that protection can be achieved against an intra subtype 
B heterologous FIV challenge using an attenuated FIV vaccine (Pistello et al., 
2003a).  However this trial was conducted solely with FIV isolates from subtype B 
and this finding has not been reproduced in trials involving other subtypes or in a 
wider geographical area.  It has been suggested that subtype B isolates may be 
more  ancient  and  host  adapted  and  as  a  consequence  may  be  less  virulent 
(Bachmann  et  al.,  1997).    In  countries  where  a  more  heterogeneous  FIV 
population  exists,  an  effective  vaccine  would  be  required  to  protect  against 
diverse strains which may belong to more than one subtype.  Moreover, in such 
circumstances,  recombination  between  FIV  isolates  of  different  subtypes  may 
occur as a result of co infection and result in chimaeric strains which may be 
resistant to vaccine induced protection. 
Another consideration is whether genetic subtyping is actually relevant for the 
development  of  regional  vaccines.    Several  studies,  that  were  conducted  to 
investigate  cross neutralisation  in  HIV 1,  have  demonstrated  that  a  more 
accurate means of linking the capability of NAbs to cross neutralise heterologous 
isolates  is  to  classify  viral  strains  into  ‘serotypes’  (Kostrikis  et  al.,  1996b; 
Nyambi  et  al.,  1996).    Although  there  is  little  known  about  the  relationship 
between genetic subtypes and neutralisation serotypes, it has been speculated 
that there may be no or only little significant correlation (Weber et al., 1996; 
Kostrikis et al., 1996a).  The evidence in support of there being a correlation 
between genetic subtypes and neutralisation serotypes is that it has been shown 
that protective NAbs are directed towards determinants throughout Env that are 
highly conserved amongst isolates from different subtypes (Kessler et al., 1997).  
Indeed,  serotype  classification  requires  neutralisation  determinants  to  be 
mapped; as a result, viral strains can subsequently be classified according to 
their antigenic features.  However, it has been proposed that conformational 
epitopes  are  common  throughout  Env  and  so  antigenic  mapping  may  not  be 
straightforward.  Little work has been conducted to date with regards to FIV Chapter eight 
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serotyping  but,  once  highly  conserved  epitopes  have  been  mapped,  epitope 
focused antigen design could be considered. 
 
8.3 Significance of Env variable loops in viral resistance to NAbs 
In order to escape the host’s immune response, both FIV and HIV have developed 
effective  mechanisms  in  order  to  maintain  viral  survival  and  replication.    An 
important protective mechanism of immune escape occurs via evolution within 
the  hyper variable  domains  throughout  Env  that  serve  as  a  defence  line  in 
several  ways.    For  example,  the  V1/V2  region  in  HIV 1  occludes  important 
conserved epitopes such as the co receptor binding site (Pinter et al., 2004).  It 
has been speculated also that the V1/V2 analogue in FIV may play a similar role 
in shielding the FIV co receptor binding site, which has been mapped recently 
within the V3 hypervariable region (Sundstrom et al., 2008).  Another means by 
which  variable  domains  (or  loops)  could  serve  as  an  efficient  defence  is  by 
tolerating extreme sequence variation, especially at positions that are presumed 
to  directly  encounter  the  host’s  NAbs.    As  the  virus  evolves  in  response  to 
immune  pressure  exerted  by  NAbs,  new  viral  variants  appear  continuously, 
forcing the immune system to deal with newly emerged epitopes and rendering 
the  humoral  responses  generated  previously  to  be  potentially  ineffective.    A 
striking example is displayed in the sequence at the crown region of the V5 loop 
of FIV Env; this region is highly variable even amongst strains from the same 
subtype and the same geographical region (see Appendix 1). 
The variation in the V4 loop region of HIV 1 Env is similar to that observed for 
the V5 region in FIV Env.  Variation in the amino acid sequence, the length of 
the domain, and the numbers and locations of PNGSs (Belair et al., 2009), all 
appear to contribute to viral resistance (Moore et al., 2008) making the V4 loop 
an interesting target for epitope mapping.  The V3 loop of HIV 1, on the other 
hand, appears to be more conserved (Gorny et al., 2004), and has been shown to 
be a target for neutralisation in both HIV 1 (Javaherian et al., 1989; Li et al., 
2005; Binley et al., 2004) and FIV (Lombardi et al., 1993).  Moreover, the HIV 1 
V3 loop contributes to viral tropism (Hwang et al., 1991; Cheng Mayer et al., 
1988), cell fusion (Rusche et al., 1988), virus infectivity (Freed et al., 1991), and 
co receptor interaction (Suphaphiphat et al., 2003), perhaps accounting for V3 
tolerating less variation compared to other loops on Env.  The importance of the Chapter eight 
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V3 region to viral productivity suggests that the virus would be susceptible to 
NAb directed against this target.  However, it is evident that the V3 region is 
less exposed to the immune system compared to the other variable regions (Bou 
Habib et al., 1994), being occluded within the trimeric Env structure (Hartley et 
al., 2005). 
In  this  thesis,  neutralisation  determinants  were  identified  in  the  C3 V4  (see 
chapter six), and V5 (see chapter five) domains of FIV.  In addition, other studies 
have demonstrated that single or double mutations in either or both the V4 and 
V5 loops of the FIV Env are responsible for neutralisation resistance in subtype A 
and  B  viruses  (Verschoor  et  al.,  1995;  Pistello  et  al.,  2003b).    Indeed,  the 
contribution  of  the  variable  loops  to  neutralisation  resistance  of  viruses 
highlights that as well as playing a role in masking conserved epitopes that are 
important for viral infectivity, the variable regions also contain neutralisation 
epitopes.  Whether such epitopes are conserved among viral strains should be 
established, as this would impact upon vaccine design.  It is important also to 
define the role of key amino acids that have been shown to be responsible for 
the  conversion  of  the  viral  phenotype  and  sensitivity  to  neutralisation.    For 
example,  residues  483  and  560  described  by  Bendinelli  et  al.  (2001)  and 
Siebelink et al. (1995a), could form part of a conformational epitope or these 
residues may be vital to maintain the correct folding of Env such that conserved 
neutralisation epitopes are inaccessible to NAbs. 
It must be highlighted that it was possible to identify two neutralisation epitopes 
in  the  C3 V4  and  V5  domains  of  FIV  Env  as  a  result  of  the  neutralisation 
resistance of novel, naturally occuring isolates (observed in tests using a broadly 
neutralising plasma sample).  Cats containing such broadly reactive NAbs do not 
appear to be encountered commonly, as described in chapter six.  The role of 
residues 483 and 560 in viral resistance to NAbs was also recognised following 
the  natural  selection  of an isolate  that  bore one  or  both  mutations  at these 
residues and was resistant to neutralisation.  Consequently it is likely that a 
systematic approach may be useful to identify key residues that are responsible 
for  viral  resistance  to  NAbs  (and  probably  maintaining  the  structure  of  Env) 
without  affecting  viral  infectivity,  using  site directed  mutagenesis.    Such  an 
approach would require a critical analysis of Env sequences, focusing particularly 
on the variable regions, and then targeting key residues that change polarity, Chapter eight 
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net charge, or PNGSs.  Mutant variants could then be tested alongside their wild 
type  (WT)  counterparts  for  susceptibility  to  neutralisation  by  broadly  NAbs.  
Once a variant is isolated that demonstrates neutralisation resistance compared 
to its susceptible WT variant, then that particular mutation can be investigated 
further.  In this way, a library comprising key amino acid residues throughout 
Env  would  be  generated,  and  subsequently  key  amino  acids  (and  probably 
sequence motifs) may be identified using peptide mapping. 
 
8.4 Significance of conserved PNGSs in resistance to NAbs 
It  is  well established  that  the  immunologically  silent  carbohydrate  residues 
scattered throughout Env serve to protect neutralisation epitopes against NAbs 
(Burton  et  al.,  2004).    Longitudinal  studies  have  shown  that,  with  viral 
evolution,  there  is  an  accumulation  of  PNGSs  on  Env  (Zhang  et  al.,  2004), 
suggesting that natural selection in response to immune pressure may favour the 
existence of strains with carbohydrate shielded neutralisation epitopes. 
However, the importance of N linked glycosylation is not restricted to shielding 
important epitopes of Env; the carbohydrate moieties contribute also to viral 
structure by maintening the correctly folded conformational structure of Env (Li 
et  al.,  1993).    The  number  of  PNGSs  amongst  viral  isolates  appears  to  be 
maintained within certain limits (proposed to range between 18 and 33 in HIV 1 
(Zhang et al., 2004), but they may occur in any number of positions throughout 
Env.  Depending on their frequency and site of occurrence, PNGSs may be either 
conserved or variable.  While certain PNGSs are essential for viral viability, it 
was observed in this thesis that the deletion/creation of PNGSs was associated 
with changes in luciferase activities of HIV luciferase pseudotypes bearing FIV 
Envs,  as  well  as  their  susceptibility  to  neutralisation.    These  PNGSs  may  be 
involved in complex molecular interactions that may alter the accessibility of 
epitopes  on  Env  to  NAbs,  shielding  conserved  epitopes,  or  affecting  the 
orientation  of  the  variable  loops.    Such  different  outcomes  appear  to  be 
dependent on the positioning of more than one PNGS, or even by the interplay 
between PNGSs and amino acid residues (or motifs) dispersed throughout Env. 
For  a  more  detailed  understanding  of  their  importance  in  maintaining  the 
structure of Env, PNGSs may be targeted by site directed mutagenesis so that 
the  structure  of  mutant  variants  with  altered  phenotypes  (e.g.  luciferase Chapter eight 
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activity, receptor usage, cell tropism or susceptibility to neutralisation) may be 
observed  by  nuclear  magnetic  resonance  (NMR)  or  X ray  crystallography.    An 
investigation of concomitant changes in structural and phenotypic features may 
shed  more  light  on  the  mechanisms  by  which  broad  neutralisation  can  be 
induced,  or  provide  information  that  is  crucial  for  the  development  of  more 
effective immunogens. 
 
8.5 What are the prospects for a vaccine based on isolate 206394?  
In  this  thesis  plasma  206394  was  shown  to  contain  NAbs  with  broad  cross 
reactivity  against  HIV(FIV)  luciferase  pseudotypes  bearing  FIV  Envs  from 
different  subtypes  and  geographical  locations.    Although  the  mechanism  by 
which  cross reactivity  can  develop  with  time  is  still  uncertain,  it  can  be 
speculated that the ablation of a PNGS at residue 298 in 206394 Env played a 
role in the achievement of such broad reactivity, perhaps due to the exposure of 
a conserved epitope, early in infection, to the host’s immune system.  Since this 
key PNGS was repaired in all viral variants isolated from the same cat a few 
months after the initial isolation, it was likely that this PNGS had a significant 
role in protecting the virus from NAb. 
Interestingly, cat 206394 did not display the typical clinical signs of FIV infection 
during the course of infection, but it was not possible to conduct a long term 
follow  up  of  this  case  since  the  cat  succumbed  to  age related  urinary  tract 
problems.    It  is,  however,  thought  that  spontaneous  recovery  from  FIV  is 
unattainable  (Ishida  et  al.,  1989),  and  persistent  infections  are  established 
following both FIV and HIV infection. 
It has been shown that broad NAb responses are well developed in HIV infected 
long  term  non progressors  (LTNPs),  in  contrast  to  rapid  disease  progressors 
(Pilgrim et al., 1997; Carotenuto et al., 1998).  The serum of LTNPs contained 
not only higher titres of NAbs, but also NAbs that more frequently neutralised 
primary virulent isolates (Cao et al., 1996; Binley et al., 2008).  Such a natural 
resistance that keeps patients clinically well may  provide clues to protective 
immune mechanisms.  Thus, an understanding of the mechanisms controlling this 
response would be valuable for lentiviral vaccine design.   Chapter eight 
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Following the observations described in this thesis, it is tempting to speculate 
that an FIV vaccine trial testing an immunogen based on 206394 may induce 
bNAbs in vaccinated cats that may protect cats from challenge.  A comparison 
with an immunogen based on a mutant variant of 206394, containing the PNGS 
that  was  reinstated  at  residue  298,  would  confirm  whether  the  PNGS  has  a 
significant  role  in  the  generation  of  a  bNAb  response.    It  is  conceivable, 
however, that individuals vaccinated with an HIV vaccine may not develop NAbs 
of similar activity or potency to those in naturally infected individuals (Doria 
Rose  et  al.,  2009),  and  it  may  not  be  possible  to  predict  the  outcome  of 
vaccination using such a vaccine in the human population. 
The question that remains is: will such a vaccine impact upon future vaccine 
design for an improved FIV vaccine or for a successful vaccine against HIV?  It is 
evident  that  the  similarities  in  the  structure  of  the  Envs  of  FIV  and  HIV  are 
significant, which perhaps means that the PNGS at residue 298 of FIV Env, if it 
were proven to be responsible for the resistance to cross neutralising NAbs, may 
have a counterpart in HIV Env playing a similar role in protecting the virus from 
NAbs.  And finally, the cat model enables researchers to test directly in vivo, in 
a  model  system  with  a  natural  host,  novel  and  potentially  improved 
immunogens.  Studies such as these may, one day, lead to the development of a 
highly effective HIV vaccine. Appendices 
Appendices 
 
Appendix 1. Amino acid sequence of V3 V5 region of Env for all FIV strains sequenced for this project. 
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170003       QMAYYNRCRW ESTDVKFHCQ RTQSQPGTWL RAISSWRQRN RWEWRPDFES EKVKVSLQCN STKNLTFAMR SSGDYGEVTG  
170141       QIAYYNSCRW ESTDVKFHCQ RTQSQPGSWN RAISSWKQRN RWVWRPDFES EKVKVSLQCN STKNLTFAMR SSGDYGEVMG  
170186       QIAYYNSCRW ESTDVKFHCQ RTQSQPGSWL RAISSWRQRN RWEWKPDFES EKVKVSLQCN STKNLTFAMR SSGDYGEVTG  
170305       QKAYYNSCRW ESTDVKFHCQ RTQSQPGSWL RTISSWRQRN RWEWRPDFES DKVKVSLQCN STRNLTFAMR SSGDYGEVTG  
170338       QIAYYNSCKW EQTNVTFQCQ RTQSQPGSWI RAISSWRQRN RWEWRPDFES EKVKVSLQCN STKNLTSAMR SSGDYGEVTG  
170415       QVAYYNSCRW EETDVKFNCQ RTQSRPGTWV RAISSWRQRN RWEWRPDFES EKVKISLQCN STQNLTFAMR SAGDYGEVTG  
170418       QIAYYNSCRW ESTDVKFHCQ RTESQPGTWL RAISSWKQRN RWEWRPDFES EKVKVSLQCN STKNLTFAMR SSGDYGEITG  
170488       QRAYYNSCRW EQTDVKFHCQ RTQSQPGSWL RTISSWRQRN RWEWRPDFES EKVKISLQCN STKNLTSAIR SSGDYEEVVA  
170617       QIAYYNSCRW EQTDVKFHCQ RNQSQPGSWV RTISSWRQGN RWEWRPDFES EKVKVSLQCN STKNLTFAMR SSGDYGEVTG  
170719       QIAYYNSCRW ERTNVKFRCQ RTQSQPGSWI RAISSWRQRN RWEWRPDFEN DKVKVSLQCN STKNLTFAMR SSGDYGEVTG  
171025       QMAYYNSCRW ESTNIKFHCQ RTQSQPGSWR RAISSWRQRN RWEWRPDFES ERVKVSLQCN STENLTFAMR SSGDYGEVTG  
171069       QIAYYNSCRW ENTDVKFHCQ RTQSQPGSWL RAISSWRQRN RWEWRPDFES EKVKVSLQCN STKNLTFAMR GSGDYGEVTG  
171070       QIAYYNSCKW EQANVTFQCQ RKQSQPGTWS RAISSWKQRN RWEWRPDFES ERVKVSLQCN ATKNLTFAMR SSGDYGEVTG  
171101       QWAYYNSCRW ESTDVKFHCQ RKQSQRGSWI RAISSWKQRN RWEWRPDFES EKVKVSVQCN STRNLTFAMR SSGDYGEVTG  
171163       QIAYYNSCRW EQTDVKFHCQ RTQSQPGSWI RAVSSWRQRN RWEWRPDFES EKVKISLQCN STKNLTFAMR SSGDYGEVVG  
171169       QMAYYNSCRW ESTNVTFHCQ RIQSQPGSWI RAISSWRQRN RWEWRPDFES EKVKVSLQCN STKNLTFAMR SSGDYEEITG  
171170       QIAYYNRCRW ESTDVKFHCQ RTQSQFGSWV RAISSWKQRH RWEWRPDFES EKVKVSLQCN STKNLTFAMR SSGDYGEVMG  
171175       QMAYYNSCRW EQTEVQFQCQ RTQSLPGSWH RAISSWRQKN RWEWRPDFES EKVKVSLQCN STKNLTFAMR SSGDYGEVMG  
171265       QLAYYNSCKW EGTDVKFHCQ RIQSRPGSWR RVISSWKQKN RWEWRPDFES ERVKVSLQCN STKNLTFAMR SSGDYGEVTG  Appendices 
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171270       QMAYYNSCKW ESTDVKFHCQ RTQSQPGSWI RAISSWRQRN RWEWKPDFES EKVKVSLQCN STKNLTFAMR SSGDYGEITG  
171303       QIAYYNSCNW EKTDVKFHCQ RTQSQSGSWL RAISSWRQRN RWEWRPDFES EKVKVSLQCN STKNLTFAMR SSGDYGEVTG  
171358       QGAYYNSCRW ERTDVKFHCQ RIQSQPGSWI RAISSWRQRN RWEWRPDFES EKVKVSLQCN STKNLTFAMR SSGDYGEITG  
171536       QIAYYNSCRW ENTDVKFHCQ RTQSQPGSWL RAISSWRQRN RWEWRPDFES EKVKVSLQCN STKNLTFAMR GSGDYGEVTG  
171700       QNAYYNSCRW ESTDVKFHCQ RKQSQPGSWR RAISSWKQRN RWEWRPDFES EKVKVSLQCN STKNLTFAMR SSSDYGEVTG  
171781       QIAYYNSCRW ESTDVKFHCQ RTQSQPGSWL RTISSWRQRN RWEWRPDFES DKVKVSLQCN STKNLTFAMR SSGDYGEVTG  
171810       QGAFFTVFGW DQAVLSFFFQ GPRVRLGPWV GLFCSWNQRI GWDWGPDFES EKVKISLQCN STNNLTFAMR SSGDYGEVTG  
171812       QLAYYNSCKW EQTNVTFHCQ RKQSQPGAWR RAIASWKQEN RWVWRPDFES EKVKVSLQCN STKNLTFAMR SSGDYGEVTG  
171838       QIAYYNSCRW ERTNVKFSCQ RIQSQPGTWR RIISSWRQRN RWEWRPDFES EKVKVSLQCN TTKNLTFAMR SSGDYGEVTG  
172325       QMAYYNSCRW ETTDVKFHCQ RTQSQPGSWR RAISSWRQRN RWEWRPDFES EKVKVSLQCN STKNLTFAMR SSGDYGEVTG  
172458       QIAYYNSCRW ESTDVKFHCQ RIQSRPGSWI RAIASWRQRN RWEWRPDFES EKVKISLQCN STKNLTFAMR SSGDYGEVTG  
172506       QVAYYNSCKW EKTDVKFHCQ RTQSQPGSWR RAISSWKQKN RWEWRPDFES EKVKVSLQCN STQNLTFAMR SSGDYGEVTG  
172527       QIAYYNSCRW ESTDVKFYCQ RTQSQPGSWH RTISSWKQKN RWVWRPDFES EKVKVSLQCN TTKNLTFAMR SSGDYGEVTG  
172532       QMAYYTSCSW EQADVKFFCQ RTQSQPGSWL RVISSWKQKN RWEWRPDFES EKVKISLQCN STNNLTFAMR SSGDYGEVTG  
178586       QIAYYNSCRW ESTDVKFHCQ RTQSQPGTWL RTISSWRQRN RWEWRPDFES EKVKVSLQCN STKNLTFAMR SSGDYGEITG  
178721       QIAYYNSCRW ESTDVKFHCQ RTQSQLGSWM RVISSWRQRN RWEWRPDFES EKVKVSLQCN STKNLTFAMR SSGDYGELTG  
179200       QIAYYNSCKW EKTDVKFQCQ RTQSQPGTWN RIISSWKQRN RWEWRPDFES DKVKISLQCN STKNLTFAMR SSGDYGEVTG  
179288       QRAYYNSCRW ESTDVKFHCQ RTQSQPGSWI RAISSWRQRN RWEWRPDFES EKVKVSLQCN STKNLTFAMR SSGDYGEVTG  
179297       QIAYYNSCKW EKTDVKFQCQ RTQSQPGTWS RIISSWKQRN RWEWRPDFES DKVKISLQCN STKNLTSAMR SSGDYGEVTG  
179369       QIAYYNSCRW ESTDVKFHCQ RTQSQPGSWL RTISSWRQRN RWEWRPDFES DKVKVSLQCN STKNLTFAMR SSGDYGEVTG  
179466       QMAYYNSCRW ESTNIKFHCQ RTQSQPGSWR RAISSWRQRN RWEWRPDFES ERVKVSLQCN STENLTFAMR SSGDYGEVTG  
180115       QNAYYNSCKW EKTDVKFQCQ RTQSQPGSWR RAISSWKQGN RWVWRPDFES EKVKISLQCN STKNLTFAMR SSSDYGDVTG  
180140       QNAYYNSCKW EKTDVKFQCQ RTQSQPGSWR RAISSWKQGN RWVWRPDFES EKVKISLQCN STKNLTFAMR SSSDYGDVTG  
180260       QNAYYNSCRW EHTDVKFHCQ RKQSQAGSWN RAISSWRQRN RWEWRPDFES EKVKVSLQCN STKNLTLAMR SSGDYGEITG  
180638       QIAYYNSCRW ESTDVKFHCQ RTQSQPGSWV RTISSWKQRN RWEWRPDFES EKVKVSLQCN STKNLTFAMR SSGDYGEVTG  
182309       QNAYYNNCKW ESTDVKFHCQ RKQSQPGSWL RAISSWRQRN RWEWRPDFES EKVKVSLQCN STRNLTFAMR SSGDYGEVTG  Appendices 
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182455       QRAYYNSCRW ESTDVKFHCQ RTQSQPGSWI RAISSWRQRN RWEWRPDFES EKVKVSLQCN STKNLTFAMR SSGDYGEVTG  
206394       QMAYYNSCRW ESTNVKFHCQ RTQSQPGSWR RIISSWRQRN RWEWRPDFES EKVKVSLQCN STKNLTFAMR SSADYGEVTG  
 
             ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|  
                 85         95        105        115        125        135        145        155                     
170003       AWIEFGCHRN KSKRHTEARF RIRCRRNVGN NTSLIDTCGE TQNVSGANPV DCTMYANKMY NCSLQDGFTM KVDDLIMHFN  
170141       AWIEFGCHRN KSIHHSAARF RIRCRWNTGK NSSLIDTCGE TQNVSGANPV DCTMYANRMY NCSLQNGFTM KVDDLIMHFN  
170186       AWIEFGCHRK KSSLHTDTRF RIRCRWNIGD NTSLIDTCGE TQNVSGANPV DCTMYANRMY NCSLQDGFTM KVDDLIMHFN  
170305       AWIEFGCHRN KSKLHSEARF RIRCRWNEGD NTSLIDTCGE TQNVTGANPV DCTMYTNKMY NCSLQDGFTM KVDDLIMHFN  
170338       AWIEFGCHRK KSNLHSEARF RIRCRWNVGD NTSLIDTCGE NKNVSGANPV DCTMYANKMY NCSLQDGFTL KVEDLIMHFN  
170415       AWIEFGCHRK KSKLHSEARF RIRCRWNAGD NTSLIDTCGN SQNVSGANPV DCTMYANRMY NCSLQNGFTM KVDDLIMHFN  
170418       AWIEFGCHRN KSKLHTEARF RIRCRWNEGN NASLIDTCGK TQNVSGANPV DCTMYANTMY NCSLQNGFTM KVDDLIVHFN  
170488       AWIEFGRHSN KSKLHTEARF RIRCRWNTGD NTSLIDTCGD TKNVSGANPV DCTTYANKMY NCSSQDGFTM KIDDLIMHFN  
170617       AWIEFGCLRN KSKLHSEARF RIRCRWNIGD NTSLIDTCGK TQNVSGANPV DCTMYTNTMY NCSLQNGFTM KVDDLIMHFN  
170719       AWIEFGCRRN KSRLHTEARF RIRCRWNVGD NTSLTDTCG- TQNVTGANPV DCTMYANKMY NCSLQDGFTL KVEDLIMHFN  
171025       AWIEFGCHRN KSKLHSEARF RIRCRWNVGD NTSLIDTCGE TQNVSGANPV DCTMYANRMY NCSLQNGFTM KVDDLIMHFN  
171069       AWIEFGCHRN KSKFHSEARF RIRCRWNMGD NASLIDTCGE TQNVSGANPV DCTMYANRMY NCSLQNGFTM KVDDLIMHFN  
171070       AWIEFGCMRN KSRRHSTARF RIRCRWNMGN NISLIDTCGK DQNVSGANPV DCTMKANTLY NCSLQDGFTM KIEDLIVHFN  
171101       AWIEFGCHRN KSKFHSDARF RIRCRWNIGE NTSLIDTCGN TPNVTGANPV NCTMYANKMY NCSLQDGFTM KVDDLIVHFN  
171163       AWIEFGCHRN KSKLHTETRF RIRCRWNEGD NTSLIDTCGK NQNVTGANPV DCTMYANKMY NCSLQDGFTM KVDDLIMHFN  
171169       AWIEFGCHRQ KSRFHTEARF RIRCRWNVGD NTSLIDTCGK TPNVTGANPV DCTMYANKMY NCSLQNGFTM KVEDLIMHFN  
171170       AWIEFGCHRN KSKLHSEARF RIRCRWNIGD NTSLIDTCGK TQNVSGANPV DCTMYANRMY NCSLQNGFTM KVDDLIMHFN  
171175       AWIEFGCHRN KSKLHSEARF RIRCRWNVGN NTSLIDTCGK TQNVSGANPV DCTMYAHKMY NCSLQSGFTM KVDDLIMHFN  
171265       AWIEFGCHRN KSKFHTEARF RIRCRWNVGN NASLIDTCGE TQNVSGANPV DCTMYANRMY NCSLQNGFTM KVDDLIMHFN  
171270       AWIEFGCHRN KSKLHSEARF RIRCRWNTGN NASLIDTCGE TQNVSGANPV DCTMYANKMY NCSLQNGFTM KVDDLIMHFN  
171303       AWIEFGCHRN KSKFHTEARF RIRCRWNVGD NTSLIDTCGE TQNVTGANPV DCTMYANRMY NCSLQDGFTM KVDDLIMHFN  Appendices 
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171358       AWIEFGCHRN KSKLHSEARF RIRCRWNVGD NTSLIDTCGE TQHVSGANPV DCTMYANKMY NCSLQDGFTM KVDDLIMHFN  
171536       AWIEFGCHRN KSKFHSEARF RIRCRWNMGD NASLIDTCGE TQNVSGANPV DCTMYANRMY NCSLQNGFTM KVDDLIMHFN 
171700       AWIEFGCHRN KSRFHTEARF RIRCRWNVGD NASLIDTCGE TRNVSGANPV DCTMYANKMY NCSLQNGFTM KIDDLIMHFN  
171781       AWIEFGCHRN KSKFHTEARF RIRCRWNVGD NISLIDTCGE TQNVTGANPV DCTMYANKMY NCSLQNGFTM KVDDLVMHFN  
171810       AWIEFGCHRN KSRLQSEARF RIRCRWNVGD NTSLIDTCGA TKNVSGANPV DCTMYANRMY NCSLQNGFTM KVDDLVMHFN  
171812       AWIEFGCHRK KSKLHSEARF RIRCRWNVGD NTSLIDTCGE TQNVSGANPV DCTMYANKMY NCSLQDGFTM RVDDLIMHFN  
171838       AWIEFGCNRN KSKFHSAARF RIRCRWNVGE NTSLIDTCGK TQNVSGANPV DCTMYANSMY NCSLQNGFTM KVDDLIMHFN  
172325       AWIEFGCHRN KSKLHSEARF RIRCRWDVGD NTSLIDTCGE TQNVSGANPV DCTMYANKMY NCSLQDGFTM KVDDLIMHFN  
172458       AWIEFGCHRN KSLRHTEARF RIRCRWNTGN NASLIDTCGE NQNVSGANPV DCTMYANKIY NCSLQEGFTM KVDDLIMHFN  
172506       AWIEFGCHRN KSKHYTEARF RIRCLWNKGN NTSLIDTCGE TKNVSGANPV DCTMYANRMY NCSLQDGFTM KVDDLIMHFN  
172527       AWIEFGCHRN KSKLHSEARF RIRCRWDVGD NTSLIDTCGK NPNVSGANPV DCTMYANKMY NCSLQNGFTM KVDDLIMHFN  
172532       AWIEFGCHRN KSRLQSEARF RIRSRWNVGD NTSLTDTCGE TKNVSGANPV DCTMYANRMY NCSLQTGFTM KVDDLVMHFN  
178586       AWIEFGCHRN KSKQHTAARF RIRCRWNIGD NTSLIDTCGE TQNVSGANPV DCTMYANKMY NCSLQNGFTM KVDDLIMHFN  
178721       AWIEFGCHRN KSKMHSEARF RIRCRWNVGD NTSLIDTCGE TQNVSGANPV DCTMYANRMY NCSLQNGFTM KVDDLIMHFN  
179200       AWIEFGCHRK KTQFHDEARF RIRCRWNVGS NTSLIDTCGE TQNVSGANPV DCTMYANKMY NCSLQDGFTM KVEDLIMHFN  
179288       AWIEFGCHRN KSKLHSEARF RIRCRWNVGD NTSLIDTCGE TKNVTGANPV DCTMYANKMY NCSLQDGFTL KVEDLIMHFN  
179297       AWIEFGCHRK KTQLHNEARF RIRCRWNVGG NTSFIDTCGE TQNVSGANPV DCTMYANKMY NCSSQDGFTM KVEDLIMHFN  
179369       AWIEFGCHRN KSKFHTEARF RIRCRWNEGD NASLIDTCGE TQNVSGANPV DCTMYANKMY NCSLQDGFTM KVDDLIMHFN  
179466       AWIEFGCHRN KSKLHSEARF RIRCRWNVGD NTSLIDTCGE TQNVSGANPV DCTMYANRMY NCSLQNGFTM KVDDLIMHFN  
180115       AWIEFGCHRN KSKLLTEARF RIRCRWNVGD NTSLIDTCGK TQNVSGANPV DCTMYTNRMY NCSLQNGFTM KIDDLIMHFN  
180140       AWIEFGCHRN KSKLLTEARF RIRCRWNVGD NTSLIDTCGK TQNVSGANPV DCTMYTNRMY NCSLQNGFTM KIDDLIMHFN  
180260       AWIEFGCHRN KSKLHSEARF RIRCRWNTGD NTSLIDTCGE TQNVSGANPV DCTMYANKMY NCSLQNGFTM KVDDLIMHFN  
180638       AWIEFGCHRN KSKLYDGARF RIRCRWNIGD NTSLIDTCGE TQNVSGANPV DCTMYANKMY NCSLQNGFTM KVDDLIMHFN  
182309       AWIEFGCHRN KSKLHDEARF RIRCRWNVGE NTSLIDTCGN TPNVSGANPV DCTMYTNKMY NCSLQSGFTM KIDDLIMHFN  
182455       AWIEFGCHRN KSKLHSEARF RIRCRWNVGD NTSLIDTCGE TKNVTGANPV DCTMYANKMY NCSLQDGFTL KVEDLIMHFN  
206394       AWIEFGCHRK KSNFHTETRF RIRCRWNVGD NTSLIDTCGK TQNVSGANPV DCTMYANRMY NCSLQNGFTM KVDDLIMHFN  Appendices 
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170003       MTKAVEMYNI AGNWSCTSDL PHGWGYMNCN CTNSSSS--- ----G-NKMA CPRTQGI 
170141       MTKAVEVYNI AGNWSCTSDL PPTWGYMNCN CTNGSSS--- ---SGSNKMA CPRSQGI 
170186       MTKAVEMYNI AGNWSCTSDL PSTWGYMNCN CTNG-TNS-- -GTYSGNKMA CPAKQGI 
170305       MTKAVEMYNI AGNWSCTSDL PNTWGYMNCN CTNVTGEN-- -------KMA CPRNQGI 
170338       MTKAVEMYNI AGNWSCTSDL PPTWGYMKCN CTNGSSNGI- ---NGINKMA CPKNEGI 
170415       MTKAVEMYNI AGNWSCTSDL PPTWGYMKCN CTNSTSTL-- ---DTSNKMA CPSNHGI 
170418       MTKAVEMYNI AGNWSCTSDL PPTWGYMNCN CTNSSSSS-- ---YSMQKMA CPRNQGI 
170488       MTKAVEMYNI AGNWCCASDL PQGWGCINCS CTNSSDS--- ---DEIDKMA CPKSQGI 
170617       MTKAVEMYNI AGNWSCTSDL PPTWGYMKCN CTNSTGN--- ---N---KMA CPRDHGI 
170719       MTKAVEMYNI AGNWSCTSDL PPTWGYMNCN CTNSTN---- ----DKSKMA CPRIQGI 
171025       MTKAVEMYNI AGNWSCTSDL PSTWGYMNCN CTNSTSSS-- --GSNGAKMA CPRNKGI 
171069       MTKAVEMYNI AGNWSCTSDL PPTWGYMNCN CTNR------ -SNNDNNKMA CPKGQGI 
171070       MTKAVEMYDI AGNWSCKSDI PKEWGYMNCN CTNSTS---- ---NTNDKMA CPDTTGI 
171101       MTRAVEMYNI AGNWSCTSDL PNTWGYMNCN CTSTNSDSY- ----GGTKMA CPGTQGI 
171163       MTKAVEMYNI AGNWSCTSDL PPTWGYMNCN CTNSSVS--- ---DN-TKMA CPSNQGI 
171169       MTKAVEMYNI AGNWSCTSDL PPTWGYMNCN CTNGSSHNN- ----Q--QMA CPKNQGI 
171170       MTKAVEMYNI AGNWSCVSDL PPTWGYMNCN CTNGSSN--- ---VGSTKMA CPGKQGI 
171175       MTKAVEMYNI AGNWSCTSDL PKDWGYMNCN CTNNT----- --GSN--KMA CPGNQGI 
171265       MTKAVEMYNI AGNWSCTSDL PQEWGYMNCN CTNST----- --GSN--KMA CPKNQGI 
171270       MTKAVEMYNI AGNWSCTSDL PPTWGYINCN CTNGSSS--- ----G-NKMA CPGNQGI 
171303       MTKAVEMYNI AGNWSCTSDL PKTWGYMNCN CTNSTG---- ----GNNKMA CPTNQGI 
171358       MTRAVEMYNI AGNWSCTSDL PPTWGYMNCN CTNNSDSN-- ------NKMA CPRNQGI Appendices 
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171536       MTKAVEMYNI AGNWSCTSDL PPTWGYMNCN CTNR------ -SNNDNNKMA CPKGQGI 
171700       MTKAVEMYNI AGNWSCMSDL PSTWGYMNCN CTNSTI---- -SGGTSNKMA CPKNQGI 
171781       MTKAVEMYNI AGNWSCTSDL PSTWGYMNCN CTNST----- ---NQVNKMA CPKNQGI 
171810       MTKAVEMYNI AGNWSCTSDL PPTWGYMNCN CTNSSGDS-- --GGVNNKMA CPTKRGI 
171812       MTKAVEMYNI AGNWSCTSDL PPTWGYMNCN CTN-STNS-- ---MGSNKMA CPRIQGI 
171838       MTKAVEMYNI AGNWSCTSDL PPTWGYMNCN CTNKN----- ---NDSDKMA CPNNQGI 
172325       MTKAVEMYNI AGNWSCTSDL PQEWGYMNCN CTNST----- --GNN--KMA CPRNQGI 
172458       MTKAVEMYNI AGNWSCTSDL PPTWGYMNCN CTNSSKN--- -----HNKMA CPGNQGI 
172506       MTKAVEMYNI AGNWSCTSDL PPTWGYMNCN CTNSSSN--- ----DNNKMA CPRSQGI 
172527       MTKAVEMYNI AGNWSCTSDL PPTWGYMNCN CTNSST---- ----DSNKMA CPTNQGI 
172532       MTKAVEMYNI AGNWSCTSDL PPTWGYMNCN CTNSSGDSG- ---GVNNKMA CPTKRGI 
178586       MTKAVEMYNI AGNWSCTSDL PPTWGYMNCN CTNSSS---- ----NQGKMA CPSTQGI 
178721       MTKAVEMYNI AGNWSCTSDL PPTWGYMNCN CTNSSTISSN SSTISSKKMA CPRNKGI 
179200       MTKAVEMYNI AGNWSCMSDL PQEWGYMNCN CTNSTDS--- ---GSNNRMA CPRERGI 
179288       MTKAVEMYNI AGNWSCTSDL PPTWGYMKCN CTNGTNSS-- ---DGKDKMA CPGNQGI 
179297       MTKAVEMYNI AGNWSCMFDL PQEWGYMNCN CTNSSDY--- ---GSNNRMA CPRERGI 
179369       MTKAVEMYNI AGNWSCTSDL PQEWGYMNCN CTNNTE---- ---TNYNKMA CPRNQGI 
179466       MTKAVEMYNI AGNWSCTSDL PSTWGYMNCN CTNSTSSS-- --GSNGAKMA CPRNKGI 
180115       MTKAVEMYNI AGNWSCTSDL PPTWGYMKCN CTNST----- -SQGTSNKMV CPESQGI 
180140       MTKAVEMYNI AGNWSCTSDL PPTWGYMKCN CTNST----- -SQGTSNKMV CPESQGI 
180260       MTKAVEMYNI AGNWSCTSDL PSTWGYMNCN CTNGTSN--- ---DGINKMA CPNREGI 
180638       MTKAVEMYNI AGNWSCTSDL PSNWGYMNCN CTN------- -STNSINQMA CPKEQGI 
182309       MTKAVEMYNI AGNWSCMSDL PPTWGYMNCN CSNST----- ----GNNKMA CPSKQGI 
182455       MTKAVEMYNI AGNWSCTSDL PPTWGYMKCN CTNGTNSSD- ----GKDKMA CPGNQGI 
206394       MTKAVEMYNI AGNWSCTSDL PPTWGYMNCN CTNSSGNS-- ------NKMA CPRNQGI 
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Appendix 2. Details of the naturally FIV infected cats included in the project. 
 
Sample #  Age 
(years)  Sex  Breed  Condition  Clinical Signs / Notes  % neutralisation 
(GL8) 
169267  10  Male  DLH  Sick  severe stomatitis/gingivitis  25 
169244  8  Male  DSH  Healthy  sore mouth  15 
169248  7  Female  DSH  Healthy  cat tested FIV+ several years ago but still healthy 
  has a bout of allergic skin disease  92 
169364  17  Male  Birmese  NA  previously snap test positive for FIV  47 
169421  6  Male  DMS  Sick  jaundice  43 
169422  9  Male  DSH  Sick  gingivitis  92 
169425  <1  Female  DSH  Healthy  mother tested FIV+  38 
169426  <1  Male  DSH  Healthy  mother tested FIV+  40 
169429  NA  Male  DLH  Healthy  no apparent lesion  46 
169431  3  Male  DSH  NA  NA  52 
169433  NA  Male  DSH  Healthy  no apparent lesion  25 
169467  11  Male  DSH  NA  anaemia   sneezing  19 
169468  11  Male  DSH  Sick  damaged tail  37 
169485  14  Male  DSH  Sick   left eye ulceration  34 
136590  NA  Male  DSH  NA  recurrent URT symptoms  22 
169591  12  Male  DSH  NA  sore mouth   dullness   anorexia  43 
169543  12  Male  DSH  Sick  recurrent gingivitis   slight weight loss   59 
169630  12  Female  DSH  Sick  gingivitis  92 
169649  3  Male  DSH  Healthy  stray cat  20 
169671  NA  Male  DSH  Healthy  iritis and luxated lens  64 
169729  5  Male  DSH  NA  NA  51 
169762  NA  Male  DLH  NA  stray cat  34 
169768  NA  Female  DSH  Sick  enlarged lymph nodes  39 
169904  8  Male  DSH  NA  ulceration around ear & nose  69 
169918  NA  Male  DSH  Healthy  dental problems  75 
169920  13  Male  DSH  NA  NA  67 
169926  8  Male  DSH  Sick  severe gingivitis  19 Appendices 
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169944  NA  Male  DSH  Healthy  entire male  26 
170003  3  Male  DLH  NA  no apparent lesion  48 
170014  12  Male  DSH  NA  NA  48 
170091  6  Female  DSH  NA  positive snap combo  6 
170122  10  Female  DSH  Sick  off colour   went missing for 2 weeks   anaemia   
off food  36 
170131  7  Male  DLH  NA  NA  30 
170141  12  Male  Tonkinese  Sick  coughing   lung worms   off food   weight loss – 
loss of voice   93 
170152  9  Female  DSH  Healthy  no apparent lesion  35 
170186  15  Male  DSH  Sick  anemia  9 
170226  10  Male  DSH  Sick  skin disease  19 
170227  NA  Male  DSH  NA  feral cat in garden  44 
170282  6  Male  DSH  Sick  severe gingivitis  65 
170305  NA  Female  Domestic  NA  NA  83 
170335  1  Female  DSH  Sick  poor growth   widespread crusting skin lesions on 
face and neck  83 
170338  11  Male  DSH  Sick  NA  85 
170396  12  Male  DSH  Healthy  FIV positive on in house test  75 
170415  NA  Male  DSH  NA  NA  69 
170418  1  Male  DSH  NA  NA  72 
170420  NA  Male  DSH  Sick  chronic gingivitis  61 
170437  11  Female  NA  NA  NA  80 
170488  4  Male  DSH  NA  pale   poor condition  58 
170617  NA  Female  DLH  Sick  NA  80 
170630  1  Male  DSH  Healthy  stray cat  78 
170688  NA  NA  NA  Healthy  NA  75 
170719  9  Male  DSH  Sick  anaemia   dehydration  68 
170764  12  Male  DSH  Sick  stomatitis  81 
170773  11  Male  DLH  Sick  weight loss  72 
170777  13  Male  DLH  NA  NA  84 
170875  11  Female  DSH  Sick  persistent pyrexia (>40
oC)  78 
170901  6  Male  DSH  Healthy  no apparent lesion  79 Appendices 
 
  166 
170959  2  Male  DSH  Healthy  stray cat  75 
170962  8  Male  DSH  NA  NA  81 
170973  NA  Male  DSH  NA  Gingivitis  89 
171025  3  Male  DSH  NA  NA  75 
171037  NA  Male  DSH  Sick  oral hyperplasia   poor condition   weight loss  49 
171069  NA  Male  DSH  Healthy  no apparent lesion  47 
171070  8  Male  DSH  Healthy  ulcerative pharyngitis  61 
171086  7  Male  DLH  Sick  PCV: 19%   pale mucous membranes   lethargy   
weight loss   previous history of fibrosarcoma  54 
171101  <1  Male  DSH  Sick  Alopecia  67 
171163  <1  Female  DSH  Sick  cyclical pyrexia (104
oF)  58 
171167  11  Female  DSH  NA  NA   66 
171169  2  Female  DSH  Healthy  slight conjunctivitis  41 
171170  NA  Male  DSH  Healthy  ex  stray  54 
171175  16  Female  DSH  Sick  upper respiratory tract signs  67 
171265  NA  Male  DLH  Healthy  abscess on head   63 
171267  NA  Male  DSH  NA  Stray cat  35 
171270  3  Male  DSH  Healthy  no apparent lesion  14 
171271  NA  Male  DSH  NA  stray cat   large abscess left face  40 
171272  13  Female  DSH  NA  Dermatitis  38 
171302  13  Male  DSH  Healthy  no apparent lesion  47 
171303  NA  Male  DSH  Sick  NA  45 
171358  16  Male  DLH  Sick  persistent non regenerative anaemia – 
leucopenia  53 
171437  NA  Female  DSH  Sick  upper respiratory tract signs  34 
171440  4  Male  DSH  Healthy  no apparent lesion  44 
171505  4  Male  Siamese  Sick  recurrent bouts pyrexia   has been a fighter  40 
171512  NA  Male  DSH  NA  Stray cat  41 
171532  5  Male  DSH  Sick  recurrent gingivitis/stomatitis   37 
171555  NA  Male  DSH  NA   NA  70 
171640  NA  Male  DSH  NA   NA  67 
171653  NA  Female  DSH  Healthy  no apparent lesion  66 
171697  10  Male  DSH  NA  NA   74 Appendices 
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171700  NA  Male  DLH  NA   NA   4 
171753  10  Male  DSH  NA   NA  63 
171781  10  Male  DSH  Healthy  anorexia   recurrent gingivitis  39 
171804  NA  Male  DLH  Sick  enlarged lymph nodes   63 
171806  8  Male  DSH  Healthy  Stray  87 
171807  4  Male  DSH  Healthy  outdoor cat   has been a fighter  28 
171810  NA  Female  DLH  Sick  feral   eating fine   change of coat colour  24 
171812  5  Male  DSH  Healthy  no apparent lesion  24 
171838  2  Female  DLH  Sick  dullness   off food   90 
171851  NA  Female  DSH  Healthy  no apparent lesion  39 
171877  NA  Male  DLH  Healthy  no apparent lesion  49 
171885  10  Male  DSH  Sick  jaundice   weight loss – anorexia  65 
171985  NA  Male  DSH  Sick  slow healing abscess   has multiple fights in past   59 
172010  NA  Male  DSH  Healthy  no apparent lesion  54 
172025  NA  NA  DSH  NA   NA  20 
172260  NA  Male  DSH  Healthy  stray  16 
172264  6  Male  DLH  Sick  anorexia   leathery   not passing urine   high 
respiration rate  30 
172279  12  Male  DSH  Sick  tongue ulceration   laryngeal swelling  97 
172300  9  Male  DSH  Healthy  no apparent lesion  48 
172308  1  Male  DSH  Sick  oropharyngeal infection  67 
172320  NA  NA  NA  Healthy  no apparent lesion  48 
172323  NA  Male  DSH  NA  was free roaming   poor coat condition  66 
172325  12  Female  DSH  NA   NA  65 
172407  7  Male  DSH  NA   NA  8 
172429  2  Male  DSH  Sick  severe uveitis   increased intraocular pressure  29 
172458  4  Male  DSH  Sick  gingivitis   stomatitis  7 
172471  2  Male  DSH  Healthy  was stray cat  30 
172506  11  Male  DSH  Sick   NA  34 
172527  9  Female  DSH  Sick  ataxia (4 legs)  39 
172532  NA  Male  DSH  NA  free roaming  100 
172610  11  Female  DSH  Healthy   NA  46 
172695  10  Male  DSH  sick  gingivitis  off food   nasal discharge   sore mouth  79 Appendices 
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172839  13  Male  DSH  Sick  severe gingivostomatitis  49 
172840  9  Female  DSH  NA   NA  63 
172843  5  Female  DSH  NA  lymphadenopathy  50 
172844  NA  Male  DSH  Healthy  no apparent lesion  29 
172851  9  Female  DSH  NA   NA  49 
172863  9  Male  DSH  Sick  lethargy  7 
172867  6  Male  DSH  NA   NA  43 
172878  2  Male  DSH  Healthy   NA  13 
178384  NA  Male  DSH  Sick   NA  25 
178407  NA  Male  DSH  Healthy  Adopted stray  53 
178410  2  Male  DSH  Healthy  no apparent lesion  30 
178416  6  Male  DSH  Sick  gradual weight loss   reduced appetite   malaise 
  poor body & coat condition   HR 220  41 
178423  NA  Male  DSH  NA   NA  52 
178424  NA  Female  DSH  NA   NA  39 
178539  8  Male  DSH  Sick   NA  46 
178564  4  Male  DSH  Sick   NA  35 
178571  NA  NA  NA  Healthy  no apparent lesion  43 
178586  5  Female  DSH  Sick  severe gingivitis  41 
178635  NA  NA  NA  Sick   NA  57 
178636  2  Male  DSH  Healthy  severe stomatitis  50 
178637  11  Female  DSH  Healthy  gingivitis  48 
178639  10  Male  DSH  Sick  stray  99 
178706  NA  Female  DSH  Healthy  no apparent lesion  14 
178717  5  Male  DSH  Sick  dullness   dehydration   URT infections  48 
178721  5  Male  DSH  Sick  large abscess on side of the face  45 
178753  6  Male  DSH  Sick   NA  56 
178780  4  Male  DSH  Healthy  no apparent lesion  1 
178784  NA  Male  DSH  NA  NA  68 
178837  3  Male  DSH  Healthy  no apparent lesion  72 
178898  5  Female  DSH  Healthy  off colour  47 
178911  NA  Male  X breed  Healthy  chronic gingivitis/stomatitis  62 
178982  NA  Female  DLH  NA   NA  40 Appendices 
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179028  11  Male  DSH  Sick  chronic gingivitis  28 
179035  NA  Male  DSH  Sick  poor coat condition   granulation tissue at back 
of mouth  92 
179056  11  Male  DSH  Sick  poor condition    weight loss   2 
179059  2  Male  DSH  Healthy  no apparent lesion  11 
179105  3  Male  DSH  NA   NA  37 
179114  10  Male  DSH  NA   NA  53 
179117  1  Male  DLH  Healthy  no apparent lesion   37 
179118  8  Male  DSH  Sick  Weight loss  8 
179120  NA  Male  DSH  Healthy  no apparent lesion  25 
179176  NA  Male  DSH  Healthy  no apparent lesion  48 
179181  3  Male  DSH  Sick   NA  25 
179200  10  Male  DSH  Sick  weight loss   lethargy   pyrexia  41 
179288  3  Male  DSH  Sick  mild gingivitis   neck lesions  31 
179297  8  Male  DSH  Healthy  no apparent lesion  24 
179323  11  Male  DSH  sick  Raised liver enzymes + abdominal fluids  7 
179369  NA  Male  DSH  NA   NA  31 
179383  NA  NA  DSH  NA   NA  24 
179466  5  Male  NA  NA   NA  39 
179481  14  Male  DSH  Healthy  previously tested FIV+  38 
179550  2  Female  DSH  Healthy  no apparent lesion  32 
179582  2  Male  DSH  Healthy  Halitosis   severe gingivitis   dental caries   
slightly muffled heart sounds  54 
179638  8  Male  DSH  Healthy  no apparent lesion  50 
179795  9  Male  DSH  sick  intermittent vomiting   weight loss   pale mucous 
membranes  60 
179837  2  NA  Persian  NA   NA  64 
179845  12  Male  DLH  sick  gingivitis   pancytopaenia   hypoalbuminaemia   
hyperglobulinaemia  58 
179850  13  Female  DSH  NA   NA  28 
179876  10  Female  DSH  sick  generalised malaise   leukopaenia (neutropaenia)  60 
179898  NA  Female  DSH  NA   NA  56 
180111  12  Male  DSH  Healthy  gingivitis   previously tested FIV+  15 Appendices 
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180115  12  Female  DSH  sick  mucopurlent ocular and nasal discharges   
stomatitis   bilateral conjunctivitis  1 
180116  8  Male  DSH  sick  lethargy   anorexia   off colour  10 
180136  12  Male  DSH  sick   NA  0 
180138  NA  Male  DSH  NA   NA  3 
180140  NA  Male  DSH  Healthy  no apparent lesion  63 
180223  8  Male  DSH  Healthy  no apparent lesion  58 
180229  10  Male  DSH  sick  anorexia   pyrexia  50 
180255  10  Male  DSH  sick  weight loss   unhealed wounds   behavioural 
change  63 
180260  10  Male  DSH  NA   NA  23 
180302  NA  NA  NA  NA   NA  51 
180313  4  Male  DSH  NA  gingivitis   all teeth removed  54 
180354  11  Male  DSH  sick  chronic gingivostomatitis  67 
180370  1  Female  DLH  sick  slightly off colour   persistent mild pyrexia   mild 
lymphomegaly  49 
180389  9  Male  DSH  sick  diabetes   influenza like symptoms  12 
180392  7  Male  DSH  Healthy  no apparent lesion  51 
180458  <1  NA  DSH  Healthy  no apparent lesion  27 
180498  8  Female  DSH  sick  chronic gingivitis  23 
180536  11  Male  British  sick  Ulcerative glossitis   31 
180638  NA  Male  DSH  sick  severe periodontitis   all teeth lost   swollen and 
lysed jaws bones   thickened bowel loops   13 
180644  9  Male  DSH  NA   NA  85 
180647  NA  Male  DSH  sick   NA  2 
180652  4  Male  DSH  NA   NA  24 
180653  12  Male  NA  NA   NA  32 
180659  13  Female  Siamese  NA   NA  49 
180662  1  Female  DSH  Healthy  no apparent lesion  36 
180724  10  Male  DSH  NA  9 months history of gingivitis and dental 
problems  5 
180779  NA  Male  DSH  sick  Bilateral epitasis   NAD on biochemistry and X 
rays  84 Appendices 
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180795  NA  Male  DSH  sick  tongue ulcerations   purulent discharges  14 
180800  NA  Male  DSH  NA   NA  47 
180801  5  Male  DSH  Healthy  no apparent lesion  8 
180850  NA  Male  DSH  Healthy  no apparent lesion  17 
180871  1  Male  DSH  sick  pyrexia   inappetance+O179   lethargy  86 
180911  2  Female  DSH  Healthy  no apparent lesion  29 
180914  5  Male  DSH  sick  lethargy   mild dyspnea for 2 3 months   with 
history of fights   6 
180949  NA  Male  DSH  NA   NA  5 
180956  14  Male  DSH  Healthy  chronic gingivitis   3 
180961  5  Male  DSH  NA   NA  22 
180966  7  Male  DSH  sick  lethargy   vomiting  35 
181091  2  Female  DSH  Healthy  no apparent lesion   2 
181143  10  Male  Persian  Healthy  no apparent lesion   4 
181146  <1  Male  DSH  NA   NA  6 
181215  12  Male  DSH  sick  weight loss   tongue ulcerations  21 
181218  NA  NA  DSH  Healthy  no apparent lesion  43 
181255  2  Male  DSH  NA   NA  27 
181256  13  Male  DSH  sick  general malaise   recurrent drooling lingual 
ulcers   halitosis   marginal anaemia  24 
181259  2  Male  DSH  Healthy  stray cat – fighter  55 
181291  3  Male  DSH  Healthy  no apparent lesion  47 
181294  5  Male  DSH  Healthy  scars from previous fight  52 
181369  5  Male  DSH  Healthy  no apparent lesion  27 
181380  8  Male  DSH  sick   NA  95 
181423  6  Female  DSH  Healthy  no apparent lesion  34 
181439  4  Male  DSH  sick  pyrexia  62 
181440  NA  Male  DSH  Healthy  no apparent lesion  48 
181459  5  Male  DSH  sick  off food    poor condition   enlarged lymph nodes 
  chronic stomatitis/gingivitis   70 
181466  11  Female  Siamese  sick  mouth breathing   inappetance   nasal discharge  75 
181516  NA  Male  DSH  sick  conjunctivitis  85 
181574  7  Male  DSH  Healthy   NA  71 Appendices 
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181581  12  Male  DSH  sick  lethargy   inappetance   74 
181606  <1  Female  DSH  Healthy  NA   73 
181650  8  Male  DSH  NA  NA  81 
181670  NA  Male  DSH  Healthy  very old   poor condition  87 
181725  NA  NA  DSH  NA  NA   66 
181793  12  Male  DSH  sick  recurrent episodes of gingivitis   pain – 
inappetance   anorexia  97 
181809  10  Male  DSH  sick  lethargy   pyrexia   inappetance   slight ataxia  68 
181831  8  Male  DSH  sick  marked gingivostomatitis   halitosis   off food   
dehydration  76 
181834  NA  Male  DSH  sick  chronic recurrent gingivitis  59 
181838  11  Male  DSH  sick   NA  77 
181882  5  Female  DSH  NA   NA  67 
181940  14  Male  Burmese  sick  gingivitis   stomatitis  79 
181946  10  Male  DSH  Healthy  no apparent lesion  50 
181948  5  Male  DSH  sick  chronic weight loss  61 
182000  12  Male  DSH  Healthy  no apparent lesion  69 
182189  11  Male  DSH  sick  lethargy   weight loss  23 
182193  NA  Male  DSH  Healthy  stray  42 
182246  9  Male  DSH  sick  severe gingivitis   15 
182250  18  Female  DSH  sick  anorexia  11 
182263  17  Male  DSH  sick  pyrexia   dullness   lethargy   severe ulcerative 
stomatitis  32 
182304  2  Male  DSH  sick  off food   mild dehydration   lameness  44 
182309  10  Male  DSH  NA  inappetance   halitosis  34 
182312  8  Male  DSH  sick  severe depression   normal TPR   maintaining 
weight  18 
182313  7  Male  DSH  sick  inappetance – lethargy   ocular discharges  37 
182337  4  Male  DSH  Healthy  stray cat   uncontrollable bleeding during 
castration  42 
182342  7  Male  DSH  Healthy  no apparent lesion  56 
182349  10  Male  DSH  sick  URT infection   cough   enlarged sub nasal LN   
mild anemia   PCV 26%  42 Appendices 
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182387  3  Male  DSH  Healthy  no apparent lesion  72 
182421  5  Male  DSH  sick  severe trauma on back (very pruritic)   mild 
gingivitis  49 
182426  4  Male  DSH  Healthy  no apparent lesion  51 
182427  7  Male  DSH  Healthy  no apparent lesion  54 
182428  7  Male  DSH  Healthy  no apparent lesion  30 
182453  7  Male  DSH  sick  chronic lethargy   inappetance   mild anemia & 
lymphopenia  32 
182454  1  Male  DSH  Healthy  no apparent lesion  58 
182455  NA  Female  DSH  NA   NA  37 
182457  <1   Male  DSH  NA   NA  60 
182461  12  Male  DSH  sick   NA  28 
182470  9  Male  DSH  sick  nervous signs  46 
182511  6  Male  DSH  NA   NA  39 
182517  NA  Female  DSH  NA   NA  39 
182591  NA  Male  DSH  Healthy  no apparent lesion  45 
182631  9  Male  DSH  sick  lumbo sacral pain   amorphous mass within bone  41 
182640  7  Male  DSH  sick  intermittent pyrexia   gingivitis  42 
182789  2  Male  Siamese  Healthy  was stray in Portugal  50 
182795  8  Male  DSH  Healthy  gingivitis  57 
182842  2  Female  COSH  Healthy  no apparent lesion  66 
182942  NA  Male  NA  sick  stray  57 
182943  11  Male  DLH  Healthy  Gallop rhythm   weight loss  76 
182945  10  Female  DSH  sick   NA  52 
182970  15  Male  DSH  sick   NA  65 
183039  6  Male  DSH  sick  keratitis  anterior uveitis  68 
183045  2  Female  DSH  NA   NA  78 
183053  NA  Female  DSH  Healthy  previous tested FIV+  81 
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Appendix 3. Raw luciferase activity counts. 
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Appendix 4. A list of plasma/serum samples and pseudotypes used in this 
project 
 
A) Plasma/serum samples 
A411 A413: cats experimentally infected with molecularly cloned FIV PET. 
A414 A416: cats experimentally infected with molecularly cloned FIV GL8. 
Q253: a cat experimentally infected with molecularly cloned FIV GL8. 
169267 210101: cats naturally infected with FIV in the UK. 
KNG1, KNG2, NG4, TOI1 and TOT1: cats naturally infected with FIV in Japan. 
 
B) Pseudotypes 
 
180638  primary subtype A pseudotype prepared in this project (UK) 
171838  primary subtype A pseudotype prepared in this project (UK) 
180260  primary subtype A pseudotype prepared in this project (UK) 
182309  primary subtype A pseudotype prepared in this project (UK) 
180140  primary subtype A pseudotype prepared in this project (UK) 
178721  primary subtype A pseudotype prepared in this project (UK) 
179200  primary subtype A pseudotype prepared in this project (UK) 
206394  primary subtype A pseudotype prepared in this project (UK) 
KNG1  primary subtype B pseudotype, previously prepared (Japan) 
KNG2  primary subtype B pseudotype, previously prepared (Japan) 
NG4  primary subtype B pseudotype, previously prepared (Japan) 
TOI1  primary subtype B pseudotype, previously prepared (Japan) 
TOT1  primary subtype B pseudotype, previously prepared (Japan) 
TM2  subtype B pseudotype, previously prepared in the lab (Japan) 
GL8  subtype A pseudotype, previously prepared in the lab (UK) 
B2542  subtype B pseudotype, previously prepared in the lab (USA) 
CPG 41  subtype C pseudotype, previously prepared in the lab (USA) 
PPR  subtype A pseudotype, previously prepared in the lab (USA) 
PET KKS  subtype A pseudotype, previously prepared in the lab (USA) 
0425  primary subtype A pseudotype, previously prepared (UK) 
1419  primary subtype A pseudotype, previously prepared (UK) 
0556  primary subtype A pseudotype, previously prepared (UK) 
0827  primary subtype A pseudotype, previously prepared (UK) 
M2  primary subtype B pseudotype, previously prepared (Italy) 
Leviano  primary subtype B pseudotype, previously prepared (Brazil) 
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